[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fEBbAXULn9pGNUEI5EiyqbsCNxzhs9BBM1mN7T6tMXF0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"West China Hospital",[4],453,false,203,32,4046350,199,221,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Colorectal Cancer",13,{"name":18,"count":19},"Head and Neck Squamous Cell Carcinoma",11,{"name":21,"count":22},"Portal Hypertension",10,{"name":24,"count":25},"Rectal Cancer",9,{"name":27,"count":28},"Liver Cancer",8,{"name":30,"count":28},"Immunotherapy",{"name":32,"count":28},"Gastric Cancer",{"name":34,"count":35},"Sepsis",7,[37,42,47,52,57,61,66,71,76,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04912167","The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction","2022-03","Sacubitril-Valsartan",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04032860","RCT of Different Effects of Nucleot(s)Ide Analogues on the Prognosis of HBV-HCC Patients After Curative Resection","2022-07-01","Tenofovir Disoproxil",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04316039","Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery","2023-04-10","Temozolomide",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT04318730","Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma","2023-12-01","Camrelizumab",{"nctId":58,"briefTitle":59,"date":60,"intervention":56},"NCT05447702","Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","2023-12-31",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05707910","Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors","2024-04-24","EBV immunological agent",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06405776","Effect of Lidocaine on Postoperative Pain and Long-term Survival in Elderly Patients Undergoing Colorectal Surgery","2024-06-01","lidocaine",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04922853","Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low\u002FIntermediate Risk II\u002FIII Rectal Cancer","2024-10-01","Capox chemotherapy",{"nctId":77,"briefTitle":78,"date":79,"intervention":56},"NCT06109207","Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas","2024-10-31",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT05640609","Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer","2024-11-01","Capeox regimen combined with Sintilimab and Bevacizumab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,123,141,169,187,212,230,258,289,355,394,469,499,521,545,571,592,610,635,665,683,701,727,745,770,794,812,830,908,1007,1129,1182,1251,1307,1354,1380,1417,1439,1476,1508,1530,1564,1591,1625,1658,1680,1702,1724,1757,1781,1807,1833,1858,1876,1901,1924,1942,1960,1978,2002,2026,2050,2076,2094,2112,2137,2155,2173,2191,2214,2239,2257,2275,2301,2326,2344,2362,2380,2398,2416,2434,2452,2470,2488,2506,2529,2547,2569,2594,2612,2637,2655,2673,2691,2721,2739,2757,2775,2793,2811,2829,2847,2865,2883,2909,2927,2951,2972,3000,3018,3036,3054,3078,3102,3120,3143,3166,3184,3202,3225,3250,3268,3290,3308,3326,3344,3384,3416,3438,3460,3482,3515,3545,3567,3589,3619,3660,3684,3707,3725,3743,3761,3786,3808,3834,3858,3880,3904,3928,3946,3964,3990,4008,4026,4044,4070,4094,4119,4144,4168,4190,4212,4233,4251,4269,4287,4305,4323,4341,4359,4377,4395,4421,4439,4457,4478,4502,4525,4549,4573,4596,4632,4669,4697,4721,4745,4763,4790,4808,4831,4856,4880,4907,4925,4948,4972,4994,5020,5038,5064,5104,5122,5146,5164,5193,5211,5229,5247,5265,5283,5308,5333,5351,5377,5395,5421,5439,5464,5482,5500,5527,5545,5568,5610,5639,5657,5683,5701,5719,5744,5774,5799,5817,5854,5876,5899,5917,5941,5964,5982,6000,6025,6043,6069,6087,6105,6123,6141,6164,6182,6210,6228,6252,6270,6288,6306,6324,6347,6374,6392,6410,6434,6460,6478,6501,6524,6550,6574,6602,6620,6638,6656,6674,6692,6717,6739,6757,6812,6851,6877,6918,6954,6976,6998,7035,7061,7085,7103,7128,7150,7176,7194,7219,7244,7262,7287,7305,7330,7355,7373,7397,7426,7451,7469,7496,7514,7536,7559],{"intervention":94,"totalTrials":95,"cells":96},"Proton Pump Inhibitors",1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":121},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":113},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":117,"interventions":119},"NCT05624229","Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","NOT_YET_RECRUITING",[90],"2025-12-31","2028-12-31","2023-10-01",672,[118],"Upper Gastrointestinal Hemorrhage",[94,120],"No Proton Pump Inhibitors",{"trials":122,"activeCount":99},[],{"intervention":120,"totalTrials":95,"cells":124},{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":139},{"trials":126,"activeCount":99},[],{"trials":128,"activeCount":99},[],{"trials":130,"activeCount":99},[],{"trials":132,"activeCount":99},[],{"trials":134,"activeCount":95,"soonestReadout":113},[135],{"nctId":109,"briefTitle":110,"status":111,"phases":136,"primaryCompletion":113,"completion":114,"start":115,"enrollment":116,"conditions":137,"interventions":138},[90],[118],[94,120],{"trials":140,"activeCount":99},[],{"intervention":142,"totalTrials":95,"cells":143},"Evolocumab",{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":167},{"trials":145,"activeCount":99},[],{"trials":147,"activeCount":99},[],{"trials":149,"activeCount":99},[],{"trials":151,"activeCount":99},[],{"trials":153,"activeCount":95,"soonestReadout":114},[154],{"nctId":155,"briefTitle":156,"status":157,"phases":158,"primaryCompletion":114,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":165},"NCT07612774","CAPER-EVO: a Randomized Serial PCCT Trial of Early Evolocumab After ACS","RECRUITING",[90],"2029-01-31","2026-05-19",233,[163,164],"Coronary","Coronary Artery Disease",[142,166],"Standard Lipid-Lowering Therapy",{"trials":168,"activeCount":99},[],{"intervention":166,"totalTrials":95,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":185},{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":99},[],{"trials":176,"activeCount":99},[],{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":95,"soonestReadout":114},[181],{"nctId":155,"briefTitle":156,"status":157,"phases":182,"primaryCompletion":114,"completion":159,"start":160,"enrollment":161,"conditions":183,"interventions":184},[90],[163,164],[142,166],{"trials":186,"activeCount":99},[],{"intervention":46,"totalTrials":95,"cells":188},{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":210},{"trials":190,"activeCount":99},[],{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":95,"soonestReadout":45},[199],{"nctId":43,"briefTitle":44,"status":200,"phases":201,"primaryCompletion":45,"completion":202,"start":203,"enrollment":204,"conditions":205,"interventions":208},"ACTIVE_NOT_RECRUITING",[90],"2026-07-01","2017-07-01",104,[206,207],"HCC","HBV Coinfection",[46,209],"Entecavir",{"trials":211,"activeCount":99},[],{"intervention":209,"totalTrials":95,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":222,"NA":228},{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":99},[],{"trials":221,"activeCount":99},[],{"trials":223,"activeCount":95,"soonestReadout":45},[224],{"nctId":43,"briefTitle":44,"status":200,"phases":225,"primaryCompletion":45,"completion":202,"start":203,"enrollment":204,"conditions":226,"interventions":227},[90],[206,207],[46,209],{"trials":229,"activeCount":99},[],{"intervention":231,"totalTrials":95,"cells":232},"Oxycodone Hydrochloride",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":256},{"trials":234,"activeCount":99},[],{"trials":236,"activeCount":99},[],{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":95,"soonestReadout":248},[243],{"nctId":244,"briefTitle":245,"status":246,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":252,"interventions":254},"NCT03685188","Oxycodone and Sufentanil for Analgesia in Hip Surgery","ENROLLING_BY_INVITATION",[90],"2024-12-31","2025-07-31","2018-12-01",570,[253],"Analgesia, Patient-Controlled",[231,255],"Sufentanil Citrate",{"trials":257,"activeCount":99},[],{"intervention":255,"totalTrials":259,"cells":260},2,{"EARLY_PHASE1":261,"PHASE1":263,"PHASE2":265,"PHASE3":267,"PHASE4":269,"NA":275},{"trials":262,"activeCount":99},[],{"trials":264,"activeCount":99},[],{"trials":266,"activeCount":99},[],{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":95,"soonestReadout":248},[271],{"nctId":244,"briefTitle":245,"status":246,"phases":272,"primaryCompletion":248,"completion":249,"start":250,"enrollment":251,"conditions":273,"interventions":274},[90],[253],[231,255],{"trials":276,"activeCount":99},[277],{"nctId":278,"briefTitle":279,"status":280,"phases":281,"primaryCompletion":282,"completion":60,"start":283,"enrollment":284,"conditions":285,"interventions":287},"NCT05548465","Long-term-opioid-free Anesthesia in Anterior Cervical Surgery","COMPLETED",[91],"2023-10-31","2022-09-26",100,[286],"Long-term-opioid-free Anesthesia",[288,255],"Remifentanil Hydrochloride",{"intervention":290,"totalTrials":291,"cells":292},"Toripalimab",4,{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":309,"PHASE3":336,"PHASE4":351,"NA":353},{"trials":294,"activeCount":99},[],{"trials":296,"activeCount":95,"soonestReadout":301},[297],{"nctId":298,"briefTitle":299,"status":157,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT07562841","Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy",[87],"2028-04-30","2029-04-30","2026-04-28",6,[306],"Advanced Melanoma",[308,290],"Au-TMP",{"trials":310,"activeCount":99},[311,326],{"nctId":312,"briefTitle":313,"status":314,"phases":315,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":324},"NCT04385654","Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced\u002FMetastatic Non-clear Cell Renal Cell Carcinoma","UNKNOWN",[88],"2021-12","2022-06","2020-06",40,[321,322,323],"Neoadjuvant Therapy","Advanced Cancer","Metastatic Kidney Cancer",[290,325],"Axitinib",{"nctId":327,"briefTitle":328,"status":314,"phases":329,"primaryCompletion":74,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":334},"NCT05763927","Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT",[88],"2025-04-01","2022-09-01",44,[24],[335,290],"Fruquintinib",{"trials":337,"activeCount":95,"soonestReadout":342},[338],{"nctId":339,"briefTitle":340,"status":111,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":348},"NCT07608224","HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC",[88,89],"2030-06-30","2030-12-31","2026-06-20",240,[347],"Urinary Bladder Neoplasms",[349,350,290,290],"Disitamab Vedotin","Gemcitabine + Cisplatin（GC）+Toripalimab",{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":99},[],{"intervention":356,"totalTrials":259,"cells":357},"Serplulimab",{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":376,"PHASE4":390,"NA":392},{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":95,"soonestReadout":368},[364],{"nctId":365,"briefTitle":366,"status":111,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":22,"conditions":371,"interventions":374},"NCT07175389","JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure",[87,88],"2027-09-01","2027-10-01","2025-10-01",[372,373],"Refractory Pancreatic Ductal Adenocarcinoma","Refractory Pancreatic Adenocarcinoma",[375,356],"JDB153",{"trials":377,"activeCount":95,"soonestReadout":382},[378],{"nctId":379,"briefTitle":380,"status":111,"phases":381,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},"NCT07336953","A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006\u002FICSBR-2)",[89],"2027-07","2028-07","2026-02",198,[387],"PDAC - Pancreatic Ductal Adenocarcinoma",[389,356],"GnP",{"trials":391,"activeCount":99},[],{"trials":393,"activeCount":99},[],{"intervention":395,"totalTrials":304,"cells":396},"Sirolimus",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":443,"PHASE4":455,"NA":457},{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":99},[],{"trials":402,"activeCount":95,"soonestReadout":368},[403,414,425,434],{"nctId":404,"briefTitle":405,"status":314,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":413},"NCT05324384","Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma",[88],"2025-04-30","2025-11-30","2022-04-05",30,[412],"Hemangioendothelioma",[395],{"nctId":415,"briefTitle":416,"status":280,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":410,"conditions":420,"interventions":423},"NCT03188068","Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma",[88],"2021-12-31","2017-06-01",[421,422],"Kaposiform Hemangioendothelioma","Kasabach Merritt Phenomenon",[395,424],"Prednisolone",{"nctId":426,"briefTitle":427,"status":280,"phases":428,"primaryCompletion":429,"completion":429,"start":430,"enrollment":431,"conditions":432,"interventions":433},"NCT04775173","Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.",[88],"2023-08-10","2021-02-17",79,[421],[395],{"nctId":435,"briefTitle":436,"status":111,"phases":437,"primaryCompletion":368,"completion":438,"start":439,"enrollment":440,"conditions":441,"interventions":442},"NCT07131644","Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma",[88],"2028-02-01","2025-09-13",120,[421],[395],{"trials":444,"activeCount":95,"soonestReadout":449},[445],{"nctId":446,"briefTitle":447,"status":157,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT06673290","Different Doses of Sirolimus for the Treatment of Cystic Lymphatic Malformations",[88,89],"2026-12-30","2024-11-30",150,[453],"Lymphatic Malformation",[395],{"trials":456,"activeCount":99},[],{"trials":458,"activeCount":99},[459],{"nctId":460,"briefTitle":461,"status":280,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":468},"NCT03583307","Efficacy and Safety of Sirolimus to Vascular Anomalies",[91],"2021-02-19","2018-06-01",126,[467],"Vascular Anomaly",[395],{"intervention":349,"totalTrials":259,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":489,"PHASE4":495,"NA":497},{"trials":472,"activeCount":99},[],{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":99},[477],{"nctId":478,"briefTitle":479,"status":314,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":485,"interventions":487},"NCT05726175","Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer",[88],"2024-07-31","2024-08-31","2023-03-01",20,[486],"Breast Cancer",[349,488],"Penpulimab",{"trials":490,"activeCount":95,"soonestReadout":342},[491],{"nctId":339,"briefTitle":340,"status":111,"phases":492,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":493,"interventions":494},[88,89],[347],[349,350,290,290],{"trials":496,"activeCount":99},[],{"trials":498,"activeCount":99},[],{"intervention":75,"totalTrials":95,"cells":500},{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":517,"NA":519},{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":99},[],{"trials":506,"activeCount":99},[],{"trials":508,"activeCount":95,"soonestReadout":74},[509],{"nctId":72,"briefTitle":73,"status":200,"phases":510,"primaryCompletion":74,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},[89],"2027-12-01","2021-08-26",554,[24,515],"Neoadjuvant Chemotherapy",[75],{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[],{"intervention":522,"totalTrials":95,"cells":523},"patients were assigned to receive TNT or iTNT management",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":530,"PHASE4":541,"NA":543},{"trials":525,"activeCount":99},[],{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[],{"trials":531,"activeCount":95,"soonestReadout":536},[532],{"nctId":533,"briefTitle":534,"status":157,"phases":535,"primaryCompletion":536,"completion":537,"start":83,"enrollment":538,"conditions":539,"interventions":540},"NCT07070622","Planed Organ Preservation for Low Rectal Cancer After Neoadjuvant Chemotherapy (OPLAR)",[89],"2027-12-31","2029-12-31",186,[24],[522],{"trials":542,"activeCount":99},[],{"trials":544,"activeCount":99},[],{"intervention":546,"totalTrials":95,"cells":547},"Topical application of Periplaneta americana-derived Meilian Fuxin Solution",{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":552,"PHASE3":554,"PHASE4":567,"NA":569},{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":99},[],{"trials":553,"activeCount":99},[],{"trials":555,"activeCount":95,"soonestReadout":560},[556],{"nctId":557,"briefTitle":558,"status":157,"phases":559,"primaryCompletion":560,"completion":561,"start":562,"enrollment":563,"conditions":564,"interventions":566},"NCT07353671","Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis",[88,89],"2026-12-31","2027-06-30","2026-03-01",60,[565],"Radiation-induced Dermatitis",[546],{"trials":568,"activeCount":99},[],{"trials":570,"activeCount":99},[],{"intervention":51,"totalTrials":95,"cells":572},{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":588,"NA":590},{"trials":574,"activeCount":99},[],{"trials":576,"activeCount":99},[],{"trials":578,"activeCount":99},[],{"trials":580,"activeCount":95,"soonestReadout":50},[581],{"nctId":48,"briefTitle":49,"status":157,"phases":582,"primaryCompletion":50,"completion":114,"start":583,"enrollment":584,"conditions":585,"interventions":587},[88,89],"2018-04-10",250,[586],"Low-grade Glioma",[51],{"trials":589,"activeCount":99},[],{"trials":591,"activeCount":99},[],{"intervention":389,"totalTrials":95,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":606,"NA":608},{"trials":595,"activeCount":99},[],{"trials":597,"activeCount":99},[],{"trials":599,"activeCount":99},[],{"trials":601,"activeCount":95,"soonestReadout":382},[602],{"nctId":379,"briefTitle":380,"status":111,"phases":603,"primaryCompletion":382,"completion":383,"start":384,"enrollment":385,"conditions":604,"interventions":605},[89],[387],[389,356],{"trials":607,"activeCount":99},[],{"trials":609,"activeCount":99},[],{"intervention":611,"totalTrials":95,"cells":612},"Mecobalamin",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":619,"PHASE4":631,"NA":633},{"trials":614,"activeCount":99},[],{"trials":616,"activeCount":99},[],{"trials":618,"activeCount":99},[],{"trials":620,"activeCount":95,"soonestReadout":511},[621],{"nctId":622,"briefTitle":623,"status":111,"phases":624,"primaryCompletion":511,"completion":625,"start":626,"enrollment":627,"conditions":628,"interventions":630},"NCT07274696","Mecobalamin in Promoting Recurrent Laryngeal Nerve Function Recovery After Thyroid Surgery",[89],"2028-12-01","2025-12-01",528,[629],"Patients Undergoing Open Thyroid Surgery",[611],{"trials":632,"activeCount":99},[],{"trials":634,"activeCount":99},[],{"intervention":636,"totalTrials":95,"cells":637},"Anti-PD-1 antibody drug named Serplulimab",{"EARLY_PHASE1":638,"PHASE1":640,"PHASE2":642,"PHASE3":644,"PHASE4":661,"NA":663},{"trials":639,"activeCount":99},[],{"trials":641,"activeCount":99},[],{"trials":643,"activeCount":99},[],{"trials":645,"activeCount":95,"soonestReadout":650},[646],{"nctId":647,"briefTitle":648,"status":157,"phases":649,"primaryCompletion":650,"completion":651,"start":652,"enrollment":653,"conditions":654,"interventions":659},"NCT07020247","Personalized Long-course Radiotherapy Plus Chemotherapy With or Without Immunotherapy for LARC: PALACE Study",[89],"2027-07-31","2028-01-31","2024-11-19",184,[655,30,656,657,658],"Locally Advanced Rectal Cancer (LARC)","Radiotherapy","Total Neoadjuvant Therapy","Anal Function Preservation",[636,660],"Chemotherapy",{"trials":662,"activeCount":99},[],{"trials":664,"activeCount":99},[],{"intervention":660,"totalTrials":95,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":679,"NA":681},{"trials":668,"activeCount":99},[],{"trials":670,"activeCount":99},[],{"trials":672,"activeCount":99},[],{"trials":674,"activeCount":95,"soonestReadout":650},[675],{"nctId":647,"briefTitle":648,"status":157,"phases":676,"primaryCompletion":650,"completion":651,"start":652,"enrollment":653,"conditions":677,"interventions":678},[89],[655,30,656,657,658],[636,660],{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"intervention":350,"totalTrials":95,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":691,"PHASE4":697,"NA":699},{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":95,"soonestReadout":342},[693],{"nctId":339,"briefTitle":340,"status":111,"phases":694,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":695,"interventions":696},[88,89],[347],[349,350,290,290],{"trials":698,"activeCount":99},[],{"trials":700,"activeCount":99},[],{"intervention":702,"totalTrials":95,"cells":703},"SBRT+PD-1 Inhibitor + Chemotherapy",{"EARLY_PHASE1":704,"PHASE1":706,"PHASE2":708,"PHASE3":710,"PHASE4":723,"NA":725},{"trials":705,"activeCount":99},[],{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":95,"soonestReadout":716},[712],{"nctId":713,"briefTitle":714,"status":157,"phases":715,"primaryCompletion":716,"completion":717,"start":83,"enrollment":718,"conditions":719,"interventions":721},"NCT06627712","SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC",[89],"2029-11-01","2031-11-01",318,[720],"TNBC - Triple-Negative Breast Cancer",[702,722],"PD-1 Inhibitor + Chemotherapy",{"trials":724,"activeCount":99},[],{"trials":726,"activeCount":99},[],{"intervention":722,"totalTrials":95,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":741,"NA":743},{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":99},[],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":95,"soonestReadout":716},[737],{"nctId":713,"briefTitle":714,"status":157,"phases":738,"primaryCompletion":716,"completion":717,"start":83,"enrollment":718,"conditions":739,"interventions":740},[89],[720],[702,722],{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"intervention":746,"totalTrials":95,"cells":747},"desiccated thyroid extract",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":766,"NA":768},{"trials":749,"activeCount":99},[],{"trials":751,"activeCount":99},[],{"trials":753,"activeCount":99},[],{"trials":755,"activeCount":95,"soonestReadout":760},[756],{"nctId":757,"briefTitle":758,"status":111,"phases":759,"primaryCompletion":760,"completion":761,"start":408,"enrollment":762,"conditions":763,"interventions":765},"NCT07239674","Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC",[89],"2027-11-30","2028-06-30",646,[764],"Intermediate-to-High Risk Differentiated Thyroid Cancer",[746],{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":99},[],{"intervention":41,"totalTrials":95,"cells":771},{"EARLY_PHASE1":772,"PHASE1":774,"PHASE2":776,"PHASE3":778,"PHASE4":790,"NA":792},{"trials":773,"activeCount":99},[],{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":95,"soonestReadout":40},[780],{"nctId":38,"briefTitle":39,"status":111,"phases":781,"primaryCompletion":40,"completion":782,"start":783,"enrollment":784,"conditions":785,"interventions":787},[89],"2026-06","2021-11",376,[786],"STEMI",[41,788,789],"Enalapril","Valsartan",{"trials":791,"activeCount":99},[],{"trials":793,"activeCount":99},[],{"intervention":788,"totalTrials":95,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":808,"NA":810},{"trials":797,"activeCount":99},[],{"trials":799,"activeCount":99},[],{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":95,"soonestReadout":40},[804],{"nctId":38,"briefTitle":39,"status":111,"phases":805,"primaryCompletion":40,"completion":782,"start":783,"enrollment":784,"conditions":806,"interventions":807},[89],[786],[41,788,789],{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":99},[],{"intervention":789,"totalTrials":95,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":826,"NA":828},{"trials":815,"activeCount":99},[],{"trials":817,"activeCount":99},[],{"trials":819,"activeCount":99},[],{"trials":821,"activeCount":95,"soonestReadout":40},[822],{"nctId":38,"briefTitle":39,"status":111,"phases":823,"primaryCompletion":40,"completion":782,"start":783,"enrollment":784,"conditions":824,"interventions":825},[89],[786],[41,788,789],{"trials":827,"activeCount":99},[],{"trials":829,"activeCount":99},[],{"intervention":831,"totalTrials":304,"cells":832},"Propranolol",{"EARLY_PHASE1":833,"PHASE1":835,"PHASE2":837,"PHASE3":839,"PHASE4":863,"NA":865},{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":95,"soonestReadout":856},[841,852],{"nctId":842,"briefTitle":843,"status":280,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT02342275","Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma",[89],"2018-09","2013-10",377,[849],"Hemangioma",[831,851],"Atenolol",{"nctId":853,"briefTitle":854,"status":157,"phases":855,"primaryCompletion":856,"completion":857,"start":858,"enrollment":319,"conditions":859,"interventions":861},"NCT06798363","Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma",[88,89],"2026-06-30","2026-08-01","2025-05-02",[860],"Infantile Hemangioma",[862],"propranolol",{"trials":864,"activeCount":99},[],{"trials":866,"activeCount":99},[867,878,890,899],{"nctId":868,"briefTitle":869,"status":314,"phases":870,"primaryCompletion":871,"completion":872,"start":419,"enrollment":873,"conditions":874,"interventions":877},"NCT03171805","The Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices",[91],"2022-05-15","2022-12-30",74,[875,21,876],"Liver Cirrhoses","Gastric Varix",[831],{"nctId":879,"briefTitle":880,"status":314,"phases":881,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":888},"NCT05651789","Carvedilol vs. Propranolol in Second Prophylaxis of Variceal Bleeding",[91],"2024-12","2023-01",160,[21,886,887],"Varice Bleed","Cirrhosis, Liver",[889,831],"Carvedilol",{"nctId":891,"briefTitle":892,"status":314,"phases":893,"primaryCompletion":894,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":898},"NCT03094234","8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis",[91],"2022-03-28","2017-04-28",72,[21],[831],{"nctId":900,"briefTitle":901,"status":280,"phases":902,"primaryCompletion":903,"completion":904,"start":905,"enrollment":284,"conditions":906,"interventions":907},"NCT02477384","8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding",[91],"2018-11","2021-07","2015-06",[21],[831],{"intervention":56,"totalTrials":28,"cells":909},{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":946,"PHASE3":1001,"PHASE4":1003,"NA":1005},{"trials":911,"activeCount":99},[],{"trials":913,"activeCount":259,"soonestReadout":79},[914,925,932],{"nctId":915,"briefTitle":916,"status":200,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":304,"conditions":921,"interventions":923},"NCT06654297","Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas",[87],"2025-06-03","2027-02-07","2024-10-27",[922],"Esophageal Squamous Cell Carcinoma",[56,924,924],"Palbociclib",{"nctId":77,"briefTitle":78,"status":157,"phases":926,"primaryCompletion":79,"completion":927,"start":282,"enrollment":304,"conditions":928,"interventions":929},[87],"2025-10-31",[18],[56,930,931],"Dalpiciclib 100mg","Dalpiciclib 150mg",{"nctId":933,"briefTitle":934,"status":314,"phases":935,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":943},"NCT05019534","Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated \u002FMSS Metastatic Colorectal Cancer",[87],"2022-08-01","2022-12-01","2021-08-15",12,[941,942],"BRAF V600E-mutated \u002FMSS Metastatic Colorectal Cancer","Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal Antibody",[944,945,56],"Vemurafenib Oral Tablet [Zelboraf]","Cetuximab Injection [Erbitux]",{"trials":947,"activeCount":291,"soonestReadout":55},[948,959,970,981,994],{"nctId":58,"briefTitle":59,"status":157,"phases":949,"primaryCompletion":60,"completion":560,"start":950,"enrollment":951,"conditions":952,"interventions":954},[88],"2022-11-01",35,[953],"Triple Negative Breast Cancer",[56,955,956,957,958],"Apatinib","Nab-paclitaxel","Epirubicin","Cyclophosphamide",{"nctId":960,"briefTitle":961,"status":111,"phases":962,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":967,"interventions":969},"NCT07191977","Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma",[88],"2027-12","2029-12","2026-01",41,[968],"Esophageal Squamour Cell Cancer",[56,924],{"nctId":971,"briefTitle":972,"status":314,"phases":973,"primaryCompletion":974,"completion":975,"start":976,"enrollment":9,"conditions":977,"interventions":979},"NCT04405154","A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer",[88],"2023-05-31","2025-05-31","2020-06-01",[978],"Head and Neck Neoplasms",[56,980],"Cisplatin",{"nctId":982,"briefTitle":983,"status":157,"phases":984,"primaryCompletion":560,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":992},"NCT06831175","Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma",[88],"2031-12-31","2025-03-15",28,[989,990,991],"Adrenal Cortical Carcinoma","Adrenal Cortical Cancer","Adrenal Cancer",[56,955,993],"mitotane",{"nctId":53,"briefTitle":54,"status":157,"phases":995,"primaryCompletion":55,"completion":330,"start":996,"enrollment":997,"conditions":998,"interventions":1000},[88],"2020-10-01",21,[999],"Adrenocortical Carcinoma",[56],{"trials":1002,"activeCount":99},[],{"trials":1004,"activeCount":99},[],{"trials":1006,"activeCount":99},[],{"intervention":1008,"totalTrials":19,"cells":1009},"Tislelizumab",{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1056,"PHASE3":1123,"PHASE4":1125,"NA":1127},{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":1055,"soonestReadout":1038},[1014,1025,1034,1047],{"nctId":1015,"briefTitle":1016,"status":157,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":25,"conditions":1021,"interventions":1023},"NCT07565740","Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC",[87],"2027-05-10","2028-05-10","2026-05-10",[1022],"HPV-positive Oropharyngeal Squamous Cell Carcinoma",[1024,1024,1024,1008],"WSK-IM05",{"nctId":1026,"briefTitle":1027,"status":111,"phases":1028,"primaryCompletion":536,"completion":114,"start":1029,"enrollment":22,"conditions":1030,"interventions":1032},"NCT07077369","WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy",[87],"2025-08-01",[1031],"Hepatocellular Carcinoma (HCC)",[1033,1008],"WGc-0201",{"nctId":1035,"briefTitle":1036,"status":157,"phases":1037,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":997,"conditions":1040,"interventions":1044},"NCT06741982","A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus",[87],"2026-12-15","2024-12-15",[1041,1042,321,30,1043],"HNSCC","Lysogenic HSV Virus","Targeted Therapy",[1045,1008,1046],"Lysogenic HSV virus.","Afatinib",{"nctId":1048,"briefTitle":1049,"status":280,"phases":1050,"primaryCompletion":1051,"completion":1051,"start":481,"enrollment":25,"conditions":1052,"interventions":1054},"NCT06494189","Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma",[87],"2025-04-10",[1053],"Head and Neck Cancer",[1008,1046],3,{"trials":1057,"activeCount":259,"soonestReadout":202},[1058,1071,1080,1090,1099,1107,1115],{"nctId":1059,"briefTitle":1060,"status":314,"phases":1061,"primaryCompletion":1062,"completion":1063,"start":1064,"enrollment":1065,"conditions":1066,"interventions":1069},"NCT04865705","Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer",[88],"2021-12-10","2022-06-10","2020-11-10",33,[1067,1068],"Stage III","Non-small Cell Lung Cancer",[1070],"tislelizumab",{"nctId":1072,"briefTitle":1073,"status":157,"phases":1074,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1078,"interventions":1079},"NCT07010120","A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma",[87,88],"2027-05-31","2025-06-10",29,[1041,1042,321,30,1043],[1008,1046,1045],{"nctId":1081,"briefTitle":1082,"status":314,"phases":1083,"primaryCompletion":1084,"completion":1085,"start":872,"enrollment":484,"conditions":1086,"interventions":1088},"NCT05659186","PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer",[88],"2024-12-30","2025-12-30",[1087],"Thyroid Cancer",[1008,1089],"Anlotinib",{"nctId":1091,"briefTitle":1092,"status":157,"phases":1093,"primaryCompletion":202,"completion":202,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1098},"NCT07040956","A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.",[88],"2025-06-28",98,[18,1097,30,1043],"Low-dose Radiotherapy",[1008,1046],{"nctId":1100,"briefTitle":1101,"status":1102,"phases":1103,"primaryCompletion":856,"completion":856,"start":1104,"enrollment":99,"conditions":1105,"interventions":1106},"NCT06804850","Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC","WITHDRAWN",[88],"2025-01-20",[1053],[1008,1046],{"nctId":1108,"briefTitle":1109,"status":280,"phases":1110,"primaryCompletion":60,"completion":481,"start":1111,"enrollment":1112,"conditions":1113,"interventions":1114},"NCT05517330","Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma",[88],"2022-09-19",23,[1053],[1008,1046],{"nctId":1116,"briefTitle":1117,"status":280,"phases":1118,"primaryCompletion":1119,"completion":248,"start":1120,"enrollment":319,"conditions":1121,"interventions":1122},"NCT05516589","Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC",[88],"2023-10-29","2022-09-12",[18],[956,980,1008,1046],{"trials":1124,"activeCount":99},[],{"trials":1126,"activeCount":99},[],{"trials":1128,"activeCount":99},[],{"intervention":1046,"totalTrials":28,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1143,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1132,"activeCount":99},[],{"trials":1134,"activeCount":95,"soonestReadout":1038},[1135,1139],{"nctId":1035,"briefTitle":1036,"status":157,"phases":1136,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":997,"conditions":1137,"interventions":1138},[87],[1041,1042,321,30,1043],[1045,1008,1046],{"nctId":1048,"briefTitle":1049,"status":280,"phases":1140,"primaryCompletion":1051,"completion":1051,"start":481,"enrollment":25,"conditions":1141,"interventions":1142},[87],[1053],[1008,1046],{"trials":1144,"activeCount":1055,"soonestReadout":202},[1145,1149,1160,1164,1168,1172],{"nctId":1072,"briefTitle":1073,"status":157,"phases":1146,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1147,"interventions":1148},[87,88],[1041,1042,321,30,1043],[1008,1046,1045],{"nctId":1150,"briefTitle":1151,"status":157,"phases":1152,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1159},"NCT06753747","A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma",[87,88],"2027-09","2028-09","2025-09-10",45,[1158],"Esophagus Cancer",[924,1046,1046,1046],{"nctId":1091,"briefTitle":1092,"status":157,"phases":1161,"primaryCompletion":202,"completion":202,"start":1094,"enrollment":1095,"conditions":1162,"interventions":1163},[88],[18,1097,30,1043],[1008,1046],{"nctId":1100,"briefTitle":1101,"status":1102,"phases":1165,"primaryCompletion":856,"completion":856,"start":1104,"enrollment":99,"conditions":1166,"interventions":1167},[88],[1053],[1008,1046],{"nctId":1108,"briefTitle":1109,"status":280,"phases":1169,"primaryCompletion":60,"completion":481,"start":1111,"enrollment":1112,"conditions":1170,"interventions":1171},[88],[1053],[1008,1046],{"nctId":1116,"briefTitle":1117,"status":280,"phases":1173,"primaryCompletion":1119,"completion":248,"start":1120,"enrollment":319,"conditions":1174,"interventions":1175},[88],[18],[956,980,1008,1046],{"trials":1177,"activeCount":99},[],{"trials":1179,"activeCount":99},[],{"trials":1181,"activeCount":99},[],{"intervention":955,"totalTrials":1183,"cells":1184},5,{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1245,"PHASE4":1247,"NA":1249},{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[],{"trials":1190,"activeCount":1055,"soonestReadout":60},[1191,1195,1205,1225,1241],{"nctId":58,"briefTitle":59,"status":157,"phases":1192,"primaryCompletion":60,"completion":560,"start":950,"enrollment":951,"conditions":1193,"interventions":1194},[88],[953],[56,955,956,957,958],{"nctId":1196,"briefTitle":1197,"status":314,"phases":1198,"primaryCompletion":1199,"completion":1200,"start":1201,"enrollment":410,"conditions":1202,"interventions":1204},"NCT03390062","A Study of Apatinib in Recurrent or Recurrent High-grade Glioma",[88],"2019-12-20","2020-08-01","2018-01-04",[1203],"Glioma",[955],{"nctId":1206,"briefTitle":1207,"status":157,"phases":1208,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":1212,"interventions":1214},"NCT06482086","Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer",[88],"2024-12-01","2021-06-01",75,[1213],"Locally Advanced Thyroid Gland Carcinoma",[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],"Lenvatinib","Sorafenib","Donafenib","Everolimus","Dabrafenib + Trametinib","Cabozantinib","Vandetanib","Entrectinib","Pralsetinib","Larotrectinib",{"nctId":1226,"briefTitle":1227,"status":314,"phases":1228,"primaryCompletion":1229,"completion":1200,"start":1230,"enrollment":1231,"conditions":1232,"interventions":1236},"NCT03201146","Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC",[87,88],"2020-07-01","2017-06-27",48,[1233,1234,1235,955],"Lung Cancer","Non Small Cell Lung Cancer","Combination Chemotherapy",[955,1237,1238,1239,1240],"AP or AC","Apatinib 250mg","Apatinib 500mg","Apatinib 750mg",{"nctId":982,"briefTitle":983,"status":157,"phases":1242,"primaryCompletion":560,"completion":985,"start":986,"enrollment":987,"conditions":1243,"interventions":1244},[88],[989,990,991],[56,955,993],{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":99},[],{"trials":1250,"activeCount":99},[],{"intervention":1252,"totalTrials":291,"cells":1253},"Sintilimab",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1269,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1255,"activeCount":99},[],{"trials":1257,"activeCount":95,"soonestReadout":1262},[1258],{"nctId":1259,"briefTitle":1260,"status":157,"phases":1261,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":25,"conditions":1265,"interventions":1267},"NCT07457281","GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study",[87],"2027-04-01","2028-06-01","2026-04-01",[1266],"Head and Neck Squamous Cell Carcinoma HNSCC",[1268,1252],"GV20-0251",{"trials":1270,"activeCount":259,"soonestReadout":882},[1271,1282,1291],{"nctId":1272,"briefTitle":1273,"status":314,"phases":1274,"primaryCompletion":1275,"completion":1276,"start":976,"enrollment":1277,"conditions":1278,"interventions":1281},"NCT04146831","Sintilimab in FH-deficient Renal Cell Carcinoma",[88],"2022-06-01","2023-04-01",37,[1279,1280,1252],"Renal Cell Carcinoma","FH-deficient",[1252],{"nctId":1283,"briefTitle":1284,"status":157,"phases":1285,"primaryCompletion":1286,"completion":1287,"start":1288,"enrollment":1065,"conditions":1289,"interventions":1290},"NCT06664996","Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT",[88],"2025-10","2026-10","2024-10-15",[1031],[1252],{"nctId":1292,"briefTitle":1293,"status":157,"phases":1294,"primaryCompletion":882,"completion":882,"start":1295,"enrollment":484,"conditions":1296,"interventions":1300},"NCT04636008","Sintilimab Plus Hypofractionated Radiotherapy for MSI-H\u002FdMMR Rectal Cancer",[87,88],"2020-08-14",[1297,656,24,1298,1299],"Anti-PD-1 Antibody","MSI-H","Mmr Deficiency",[1252],{"trials":1302,"activeCount":99},[],{"trials":1304,"activeCount":99},[],{"trials":1306,"activeCount":99},[],{"intervention":1308,"totalTrials":1055,"cells":1309},"Bevacizumab",{"EARLY_PHASE1":1310,"PHASE1":1312,"PHASE2":1314,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"trials":1315,"activeCount":1055,"soonestReadout":1340},[1316,1327,1336],{"nctId":1317,"briefTitle":1318,"status":157,"phases":1319,"primaryCompletion":1320,"completion":1321,"start":74,"enrollment":1322,"conditions":1323,"interventions":1325},"NCT06742424","PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC",[88],"2027-04-30","2027-07-30",36,[1324],"Hepato Cellular Carcinoma (HCC)",[1326,1308],"PD-L1 antibody",{"nctId":1328,"briefTitle":1329,"status":111,"phases":1330,"primaryCompletion":1264,"completion":857,"start":1331,"enrollment":484,"conditions":1332,"interventions":1334},"NCT06341309","Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer",[87,88],"2024-08-09",[1333],"Metastatic Colorectal Cancer",[1335,1308],"Irinotecan Liposome",{"nctId":1337,"briefTitle":1338,"status":157,"phases":1339,"primaryCompletion":1340,"completion":1341,"start":1342,"enrollment":1343,"conditions":1344,"interventions":1345},"NCT06341296","Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer",[88],"2026-04","2026-12","2024-06-30",86,[1333],[1335,1346,1347,1308],"5-FU","LV",{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"intervention":924,"totalTrials":1055,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1364,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":95,"soonestReadout":918},[1360],{"nctId":915,"briefTitle":916,"status":200,"phases":1361,"primaryCompletion":918,"completion":919,"start":920,"enrollment":304,"conditions":1362,"interventions":1363},[87],[922],[56,924,924],{"trials":1365,"activeCount":259,"soonestReadout":1153},[1366,1370],{"nctId":960,"briefTitle":961,"status":111,"phases":1367,"primaryCompletion":963,"completion":964,"start":965,"enrollment":966,"conditions":1368,"interventions":1369},[88],[968],[56,924],{"nctId":1150,"briefTitle":1151,"status":157,"phases":1371,"primaryCompletion":1153,"completion":1154,"start":1155,"enrollment":1156,"conditions":1372,"interventions":1373},[87,88],[1158],[924,1046,1046,1046],{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"intervention":1381,"totalTrials":259,"cells":1382},"PD-1 inhibitor",{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1387,"PHASE3":1411,"PHASE4":1413,"NA":1415},{"trials":1384,"activeCount":99},[],{"trials":1386,"activeCount":99},[],{"trials":1388,"activeCount":259,"soonestReadout":1405},[1389,1401],{"nctId":1390,"briefTitle":1391,"status":157,"phases":1392,"primaryCompletion":1393,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1399},"NCT07182565","Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma",[87,88],"2029-08-31","2025-11-18",84,[1397,1398],"Gastroesophageal Junction Adenocarcinoma","Hypofractionated Radiotherapy",[1381,1400],"TS-1",{"nctId":1402,"briefTitle":1403,"status":157,"phases":1404,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1409},"NCT07072351","Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma",[87,88],"2028-05-14","2025-09-15",88,[1397,1398,30,660],[1410,1381],"SOX Chemotherapy",{"trials":1412,"activeCount":99},[],{"trials":1414,"activeCount":99},[],{"trials":1416,"activeCount":99},[],{"intervention":1045,"totalTrials":259,"cells":1418},{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1427,"PHASE3":1433,"PHASE4":1435,"NA":1437},{"trials":1420,"activeCount":99},[],{"trials":1422,"activeCount":95,"soonestReadout":1038},[1423],{"nctId":1035,"briefTitle":1036,"status":157,"phases":1424,"primaryCompletion":1038,"completion":1038,"start":1039,"enrollment":997,"conditions":1425,"interventions":1426},[87],[1041,1042,321,30,1043],[1045,1008,1046],{"trials":1428,"activeCount":95,"soonestReadout":1075},[1429],{"nctId":1072,"briefTitle":1073,"status":157,"phases":1430,"primaryCompletion":1075,"completion":1075,"start":1076,"enrollment":1077,"conditions":1431,"interventions":1432},[87,88],[1041,1042,321,30,1043],[1008,1046,1045],{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":99},[],{"intervention":1440,"totalTrials":259,"cells":1441},"Tagitanlimab",{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1470,"PHASE4":1472,"NA":1474},{"trials":1443,"activeCount":99},[],{"trials":1445,"activeCount":99},[],{"trials":1447,"activeCount":259,"soonestReadout":560},[1448,1460],{"nctId":1449,"briefTitle":1450,"status":111,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1458},"NCT07109284","SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+\u002FHER2- Breast Cancer",[88],"2028-01","2030-12","2025-09",55,[1457],"ER+HER2- Breast Cancer",[1459,1440],"Sacituzumab tirumotecan",{"nctId":1461,"briefTitle":1462,"status":157,"phases":1463,"primaryCompletion":560,"completion":1464,"start":1465,"enrollment":410,"conditions":1466,"interventions":1468},"NCT07492914","Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma",[88],"2031-03-31","2026-05-11",[1467],"Resectable Head and Neck Squamous Cell Carcinoma",[1469,1440],"Sacituzumab Govitecan",{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":99},[],{"intervention":1215,"totalTrials":259,"cells":1477},{"EARLY_PHASE1":1478,"PHASE1":1480,"PHASE2":1482,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1479,"activeCount":99},[],{"trials":1481,"activeCount":99},[],{"trials":1483,"activeCount":259,"soonestReadout":1209},[1484,1488],{"nctId":1206,"briefTitle":1207,"status":157,"phases":1485,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":1486,"interventions":1487},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"nctId":1489,"briefTitle":1490,"status":157,"phases":1491,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":1496,"interventions":1500},"NCT06859684","Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)",[88],"2026-09-06","2027-03-06","2025-03-01",25,[1497,1498,1499],"Intrahepatic Cholangiocarcinoma (Icc)","HAIC","Durvalumab",[1499,1501,1215],"hepatic arterial infusion chemotherapy",{"trials":1503,"activeCount":99},[],{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"intervention":1335,"totalTrials":259,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":259,"soonestReadout":1340},[1516,1520],{"nctId":1328,"briefTitle":1329,"status":111,"phases":1517,"primaryCompletion":1264,"completion":857,"start":1331,"enrollment":484,"conditions":1518,"interventions":1519},[87,88],[1333],[1335,1308],{"nctId":1337,"briefTitle":1338,"status":157,"phases":1521,"primaryCompletion":1340,"completion":1341,"start":1342,"enrollment":1343,"conditions":1522,"interventions":1523},[88],[1333],[1335,1346,1347,1308],{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":99},[],{"trials":1529,"activeCount":99},[],{"intervention":1531,"totalTrials":259,"cells":1532},"Engineered mitochondrial vaccine",{"EARLY_PHASE1":1533,"PHASE1":1535,"PHASE2":1546,"PHASE3":1558,"PHASE4":1560,"NA":1562},{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":95,"soonestReadout":560},[1537],{"nctId":1538,"briefTitle":1539,"status":157,"phases":1540,"primaryCompletion":560,"completion":301,"start":1541,"enrollment":939,"conditions":1542,"interventions":1545},"NCT06927297","Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors",[87],"2025-05-09",[1543,1544],"Advanced Solid Tumor Malignancies","Advanced Solid Malignancies",[1531],{"trials":1547,"activeCount":95,"soonestReadout":1552},[1548],{"nctId":1549,"briefTitle":1550,"status":157,"phases":1551,"primaryCompletion":1552,"completion":1553,"start":303,"enrollment":25,"conditions":1554,"interventions":1555},"NCT07572864","Neoadjuvant ICI and Mitochondrial Vaccine for Resectable HNSCC",[88],"2027-05-01","2028-05-01",[18],[1556,1557],"Engineered Mitochondrial Vaccine","Immune checkpoint inhibitor",{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":99},[],{"trials":1563,"activeCount":99},[],{"intervention":375,"totalTrials":259,"cells":1565},{"EARLY_PHASE1":1566,"PHASE1":1568,"PHASE2":1570,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1567,"activeCount":99},[],{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":259,"soonestReadout":1576},[1572,1581],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1575,"primaryCompletion":1576,"completion":1577,"start":1029,"enrollment":22,"conditions":1578,"interventions":1580},"NCT07075419","JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure",[87,88],"2027-07-01","2027-08-01",[1579],"Refractory Hepatocellular Carcinoma",[375,488],{"nctId":365,"briefTitle":366,"status":111,"phases":1582,"primaryCompletion":368,"completion":369,"start":370,"enrollment":22,"conditions":1583,"interventions":1584},[87,88],[372,373],[375,356],{"trials":1586,"activeCount":99},[],{"trials":1588,"activeCount":99},[],{"trials":1590,"activeCount":99},[],{"intervention":980,"totalTrials":1055,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1597,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":95,"soonestReadout":1607},[1599,1603,1615],{"nctId":971,"briefTitle":972,"status":314,"phases":1600,"primaryCompletion":974,"completion":975,"start":976,"enrollment":9,"conditions":1601,"interventions":1602},[88],[978],[56,980],{"nctId":1604,"briefTitle":1605,"status":157,"phases":1606,"primaryCompletion":1607,"completion":202,"start":1608,"enrollment":1609,"conditions":1610,"interventions":1612},"NCT05978609","Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer",[88],"2025-07-01","2023-07-01",65,[1611],"Cholangiocarcinoma Non-resectable",[1613,980,1614],"Candonilimab","Gemcitabine",{"nctId":1116,"briefTitle":1117,"status":280,"phases":1616,"primaryCompletion":1119,"completion":248,"start":1120,"enrollment":319,"conditions":1617,"interventions":1618},[88],[18],[956,980,1008,1046],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[],{"intervention":1626,"totalTrials":259,"cells":1627},"Adebrelimab",{"EARLY_PHASE1":1628,"PHASE1":1630,"PHASE2":1640,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1629,"activeCount":99},[],{"trials":1631,"activeCount":99},[1632],{"nctId":1633,"briefTitle":1634,"status":314,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":304,"conditions":1638,"interventions":1639},"NCT06225921","Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas",[87],"2025-01-15","2023-12-29",[922],[1626,930,931],{"trials":1641,"activeCount":95,"soonestReadout":1646},[1642],{"nctId":1643,"briefTitle":1644,"status":111,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1322,"conditions":1648,"interventions":1649},"NCT06373133","SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer",[87,88],"2026-11-01","2024-05-01",[15],[1650,1626,1651],"SHR-8068","BP102",{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"trials":1657,"activeCount":99},[],{"intervention":956,"totalTrials":259,"cells":1659},{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1661,"activeCount":99},[],{"trials":1663,"activeCount":99},[],{"trials":1665,"activeCount":95,"soonestReadout":60},[1666,1670],{"nctId":58,"briefTitle":59,"status":157,"phases":1667,"primaryCompletion":60,"completion":560,"start":950,"enrollment":951,"conditions":1668,"interventions":1669},[88],[953],[56,955,956,957,958],{"nctId":1116,"briefTitle":1117,"status":280,"phases":1671,"primaryCompletion":1119,"completion":248,"start":1120,"enrollment":319,"conditions":1672,"interventions":1673},[88],[18],[956,980,1008,1046],{"trials":1675,"activeCount":99},[],{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"intervention":1089,"totalTrials":259,"cells":1681},{"EARLY_PHASE1":1682,"PHASE1":1684,"PHASE2":1686,"PHASE3":1696,"PHASE4":1698,"NA":1700},{"trials":1683,"activeCount":99},[],{"trials":1685,"activeCount":99},[],{"trials":1687,"activeCount":95,"soonestReadout":1209},[1688,1692],{"nctId":1081,"briefTitle":1082,"status":314,"phases":1689,"primaryCompletion":1084,"completion":1085,"start":872,"enrollment":484,"conditions":1690,"interventions":1691},[88],[1087],[1008,1089],{"nctId":1206,"briefTitle":1207,"status":157,"phases":1693,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":1694,"interventions":1695},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":1697,"activeCount":99},[],{"trials":1699,"activeCount":99},[],{"trials":1701,"activeCount":99},[],{"intervention":488,"totalTrials":259,"cells":1703},{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1708,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1705,"activeCount":99},[],{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":95,"soonestReadout":1576},[1710,1714],{"nctId":478,"briefTitle":479,"status":314,"phases":1711,"primaryCompletion":481,"completion":482,"start":483,"enrollment":484,"conditions":1712,"interventions":1713},[88],[486],[349,488],{"nctId":1573,"briefTitle":1574,"status":111,"phases":1715,"primaryCompletion":1576,"completion":1577,"start":1029,"enrollment":22,"conditions":1716,"interventions":1717},[87,88],[1579],[375,488],{"trials":1719,"activeCount":99},[],{"trials":1721,"activeCount":99},[],{"trials":1723,"activeCount":99},[],{"intervention":1725,"totalTrials":259,"cells":1726},"XELOX",{"EARLY_PHASE1":1727,"PHASE1":1729,"PHASE2":1731,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":95,"soonestReadout":113},[1733,1742],{"nctId":1734,"briefTitle":1735,"status":157,"phases":1736,"primaryCompletion":113,"completion":560,"start":1737,"enrollment":563,"conditions":1738,"interventions":1740},"NCT06242418","CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)",[88],"2024-03-25",[1739],"Colon Cancer",[1741,1725],"FOLFOXIRI",{"nctId":1743,"briefTitle":1744,"status":280,"phases":1745,"primaryCompletion":1746,"completion":1747,"start":464,"enrollment":1748,"conditions":1749,"interventions":1750},"NCT03666442","Early Evaluation of Chemosensitivity for Low\u002FIntermediated-risk Mid-low Stage II\u002FIII Rectal Cancer",[88],"2020-01-01","2022-01-01",61,[24],[1725],{"trials":1752,"activeCount":99},[],{"trials":1754,"activeCount":99},[],{"trials":1756,"activeCount":99},[],{"intervention":1758,"totalTrials":95,"cells":1759},"Ensartinib",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1775,"PHASE4":1777,"NA":1779},{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":95,"soonestReadout":1770},[1766],{"nctId":1767,"briefTitle":1768,"status":111,"phases":1769,"primaryCompletion":1770,"completion":1771,"start":1636,"enrollment":1065,"conditions":1772,"interventions":1774},"NCT06779539","Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer",[88],"2028-06-12","2030-12-12",[1773],"Non-Small Cell Lung Cancer",[1758],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[],{"trials":1780,"activeCount":99},[],{"intervention":1782,"totalTrials":95,"cells":1783},"H101",{"EARLY_PHASE1":1784,"PHASE1":1786,"PHASE2":1788,"PHASE3":1801,"PHASE4":1803,"NA":1805},{"trials":1785,"activeCount":99},[],{"trials":1787,"activeCount":99},[],{"trials":1789,"activeCount":95,"soonestReadout":1794},[1790],{"nctId":1791,"briefTitle":1792,"status":111,"phases":1793,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":484,"conditions":1797,"interventions":1800},"NCT07398664","H101 Plus TACE for r\u002Fm HNSCC",[88],"2027-02-15","2028-02-15","2026-02-15",[18,1798,1799],"Oncolytic Virus","TACE",[1782],{"trials":1802,"activeCount":99},[],{"trials":1804,"activeCount":99},[],{"trials":1806,"activeCount":99},[],{"intervention":1808,"totalTrials":95,"cells":1809},"Chemotherapy plus sintilimab and bevacizumab",{"EARLY_PHASE1":1810,"PHASE1":1812,"PHASE2":1814,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1811,"activeCount":99},[],{"trials":1813,"activeCount":99},[],{"trials":1815,"activeCount":95,"soonestReadout":1820},[1816],{"nctId":1817,"briefTitle":1818,"status":200,"phases":1819,"primaryCompletion":1820,"completion":1821,"start":1822,"enrollment":1823,"conditions":1824,"interventions":1826},"NCT06667050","CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer",[88],"2026-10-31","2027-10-31","2024-10-10",58,[1825],"Gastric Adenocarcinoma",[1808],{"trials":1828,"activeCount":99},[],{"trials":1830,"activeCount":99},[],{"trials":1832,"activeCount":99},[],{"intervention":1834,"totalTrials":95,"cells":1835},"Qingying oral liquid and modified Da Huang-Huang Lian Xiexin mouthwash",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1852,"PHASE4":1854,"NA":1856},{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":95,"soonestReadout":1846},[1842],{"nctId":1843,"briefTitle":1844,"status":157,"phases":1845,"primaryCompletion":1846,"completion":1820,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT07282483","Traditional Chinese Medicine Oral Liquids and Mouthwashes for Radiation-induced Oral Mucositis in Head and Neck Cancer Patients",[88],"2026-08-31","2026-03-16",118,[1850],"Radiation-induced Oral Mucositis",[1834],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[],{"trials":1857,"activeCount":99},[],{"intervention":1326,"totalTrials":95,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1870,"PHASE4":1872,"NA":1874},{"trials":1861,"activeCount":99},[],{"trials":1863,"activeCount":99},[],{"trials":1865,"activeCount":95,"soonestReadout":1320},[1866],{"nctId":1317,"briefTitle":1318,"status":157,"phases":1867,"primaryCompletion":1320,"completion":1321,"start":74,"enrollment":1322,"conditions":1868,"interventions":1869},[88],[1324],[1326,1308],{"trials":1871,"activeCount":99},[],{"trials":1873,"activeCount":99},[],{"trials":1875,"activeCount":99},[],{"intervention":1877,"totalTrials":95,"cells":1878},"NALIRIFOX+Adebrelimab",{"EARLY_PHASE1":1879,"PHASE1":1881,"PHASE2":1883,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"trials":1884,"activeCount":95,"soonestReadout":1889},[1885],{"nctId":1886,"briefTitle":1887,"status":157,"phases":1888,"primaryCompletion":1889,"completion":1890,"start":1340,"enrollment":1455,"conditions":1891,"interventions":1894},"NCT07595172","NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer",[87,88],"2028-08","2029-03",[1892,1893],"Pancreatic Ductal Adenocarcinoma (PDAC)","Locally Advanced and Metastatic Pancreatic Cancer",[1877],{"trials":1896,"activeCount":99},[],{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"intervention":1902,"totalTrials":95,"cells":1903},"Trametinib",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":95,"soonestReadout":1576},[1910],{"nctId":1911,"briefTitle":1912,"status":200,"phases":1913,"primaryCompletion":1576,"completion":368,"start":1914,"enrollment":484,"conditions":1915,"interventions":1917},"NCT07072403","Trametinib Treatment for Complicated Vascular Anomalies",[87,88],"2025-07-07",[1916],"Vascular Anomalies",[1902],{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":99},[],{"intervention":957,"totalTrials":95,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1930,"PHASE3":1936,"PHASE4":1938,"NA":1940},{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":95,"soonestReadout":60},[1932],{"nctId":58,"briefTitle":59,"status":157,"phases":1933,"primaryCompletion":60,"completion":560,"start":950,"enrollment":951,"conditions":1934,"interventions":1935},[88],[953],[56,955,956,957,958],{"trials":1937,"activeCount":99},[],{"trials":1939,"activeCount":99},[],{"trials":1941,"activeCount":99},[],{"intervention":958,"totalTrials":95,"cells":1943},{"EARLY_PHASE1":1944,"PHASE1":1946,"PHASE2":1948,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1945,"activeCount":99},[],{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":95,"soonestReadout":60},[1950],{"nctId":58,"briefTitle":59,"status":157,"phases":1951,"primaryCompletion":60,"completion":560,"start":950,"enrollment":951,"conditions":1952,"interventions":1953},[88],[953],[56,955,956,957,958],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"trials":1959,"activeCount":99},[],{"intervention":1400,"totalTrials":95,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1966,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[],{"trials":1967,"activeCount":95,"soonestReadout":1393},[1968],{"nctId":1390,"briefTitle":1391,"status":157,"phases":1969,"primaryCompletion":1393,"completion":1393,"start":1394,"enrollment":1395,"conditions":1970,"interventions":1971},[87,88],[1397,1398],[1381,1400],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"intervention":1979,"totalTrials":95,"cells":1980},"Zishui Daohuo oral liquid combined with Kujiu mouthwash",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1996,"PHASE4":1998,"NA":2000},{"trials":1982,"activeCount":99},[],{"trials":1984,"activeCount":99},[],{"trials":1986,"activeCount":95,"soonestReadout":1820},[1987],{"nctId":1988,"briefTitle":1989,"status":157,"phases":1990,"primaryCompletion":1820,"completion":449,"start":1991,"enrollment":1992,"conditions":1993,"interventions":1995},"NCT07339774","Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients.",[88],"2026-03-30",128,[1994],"Radiotherapy-induced Oral Mucositis",[1979],{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"intervention":2003,"totalTrials":95,"cells":2004},"JWK006",{"EARLY_PHASE1":2005,"PHASE1":2007,"PHASE2":2009,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[],{"trials":2010,"activeCount":95,"soonestReadout":449},[2011],{"nctId":2012,"briefTitle":2013,"status":200,"phases":2014,"primaryCompletion":449,"completion":2015,"start":2016,"enrollment":25,"conditions":2017,"interventions":2019},"NCT06300476","Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)",[87,88],"2029-12-30","2023-11-20",[2018],"Stargardt Disease 1",[2003],{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"intervention":2027,"totalTrials":95,"cells":2028},"Nab-paclitaxel Combined With Cadonilimab",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2044,"PHASE4":2046,"NA":2048},{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":95,"soonestReadout":1320},[2035],{"nctId":2036,"briefTitle":2037,"status":111,"phases":2038,"primaryCompletion":1320,"completion":2039,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2043},"NCT06349967","Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer",[88],"2027-05-30","2024-04-30",59,[32],[2027],{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"intervention":2051,"totalTrials":95,"cells":2052},"Becotatug Vedotin",{"EARLY_PHASE1":2053,"PHASE1":2055,"PHASE2":2057,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[],{"trials":2058,"activeCount":95,"soonestReadout":2063},[2059],{"nctId":2060,"briefTitle":2061,"status":111,"phases":2062,"primaryCompletion":2063,"completion":2064,"start":2065,"enrollment":440,"conditions":2066,"interventions":2067},"NCT07381075","A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma",[88],"2028-10-01","2029-06-01","2026-02-01",[18],[2051,2068,2069],"Becotatug Vedotin Combined with Penpulimab","Becotatug Vedotin Combined with Ivonescimab",{"trials":2071,"activeCount":99},[],{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"intervention":2068,"totalTrials":95,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2079,"activeCount":99},[],{"trials":2081,"activeCount":99},[],{"trials":2083,"activeCount":95,"soonestReadout":2063},[2084],{"nctId":2060,"briefTitle":2061,"status":111,"phases":2085,"primaryCompletion":2063,"completion":2064,"start":2065,"enrollment":440,"conditions":2086,"interventions":2087},[88],[18],[2051,2068,2069],{"trials":2089,"activeCount":99},[],{"trials":2091,"activeCount":99},[],{"trials":2093,"activeCount":99},[],{"intervention":2069,"totalTrials":95,"cells":2095},{"EARLY_PHASE1":2096,"PHASE1":2098,"PHASE2":2100,"PHASE3":2106,"PHASE4":2108,"NA":2110},{"trials":2097,"activeCount":99},[],{"trials":2099,"activeCount":99},[],{"trials":2101,"activeCount":95,"soonestReadout":2063},[2102],{"nctId":2060,"briefTitle":2061,"status":111,"phases":2103,"primaryCompletion":2063,"completion":2064,"start":2065,"enrollment":440,"conditions":2104,"interventions":2105},[88],[18],[2051,2068,2069],{"trials":2107,"activeCount":99},[],{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"intervention":2113,"totalTrials":95,"cells":2114},"Selumetinib",{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2131,"PHASE4":2133,"NA":2135},{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":95,"soonestReadout":651},[2121],{"nctId":2122,"briefTitle":2123,"status":111,"phases":2124,"primaryCompletion":651,"completion":2125,"start":2126,"enrollment":2127,"conditions":2128,"interventions":2130},"NCT06763315","Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children",[88],"2028-10-31","2025-01-01",50,[2129],"Plexiform Neurofibromas (PN)",[2113],{"trials":2132,"activeCount":99},[],{"trials":2134,"activeCount":99},[],{"trials":2136,"activeCount":99},[],{"intervention":1459,"totalTrials":95,"cells":2138},{"EARLY_PHASE1":2139,"PHASE1":2141,"PHASE2":2143,"PHASE3":2149,"PHASE4":2151,"NA":2153},{"trials":2140,"activeCount":99},[],{"trials":2142,"activeCount":99},[],{"trials":2144,"activeCount":95,"soonestReadout":1452},[2145],{"nctId":1449,"briefTitle":1450,"status":111,"phases":2146,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":1455,"conditions":2147,"interventions":2148},[88],[1457],[1459,1440],{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[],{"intervention":1650,"totalTrials":95,"cells":2156},{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2167,"PHASE4":2169,"NA":2171},{"trials":2158,"activeCount":99},[],{"trials":2160,"activeCount":99},[],{"trials":2162,"activeCount":95,"soonestReadout":1646},[2163],{"nctId":1643,"briefTitle":1644,"status":111,"phases":2164,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1322,"conditions":2165,"interventions":2166},[87,88],[15],[1650,1626,1651],{"trials":2168,"activeCount":99},[],{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"intervention":1651,"totalTrials":95,"cells":2174},{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2185,"PHASE4":2187,"NA":2189},{"trials":2176,"activeCount":99},[],{"trials":2178,"activeCount":99},[],{"trials":2180,"activeCount":95,"soonestReadout":1646},[2181],{"nctId":1643,"briefTitle":1644,"status":111,"phases":2182,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1322,"conditions":2183,"interventions":2184},[87,88],[15],[1650,1626,1651],{"trials":2186,"activeCount":99},[],{"trials":2188,"activeCount":99},[],{"trials":2190,"activeCount":99},[],{"intervention":2192,"totalTrials":95,"cells":2193},"Bleomycin",{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":95,"soonestReadout":113},[2200],{"nctId":2201,"briefTitle":2202,"status":157,"phases":2203,"primaryCompletion":113,"completion":560,"start":2204,"enrollment":2205,"conditions":2206,"interventions":2207},"NCT06437158","Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients",[88],"2023-03-08",200,[453],[2192],{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[],{"intervention":2215,"totalTrials":95,"cells":2216},"Hydrogel of spirulina-derived exosomes.",{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2221,"PHASE3":2233,"PHASE4":2235,"NA":2237},{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":95,"soonestReadout":856},[2223],{"nctId":2224,"briefTitle":2225,"status":111,"phases":2226,"primaryCompletion":856,"completion":1846,"start":2227,"enrollment":2228,"conditions":2229,"interventions":2231},"NCT07324018","Spirulina Derivative for Radiation Esophagitis",[88],"2026-01-12",70,[2230],"Radiation-induced Esophagitis",[2215,2232],"Hydrogel of placebo",{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[],{"intervention":2232,"totalTrials":95,"cells":2240},{"EARLY_PHASE1":2241,"PHASE1":2243,"PHASE2":2245,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2242,"activeCount":99},[],{"trials":2244,"activeCount":99},[],{"trials":2246,"activeCount":95,"soonestReadout":856},[2247],{"nctId":2224,"briefTitle":2225,"status":111,"phases":2248,"primaryCompletion":856,"completion":1846,"start":2227,"enrollment":2228,"conditions":2249,"interventions":2250},[88],[2230],[2215,2232],{"trials":2252,"activeCount":99},[],{"trials":2254,"activeCount":99},[],{"trials":2256,"activeCount":99},[],{"intervention":1469,"totalTrials":95,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":95,"soonestReadout":560},[2265],{"nctId":1461,"briefTitle":1462,"status":157,"phases":2266,"primaryCompletion":560,"completion":1464,"start":1465,"enrollment":410,"conditions":2267,"interventions":2268},[88],[1467],[1469,1440],{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[],{"trials":2274,"activeCount":99},[],{"intervention":2276,"totalTrials":95,"cells":2277},"RC48-ADC",{"EARLY_PHASE1":2278,"PHASE1":2280,"PHASE2":2282,"PHASE3":2295,"PHASE4":2297,"NA":2299},{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":95,"soonestReadout":2288},[2284],{"nctId":2285,"briefTitle":2286,"status":111,"phases":2287,"primaryCompletion":2288,"completion":2289,"start":2290,"enrollment":2291,"conditions":2292,"interventions":2294},"NCT05996952","RC48-ADC in Adjuvant\u002FSalvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer",[88],"2025-08","2026-08","2023-08",77,[2293],"Non-muscle Invasive Bladder Cancer",[2276],{"trials":2296,"activeCount":99},[],{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"intervention":2302,"totalTrials":95,"cells":2303},"Spray of spirulina derivatives",{"EARLY_PHASE1":2304,"PHASE1":2306,"PHASE2":2308,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":95,"soonestReadout":2314},[2310],{"nctId":2311,"briefTitle":2312,"status":200,"phases":2313,"primaryCompletion":2314,"completion":2315,"start":2316,"enrollment":2228,"conditions":2317,"interventions":2318},"NCT07040969","Spirulina-Derived Product Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors",[88],"2026-01-15","2026-04-30","2025-06-27",[1850],[2302,2319],"Spray of placebo",{"trials":2321,"activeCount":99},[],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"intervention":2319,"totalTrials":95,"cells":2327},{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2338,"PHASE4":2340,"NA":2342},{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"trials":2333,"activeCount":95,"soonestReadout":2314},[2334],{"nctId":2311,"briefTitle":2312,"status":200,"phases":2335,"primaryCompletion":2314,"completion":2315,"start":2316,"enrollment":2228,"conditions":2336,"interventions":2337},[88],[1850],[2302,2319],{"trials":2339,"activeCount":99},[],{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[],{"intervention":1216,"totalTrials":95,"cells":2345},{"EARLY_PHASE1":2346,"PHASE1":2348,"PHASE2":2350,"PHASE3":2356,"PHASE4":2358,"NA":2360},{"trials":2347,"activeCount":99},[],{"trials":2349,"activeCount":99},[],{"trials":2351,"activeCount":95,"soonestReadout":1209},[2352],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2353,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2354,"interventions":2355},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2357,"activeCount":99},[],{"trials":2359,"activeCount":99},[],{"trials":2361,"activeCount":99},[],{"intervention":1217,"totalTrials":95,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2365,"activeCount":99},[],{"trials":2367,"activeCount":99},[],{"trials":2369,"activeCount":95,"soonestReadout":1209},[2370],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2371,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2372,"interventions":2373},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2375,"activeCount":99},[],{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"intervention":1218,"totalTrials":95,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[],{"trials":2387,"activeCount":95,"soonestReadout":1209},[2388],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2389,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2390,"interventions":2391},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2393,"activeCount":99},[],{"trials":2395,"activeCount":99},[],{"trials":2397,"activeCount":99},[],{"intervention":1219,"totalTrials":95,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":95,"soonestReadout":1209},[2406],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2407,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2408,"interventions":2409},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2411,"activeCount":99},[],{"trials":2413,"activeCount":99},[],{"trials":2415,"activeCount":99},[],{"intervention":1220,"totalTrials":95,"cells":2417},{"EARLY_PHASE1":2418,"PHASE1":2420,"PHASE2":2422,"PHASE3":2428,"PHASE4":2430,"NA":2432},{"trials":2419,"activeCount":99},[],{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":95,"soonestReadout":1209},[2424],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2425,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2426,"interventions":2427},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"intervention":1221,"totalTrials":95,"cells":2435},{"EARLY_PHASE1":2436,"PHASE1":2438,"PHASE2":2440,"PHASE3":2446,"PHASE4":2448,"NA":2450},{"trials":2437,"activeCount":99},[],{"trials":2439,"activeCount":99},[],{"trials":2441,"activeCount":95,"soonestReadout":1209},[2442],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2443,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2444,"interventions":2445},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2447,"activeCount":99},[],{"trials":2449,"activeCount":99},[],{"trials":2451,"activeCount":99},[],{"intervention":1222,"totalTrials":95,"cells":2453},{"EARLY_PHASE1":2454,"PHASE1":2456,"PHASE2":2458,"PHASE3":2464,"PHASE4":2466,"NA":2468},{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":95,"soonestReadout":1209},[2460],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2461,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2462,"interventions":2463},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2465,"activeCount":99},[],{"trials":2467,"activeCount":99},[],{"trials":2469,"activeCount":99},[],{"intervention":1223,"totalTrials":95,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2482,"PHASE4":2484,"NA":2486},{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":95,"soonestReadout":1209},[2478],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2479,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2480,"interventions":2481},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2483,"activeCount":99},[],{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[],{"intervention":1224,"totalTrials":95,"cells":2489},{"EARLY_PHASE1":2490,"PHASE1":2492,"PHASE2":2494,"PHASE3":2500,"PHASE4":2502,"NA":2504},{"trials":2491,"activeCount":99},[],{"trials":2493,"activeCount":99},[],{"trials":2495,"activeCount":95,"soonestReadout":1209},[2496],{"nctId":1206,"briefTitle":1207,"status":157,"phases":2497,"primaryCompletion":1209,"completion":626,"start":1210,"enrollment":1211,"conditions":2498,"interventions":2499},[88],[1213],[1089,1215,1216,1217,1218,955,1219,1220,1221,1222,1223,1224],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[],{"intervention":2507,"totalTrials":95,"cells":2508},"AK117",{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2513,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2510,"activeCount":99},[],{"trials":2512,"activeCount":99},[],{"trials":2514,"activeCount":95,"soonestReadout":857},[2515],{"nctId":2516,"briefTitle":2517,"status":111,"phases":2518,"primaryCompletion":857,"completion":1577,"start":2519,"enrollment":22,"conditions":2520,"interventions":2521},"NCT06508606","AK117 (Anti-CD47) + Anti-EGFR for R\u002FM HNSCC",[88],"2024-08-01",[18],[2507,2522],"anti-EGFR",{"trials":2524,"activeCount":99},[],{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[],{"intervention":2522,"totalTrials":95,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2532,"activeCount":99},[],{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":95,"soonestReadout":857},[2537],{"nctId":2516,"briefTitle":2517,"status":111,"phases":2538,"primaryCompletion":857,"completion":1577,"start":2519,"enrollment":22,"conditions":2539,"interventions":2540},[88],[18],[2507,2522],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"intervention":2548,"totalTrials":95,"cells":2549},"ttrium-90 microspheres in combination with nivolumab, ipilimumab, and lenvatinib in patients with unresectable hepatocellular carcinoma",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":95,"soonestReadout":856},[2556],{"nctId":2557,"briefTitle":2558,"status":157,"phases":2559,"primaryCompletion":856,"completion":761,"start":384,"enrollment":1065,"conditions":2560,"interventions":2562},"NCT07482059","A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma",[87,88],[2561],"Unresectable Hepatocellular Carcinoma",[2548],{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[],{"intervention":2570,"totalTrials":95,"cells":2571},"Spermidine",{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2576,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2573,"activeCount":99},[],{"trials":2575,"activeCount":99},[],{"trials":2577,"activeCount":95,"soonestReadout":2582},[2578],{"nctId":2579,"briefTitle":2580,"status":157,"phases":2581,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":1823,"conditions":2584,"interventions":2586},"NCT07035626","A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)",[87,88],"2026-06-08","2025-06-25",[2585],"Radiation-induced Xerostomia",[2570,2587],"Spermidine simulants",{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[],{"intervention":2587,"totalTrials":95,"cells":2595},{"EARLY_PHASE1":2596,"PHASE1":2598,"PHASE2":2600,"PHASE3":2606,"PHASE4":2608,"NA":2610},{"trials":2597,"activeCount":99},[],{"trials":2599,"activeCount":99},[],{"trials":2601,"activeCount":95,"soonestReadout":2582},[2602],{"nctId":2579,"briefTitle":2580,"status":157,"phases":2603,"primaryCompletion":2582,"completion":2582,"start":2583,"enrollment":1823,"conditions":2604,"interventions":2605},[87,88],[2585],[2570,2587],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[],{"intervention":2613,"totalTrials":95,"cells":2614},"LICSBR",{"EARLY_PHASE1":2615,"PHASE1":2617,"PHASE2":2619,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[],{"trials":2620,"activeCount":95,"soonestReadout":2625},[2621],{"nctId":2622,"briefTitle":2623,"status":157,"phases":2624,"primaryCompletion":2625,"completion":2626,"start":2627,"enrollment":1112,"conditions":2628,"interventions":2630},"NCT07101679","A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer",[88],"2027-04-15","2029-04-15","2025-04-16",[2629],"Locally Advanced Pancreatic Ductal Adenocarcinoma",[2613],{"trials":2632,"activeCount":99},[],{"trials":2634,"activeCount":99},[],{"trials":2636,"activeCount":99},[],{"intervention":1613,"totalTrials":95,"cells":2638},{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":95,"soonestReadout":1607},[2645],{"nctId":1604,"briefTitle":1605,"status":157,"phases":2646,"primaryCompletion":1607,"completion":202,"start":1608,"enrollment":1609,"conditions":2647,"interventions":2648},[88],[1611],[1613,980,1614],{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"intervention":1614,"totalTrials":95,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":95,"soonestReadout":1607},[2663],{"nctId":1604,"briefTitle":1605,"status":157,"phases":2664,"primaryCompletion":1607,"completion":202,"start":1608,"enrollment":1609,"conditions":2665,"interventions":2666},[88],[1611],[1613,980,1614],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"intervention":993,"totalTrials":95,"cells":2674},{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2685,"PHASE4":2687,"NA":2689},{"trials":2676,"activeCount":99},[],{"trials":2678,"activeCount":99},[],{"trials":2680,"activeCount":95,"soonestReadout":560},[2681],{"nctId":982,"briefTitle":983,"status":157,"phases":2682,"primaryCompletion":560,"completion":985,"start":986,"enrollment":987,"conditions":2683,"interventions":2684},[88],[989,990,991],[56,955,993],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"intervention":2692,"totalTrials":95,"cells":2693},"Cyclophosphamide+Pemetrexed+5-Fluorouracil",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2698,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[],{"trials":2699,"activeCount":95,"soonestReadout":626},[2700],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2703,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2704,"interventions":2705},"NCT06713057","Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer",[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],"Cyclophosphamide+Doxorubicin+5-Fluorouracil","Vindesine + Cisplatin","Doxorubicin + Cisplatin","Doxorubicin + Cyclophosphamide + Cisplatin","Docetaxel + Doxorubicin","Paclitaxel + Carboplatin","Paclitaxel + Doxorubicin","Paclitaxel + Cisplatin","Gemcitabine alone",{"trials":2716,"activeCount":99},[],{"trials":2718,"activeCount":99},[],{"trials":2720,"activeCount":99},[],{"intervention":2706,"totalTrials":95,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"trials":2728,"activeCount":95,"soonestReadout":626},[2729],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2730,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2731,"interventions":2732},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2734,"activeCount":99},[],{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"intervention":2707,"totalTrials":95,"cells":2740},{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2742,"activeCount":99},[],{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":95,"soonestReadout":626},[2747],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2748,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2749,"interventions":2750},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[],{"trials":2756,"activeCount":99},[],{"intervention":2708,"totalTrials":95,"cells":2758},{"EARLY_PHASE1":2759,"PHASE1":2761,"PHASE2":2763,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":95,"soonestReadout":626},[2765],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2766,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2767,"interventions":2768},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"intervention":2709,"totalTrials":95,"cells":2776},{"EARLY_PHASE1":2777,"PHASE1":2779,"PHASE2":2781,"PHASE3":2787,"PHASE4":2789,"NA":2791},{"trials":2778,"activeCount":99},[],{"trials":2780,"activeCount":99},[],{"trials":2782,"activeCount":95,"soonestReadout":626},[2783],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2784,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2785,"interventions":2786},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2788,"activeCount":99},[],{"trials":2790,"activeCount":99},[],{"trials":2792,"activeCount":99},[],{"intervention":2710,"totalTrials":95,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2796,"activeCount":99},[],{"trials":2798,"activeCount":99},[],{"trials":2800,"activeCount":95,"soonestReadout":626},[2801],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2802,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2803,"interventions":2804},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"intervention":2711,"totalTrials":95,"cells":2812},{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2814,"activeCount":99},[],{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":95,"soonestReadout":626},[2819],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2820,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2821,"interventions":2822},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[],{"trials":2828,"activeCount":99},[],{"intervention":2712,"totalTrials":95,"cells":2830},{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2841,"PHASE4":2843,"NA":2845},{"trials":2832,"activeCount":99},[],{"trials":2834,"activeCount":99},[],{"trials":2836,"activeCount":95,"soonestReadout":626},[2837],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2838,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2839,"interventions":2840},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[],{"intervention":2713,"totalTrials":95,"cells":2848},{"EARLY_PHASE1":2849,"PHASE1":2851,"PHASE2":2853,"PHASE3":2859,"PHASE4":2861,"NA":2863},{"trials":2850,"activeCount":99},[],{"trials":2852,"activeCount":99},[],{"trials":2854,"activeCount":95,"soonestReadout":626},[2855],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2856,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2857,"interventions":2858},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[],{"intervention":2714,"totalTrials":95,"cells":2866},{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2877,"PHASE4":2879,"NA":2881},{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":95,"soonestReadout":626},[2873],{"nctId":2701,"briefTitle":2702,"status":111,"phases":2874,"primaryCompletion":626,"completion":202,"start":1209,"enrollment":484,"conditions":2875,"interventions":2876},[88],[1213,1087],[2692,2706,2707,2708,2709,2710,2711,2712,2713,2714],{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[],{"intervention":2884,"totalTrials":95,"cells":2885},"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil",{"EARLY_PHASE1":2886,"PHASE1":2888,"PHASE2":2890,"PHASE3":2903,"PHASE4":2905,"NA":2907},{"trials":2887,"activeCount":99},[],{"trials":2889,"activeCount":99},[],{"trials":2891,"activeCount":95,"soonestReadout":2896},[2892],{"nctId":2893,"briefTitle":2894,"status":157,"phases":2895,"primaryCompletion":2896,"completion":2897,"start":2898,"enrollment":2899,"conditions":2900,"interventions":2902},"NCT06438822","Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma",[88],"2026-08-30","2026-11-30","2024-08-30",51,[2901],"Cholangiocarcinoma",[2884],{"trials":2904,"activeCount":99},[],{"trials":2906,"activeCount":99},[],{"trials":2908,"activeCount":99},[],{"intervention":1557,"totalTrials":95,"cells":2910},{"EARLY_PHASE1":2911,"PHASE1":2913,"PHASE2":2915,"PHASE3":2921,"PHASE4":2923,"NA":2925},{"trials":2912,"activeCount":99},[],{"trials":2914,"activeCount":99},[],{"trials":2916,"activeCount":95,"soonestReadout":1552},[2917],{"nctId":1549,"briefTitle":1550,"status":157,"phases":2918,"primaryCompletion":1552,"completion":1553,"start":303,"enrollment":25,"conditions":2919,"interventions":2920},[88],[18],[1556,1557],{"trials":2922,"activeCount":99},[],{"trials":2924,"activeCount":99},[],{"trials":2926,"activeCount":99},[],{"intervention":2928,"totalTrials":95,"cells":2929},"GnP in combination with Ivonescimab and SBRT",{"EARLY_PHASE1":2930,"PHASE1":2932,"PHASE2":2934,"PHASE3":2945,"PHASE4":2947,"NA":2949},{"trials":2931,"activeCount":99},[],{"trials":2933,"activeCount":99},[],{"trials":2935,"activeCount":95,"soonestReadout":856},[2936],{"nctId":2937,"briefTitle":2938,"status":111,"phases":2939,"primaryCompletion":856,"completion":2940,"start":2941,"enrollment":1077,"conditions":2942,"interventions":2944},"NCT06991491","Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)",[88],"2026-09-30","2025-06-01",[2943],"Pancreatic Cancer",[2928],{"trials":2946,"activeCount":99},[],{"trials":2948,"activeCount":99},[],{"trials":2950,"activeCount":99},[],{"intervention":84,"totalTrials":95,"cells":2952},{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2954,"activeCount":99},[],{"trials":2956,"activeCount":99},[],{"trials":2958,"activeCount":95,"soonestReadout":83},[2959],{"nctId":81,"briefTitle":82,"status":157,"phases":2960,"primaryCompletion":83,"completion":1646,"start":2961,"enrollment":2962,"conditions":2963,"interventions":2965},[87,88],"2023-03-10",57,[2964],"Stomach Neoplasm",[84],{"trials":2967,"activeCount":99},[],{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"intervention":2973,"totalTrials":95,"cells":2974},"Low Dose DCSZ11",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":2994,"PHASE4":2996,"NA":2998},{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":95,"soonestReadout":2985},[2981],{"nctId":2982,"briefTitle":2983,"status":157,"phases":2984,"primaryCompletion":2985,"completion":1321,"start":2986,"enrollment":25,"conditions":2987,"interventions":2990},"NCT07035249","DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors",[87,88],"2027-06-01","2025-12-16",[2988,2989,1041],"DCSZ11","Solid Tumors",[2973,2991,2992,2993],"Medium Dose DCSZ11","High Dose DCSZ11","Standard Treatment",{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[],{"trials":2999,"activeCount":99},[],{"intervention":2991,"totalTrials":95,"cells":3001},{"EARLY_PHASE1":3002,"PHASE1":3004,"PHASE2":3006,"PHASE3":3012,"PHASE4":3014,"NA":3016},{"trials":3003,"activeCount":99},[],{"trials":3005,"activeCount":99},[],{"trials":3007,"activeCount":95,"soonestReadout":2985},[3008],{"nctId":2982,"briefTitle":2983,"status":157,"phases":3009,"primaryCompletion":2985,"completion":1321,"start":2986,"enrollment":25,"conditions":3010,"interventions":3011},[87,88],[2988,2989,1041],[2973,2991,2992,2993],{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[],{"trials":3017,"activeCount":99},[],{"intervention":2992,"totalTrials":95,"cells":3019},{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3030,"PHASE4":3032,"NA":3034},{"trials":3021,"activeCount":99},[],{"trials":3023,"activeCount":99},[],{"trials":3025,"activeCount":95,"soonestReadout":2985},[3026],{"nctId":2982,"briefTitle":2983,"status":157,"phases":3027,"primaryCompletion":2985,"completion":1321,"start":2986,"enrollment":25,"conditions":3028,"interventions":3029},[87,88],[2988,2989,1041],[2973,2991,2992,2993],{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[],{"trials":3035,"activeCount":99},[],{"intervention":2993,"totalTrials":95,"cells":3037},{"EARLY_PHASE1":3038,"PHASE1":3040,"PHASE2":3042,"PHASE3":3048,"PHASE4":3050,"NA":3052},{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":99},[],{"trials":3043,"activeCount":95,"soonestReadout":2985},[3044],{"nctId":2982,"briefTitle":2983,"status":157,"phases":3045,"primaryCompletion":2985,"completion":1321,"start":2986,"enrollment":25,"conditions":3046,"interventions":3047},[87,88],[2988,2989,1041],[2973,2991,2992,2993],{"trials":3049,"activeCount":99},[],{"trials":3051,"activeCount":99},[],{"trials":3053,"activeCount":99},[],{"intervention":3055,"totalTrials":95,"cells":3056},"SOX+Tislelizumab+LDRT",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3058,"activeCount":99},[],{"trials":3060,"activeCount":99},[],{"trials":3062,"activeCount":95,"soonestReadout":856},[3063],{"nctId":3064,"briefTitle":3065,"status":111,"phases":3066,"primaryCompletion":856,"completion":3067,"start":3068,"enrollment":3069,"conditions":3070,"interventions":3071},"NCT06266871","SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer",[87,88],"2026-07-30","2024-03-10",64,[32],[3055],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[],{"trials":3077,"activeCount":99},[],{"intervention":3079,"totalTrials":95,"cells":3080},"HRS-4642",{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3082,"activeCount":99},[],{"trials":3084,"activeCount":99},[],{"trials":3086,"activeCount":95,"soonestReadout":2289},[3087],{"nctId":3088,"briefTitle":3089,"status":200,"phases":3090,"primaryCompletion":2289,"completion":3091,"start":3092,"enrollment":484,"conditions":3093,"interventions":3094},"NCT06773130","HRS-4642 Combined With Nimotuzumab in the Treatment of Recurrent or Metastatic Pancreatic Ductal Adenocarcinoma",[87,88],"2027-03","2025-02-10",[1892],[3079,3095],"Nimotuzumab",{"trials":3097,"activeCount":99},[],{"trials":3099,"activeCount":99},[],{"trials":3101,"activeCount":99},[],{"intervention":3095,"totalTrials":95,"cells":3103},{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3105,"activeCount":99},[],{"trials":3107,"activeCount":99},[],{"trials":3109,"activeCount":95,"soonestReadout":2289},[3110],{"nctId":3088,"briefTitle":3089,"status":200,"phases":3111,"primaryCompletion":2289,"completion":3091,"start":3092,"enrollment":484,"conditions":3112,"interventions":3113},[87,88],[1892],[3079,3095],{"trials":3115,"activeCount":99},[],{"trials":3117,"activeCount":99},[],{"trials":3119,"activeCount":99},[],{"intervention":3121,"totalTrials":95,"cells":3122},"Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":95,"soonestReadout":3133},[3129],{"nctId":3130,"briefTitle":3131,"status":111,"phases":3132,"primaryCompletion":3133,"completion":3133,"start":1264,"enrollment":332,"conditions":3134,"interventions":3136},"NCT07472933","Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies",[88],"2028-02-29",[3135],"Cancer of Biliary Duct",[3121],{"trials":3138,"activeCount":99},[],{"trials":3140,"activeCount":99},[],{"trials":3142,"activeCount":99},[],{"intervention":3144,"totalTrials":95,"cells":3145},"sintiliman plus LDRT",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3160,"PHASE4":3162,"NA":3164},{"trials":3147,"activeCount":99},[],{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":95,"soonestReadout":561},[3152],{"nctId":3153,"briefTitle":3154,"status":111,"phases":3155,"primaryCompletion":561,"completion":3156,"start":3157,"enrollment":1156,"conditions":3158,"interventions":3159},"NCT06426654","Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR\u002FMSI-H Gastric Cancer",[87,88],"2027-08-30","2024-06-10",[32],[3144],{"trials":3161,"activeCount":99},[],{"trials":3163,"activeCount":99},[],{"trials":3165,"activeCount":99},[],{"intervention":1346,"totalTrials":95,"cells":3167},{"EARLY_PHASE1":3168,"PHASE1":3170,"PHASE2":3172,"PHASE3":3178,"PHASE4":3180,"NA":3182},{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":95,"soonestReadout":1340},[3174],{"nctId":1337,"briefTitle":1338,"status":157,"phases":3175,"primaryCompletion":1340,"completion":1341,"start":1342,"enrollment":1343,"conditions":3176,"interventions":3177},[88],[1333],[1335,1346,1347,1308],{"trials":3179,"activeCount":99},[],{"trials":3181,"activeCount":99},[],{"trials":3183,"activeCount":99},[],{"intervention":1347,"totalTrials":95,"cells":3185},{"EARLY_PHASE1":3186,"PHASE1":3188,"PHASE2":3190,"PHASE3":3196,"PHASE4":3198,"NA":3200},{"trials":3187,"activeCount":99},[],{"trials":3189,"activeCount":99},[],{"trials":3191,"activeCount":95,"soonestReadout":1340},[3192],{"nctId":1337,"briefTitle":1338,"status":157,"phases":3193,"primaryCompletion":1340,"completion":1341,"start":1342,"enrollment":1343,"conditions":3194,"interventions":3195},[88],[1333],[1335,1346,1347,1308],{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"trials":3201,"activeCount":99},[],{"intervention":3203,"totalTrials":95,"cells":3204},"Becotatug Vedotin and Pucotenlimab",{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3209,"PHASE3":3219,"PHASE4":3221,"NA":3223},{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[],{"trials":3210,"activeCount":95,"soonestReadout":438},[3211],{"nctId":3212,"briefTitle":3213,"status":111,"phases":3214,"primaryCompletion":438,"completion":3215,"start":2065,"enrollment":410,"conditions":3216,"interventions":3218},"NCT07381699","MRG003 Combined With Immunotherapy in Recurrent\u002FMetastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial",[88],"2030-02-01",[3217],"Nasopharyngeal Cancinoma (NPC)",[3203],{"trials":3220,"activeCount":99},[],{"trials":3222,"activeCount":99},[],{"trials":3224,"activeCount":99},[],{"intervention":3226,"totalTrials":95,"cells":3227},"Tislelizumab or pembrolizumab, pemetrexed",{"EARLY_PHASE1":3228,"PHASE1":3230,"PHASE2":3232,"PHASE3":3244,"PHASE4":3246,"NA":3248},{"trials":3229,"activeCount":99},[],{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":95,"soonestReadout":3238},[3234],{"nctId":3235,"briefTitle":3236,"status":157,"phases":3237,"primaryCompletion":3238,"completion":856,"start":3239,"enrollment":3240,"conditions":3241,"interventions":3243},"NCT06132698","Immune Checkpoint Inhibitors Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC",[88],"2026-05-30","2023-11-30",17,[3242],"NSCLC Associated With Leptomeningeal Metastases",[3226],{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"trials":3249,"activeCount":99},[],{"intervention":1741,"totalTrials":95,"cells":3251},{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3256,"PHASE3":3262,"PHASE4":3264,"NA":3266},{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[],{"trials":3257,"activeCount":95,"soonestReadout":113},[3258],{"nctId":1734,"briefTitle":1735,"status":157,"phases":3259,"primaryCompletion":113,"completion":560,"start":1737,"enrollment":563,"conditions":3260,"interventions":3261},[88],[1739],[1741,1725],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"trials":3267,"activeCount":99},[],{"intervention":3269,"totalTrials":95,"cells":3270},"XELOX+Sintilimab+HBOT",{"EARLY_PHASE1":3271,"PHASE1":3273,"PHASE2":3275,"PHASE3":3284,"PHASE4":3286,"NA":3288},{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[],{"trials":3276,"activeCount":95,"soonestReadout":560},[3277],{"nctId":3278,"briefTitle":3279,"status":157,"phases":3280,"primaryCompletion":560,"completion":560,"start":248,"enrollment":2962,"conditions":3281,"interventions":3283},"NCT06742411","XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC\u002FGEJC",[87,88],[3282],"Gastric (Stomach) Cancer",[3269],{"trials":3285,"activeCount":99},[],{"trials":3287,"activeCount":99},[],{"trials":3289,"activeCount":99},[],{"intervention":1499,"totalTrials":95,"cells":3291},{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3302,"PHASE4":3304,"NA":3306},{"trials":3293,"activeCount":99},[],{"trials":3295,"activeCount":99},[],{"trials":3297,"activeCount":95,"soonestReadout":1492},[3298],{"nctId":1489,"briefTitle":1490,"status":157,"phases":3299,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":3300,"interventions":3301},[88],[1497,1498,1499],[1499,1501,1215],{"trials":3303,"activeCount":99},[],{"trials":3305,"activeCount":99},[],{"trials":3307,"activeCount":99},[],{"intervention":1501,"totalTrials":95,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3320,"PHASE4":3322,"NA":3324},{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":95,"soonestReadout":1492},[3316],{"nctId":1489,"briefTitle":1490,"status":157,"phases":3317,"primaryCompletion":1492,"completion":1493,"start":1494,"enrollment":1495,"conditions":3318,"interventions":3319},[88],[1497,1498,1499],[1499,1501,1215],{"trials":3321,"activeCount":99},[],{"trials":3323,"activeCount":99},[],{"trials":3325,"activeCount":99},[],{"intervention":1410,"totalTrials":95,"cells":3327},{"EARLY_PHASE1":3328,"PHASE1":3330,"PHASE2":3332,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3329,"activeCount":99},[],{"trials":3331,"activeCount":99},[],{"trials":3333,"activeCount":95,"soonestReadout":1405},[3334],{"nctId":1402,"briefTitle":1403,"status":157,"phases":3335,"primaryCompletion":1405,"completion":1405,"start":1406,"enrollment":1407,"conditions":3336,"interventions":3337},[87,88],[1397,1398,30,660],[1410,1381],{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[],{"trials":3343,"activeCount":99},[],{"intervention":3345,"totalTrials":1055,"cells":3346},"EBV mRNA vaccine",{"EARLY_PHASE1":3347,"PHASE1":3357,"PHASE2":3368,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3348,"activeCount":95,"soonestReadout":536},[3349],{"nctId":3350,"briefTitle":3351,"status":111,"phases":3352,"primaryCompletion":536,"completion":114,"start":3353,"enrollment":304,"conditions":3354,"interventions":3356},"NCT07563023","Exploratory Study on the Treatment of EB Virus Positive HIV Associated Lymphoma With EBV mRNA Vaccine",[86],"2026-05-01",[3355],"HIV Associated Lymphoma",[3345],{"trials":3358,"activeCount":95,"soonestReadout":975},[3359],{"nctId":3360,"briefTitle":3361,"status":200,"phases":3362,"primaryCompletion":975,"completion":975,"start":3363,"enrollment":3364,"conditions":3365,"interventions":3367},"NCT05714748","Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors",[87],"2023-02-08",19,[3366],"Malignant Tumors",[3345],{"trials":3369,"activeCount":99},[],{"trials":3371,"activeCount":99},[],{"trials":3373,"activeCount":99},[],{"trials":3375,"activeCount":95,"soonestReadout":560},[3376],{"nctId":3377,"briefTitle":3378,"status":111,"phases":3379,"primaryCompletion":560,"completion":536,"start":1029,"enrollment":319,"conditions":3380,"interventions":3382},"NCT07101536","The Application of mRNA Immunotherapy Technology in Refractory Malignancies Associated With Epstein-Barr Virus (EBV)",[91],[3381],"EBV-associated Tumors",[3345,3383],"Immune Checkpoint Inhibitors, ICIs",{"intervention":3385,"totalTrials":259,"cells":3386},"YMN-A02 100μg",{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3408,"PHASE3":3410,"PHASE4":3412,"NA":3414},{"trials":3388,"activeCount":99},[],{"trials":3390,"activeCount":259,"soonestReadout":761},[3391,3401],{"nctId":3392,"briefTitle":3393,"status":111,"phases":3394,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3395,"interventions":3397},"NCT07580261","YMN-A02 for Advanced Primary Hepatocellular Carcinoma.",[87],[3396],"Hepatocellular Carcinoma",[3385,3398,3399,3400],"YMN-A02 250μg","YMN-A02 500μg","YMN-A02 1000μg",{"nctId":3402,"briefTitle":3403,"status":111,"phases":3404,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3405,"interventions":3407},"NCT07610707","YMN-A02 for Advanced pMMR Colorectal Cancer With Liver Metastases",[87],[3406],"Colorectal Cancer With Liver Metastatic",[3385,3398,3399,3400],{"trials":3409,"activeCount":99},[],{"trials":3411,"activeCount":99},[],{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[],{"intervention":3398,"totalTrials":259,"cells":3417},{"EARLY_PHASE1":3418,"PHASE1":3420,"PHASE2":3430,"PHASE3":3432,"PHASE4":3434,"NA":3436},{"trials":3419,"activeCount":99},[],{"trials":3421,"activeCount":259,"soonestReadout":761},[3422,3426],{"nctId":3392,"briefTitle":3393,"status":111,"phases":3423,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3424,"interventions":3425},[87],[3396],[3385,3398,3399,3400],{"nctId":3402,"briefTitle":3403,"status":111,"phases":3427,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3428,"interventions":3429},[87],[3406],[3385,3398,3399,3400],{"trials":3431,"activeCount":99},[],{"trials":3433,"activeCount":99},[],{"trials":3435,"activeCount":99},[],{"trials":3437,"activeCount":99},[],{"intervention":3399,"totalTrials":259,"cells":3439},{"EARLY_PHASE1":3440,"PHASE1":3442,"PHASE2":3452,"PHASE3":3454,"PHASE4":3456,"NA":3458},{"trials":3441,"activeCount":99},[],{"trials":3443,"activeCount":259,"soonestReadout":761},[3444,3448],{"nctId":3392,"briefTitle":3393,"status":111,"phases":3445,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3446,"interventions":3447},[87],[3396],[3385,3398,3399,3400],{"nctId":3402,"briefTitle":3403,"status":111,"phases":3449,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3450,"interventions":3451},[87],[3406],[3385,3398,3399,3400],{"trials":3453,"activeCount":99},[],{"trials":3455,"activeCount":99},[],{"trials":3457,"activeCount":99},[],{"trials":3459,"activeCount":99},[],{"intervention":3400,"totalTrials":259,"cells":3461},{"EARLY_PHASE1":3462,"PHASE1":3464,"PHASE2":3474,"PHASE3":3476,"PHASE4":3478,"NA":3480},{"trials":3463,"activeCount":99},[],{"trials":3465,"activeCount":259,"soonestReadout":761},[3466,3470],{"nctId":3392,"briefTitle":3393,"status":111,"phases":3467,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3468,"interventions":3469},[87],[3396],[3385,3398,3399,3400],{"nctId":3402,"briefTitle":3403,"status":111,"phases":3471,"primaryCompletion":761,"completion":761,"start":3067,"enrollment":22,"conditions":3472,"interventions":3473},[87],[3406],[3385,3398,3399,3400],{"trials":3475,"activeCount":99},[],{"trials":3477,"activeCount":99},[],{"trials":3479,"activeCount":99},[],{"trials":3481,"activeCount":99},[],{"intervention":1268,"totalTrials":259,"cells":3483},{"EARLY_PHASE1":3484,"PHASE1":3486,"PHASE2":3507,"PHASE3":3509,"PHASE4":3511,"NA":3513},{"trials":3485,"activeCount":99},[],{"trials":3487,"activeCount":259,"soonestReadout":1262},[3488,3503],{"nctId":3489,"briefTitle":3490,"status":157,"phases":3491,"primaryCompletion":3492,"completion":3493,"start":3494,"enrollment":22,"conditions":3495,"interventions":3502},"NCT07106827","A Study of GV20-0251 in Advanced or Refractory Solid Tumors",[87],"2027-06-11","2028-06-11","2025-09-04",[3496,2901,3497,3498,3499,1041,3500,3501],"HCC - Hepatocellular Carcinoma","Melanoma","NSCLC (Non-small Cell Lung Cancer)","Pancreatic Ductal Adenocarcinoma","Endometrial Cancer","Testicular Cancer",[1268],{"nctId":1259,"briefTitle":1260,"status":157,"phases":3504,"primaryCompletion":1262,"completion":1263,"start":1264,"enrollment":25,"conditions":3505,"interventions":3506},[87],[1266],[1268,1252],{"trials":3508,"activeCount":99},[],{"trials":3510,"activeCount":99},[],{"trials":3512,"activeCount":99},[],{"trials":3514,"activeCount":99},[],{"intervention":65,"totalTrials":259,"cells":3516},{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3537,"PHASE3":3539,"PHASE4":3541,"NA":3543},{"trials":3518,"activeCount":99},[],{"trials":3520,"activeCount":259,"soonestReadout":64},[3521,3526],{"nctId":62,"briefTitle":63,"status":200,"phases":3522,"primaryCompletion":64,"completion":536,"start":3363,"enrollment":304,"conditions":3523,"interventions":3525},[87],[3524],"Malignant Tumor",[65],{"nctId":3527,"briefTitle":3528,"status":111,"phases":3529,"primaryCompletion":3530,"completion":1341,"start":3531,"enrollment":3532,"conditions":3533,"interventions":3536},"NCT06666153","Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases",[87],"2025-12","2024-10",27,[3534,3535],"CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome","PTLDs",[65],{"trials":3538,"activeCount":99},[],{"trials":3540,"activeCount":99},[],{"trials":3542,"activeCount":99},[],{"trials":3544,"activeCount":99},[],{"intervention":930,"totalTrials":259,"cells":3546},{"EARLY_PHASE1":3547,"PHASE1":3549,"PHASE2":3559,"PHASE3":3561,"PHASE4":3563,"NA":3565},{"trials":3548,"activeCount":99},[],{"trials":3550,"activeCount":95,"soonestReadout":79},[3551,3555],{"nctId":1633,"briefTitle":1634,"status":314,"phases":3552,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":304,"conditions":3553,"interventions":3554},[87],[922],[1626,930,931],{"nctId":77,"briefTitle":78,"status":157,"phases":3556,"primaryCompletion":79,"completion":927,"start":282,"enrollment":304,"conditions":3557,"interventions":3558},[87],[18],[56,930,931],{"trials":3560,"activeCount":99},[],{"trials":3562,"activeCount":99},[],{"trials":3564,"activeCount":99},[],{"trials":3566,"activeCount":99},[],{"intervention":931,"totalTrials":259,"cells":3568},{"EARLY_PHASE1":3569,"PHASE1":3571,"PHASE2":3581,"PHASE3":3583,"PHASE4":3585,"NA":3587},{"trials":3570,"activeCount":99},[],{"trials":3572,"activeCount":95,"soonestReadout":79},[3573,3577],{"nctId":1633,"briefTitle":1634,"status":314,"phases":3574,"primaryCompletion":1636,"completion":1636,"start":1637,"enrollment":304,"conditions":3575,"interventions":3576},[87],[922],[1626,930,931],{"nctId":77,"briefTitle":78,"status":157,"phases":3578,"primaryCompletion":79,"completion":927,"start":282,"enrollment":304,"conditions":3579,"interventions":3580},[87],[18],[56,930,931],{"trials":3582,"activeCount":99},[],{"trials":3584,"activeCount":99},[],{"trials":3586,"activeCount":99},[],{"trials":3588,"activeCount":99},[],{"intervention":3590,"totalTrials":259,"cells":3591},"HBV mRNA vaccine",{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3611,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3593,"activeCount":99},[],{"trials":3595,"activeCount":95,"soonestReadout":560},[3596,3603],{"nctId":3597,"briefTitle":3598,"status":157,"phases":3599,"primaryCompletion":560,"completion":536,"start":1029,"enrollment":3600,"conditions":3601,"interventions":3602},"NCT07077356","Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma",[87],15,[1031],[3590],{"nctId":3604,"briefTitle":3605,"status":314,"phases":3606,"primaryCompletion":3607,"completion":2126,"start":3608,"enrollment":25,"conditions":3609,"interventions":3610},"NCT05738447","Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma",[87],"2024-01-01","2023-02-15",[27,3396],[3590],{"trials":3612,"activeCount":99},[],{"trials":3614,"activeCount":99},[],{"trials":3616,"activeCount":99},[],{"trials":3618,"activeCount":99},[],{"intervention":3620,"totalTrials":259,"cells":3621},"Regorafenib",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3652,"PHASE3":3654,"PHASE4":3656,"NA":3658},{"trials":3623,"activeCount":99},[],{"trials":3625,"activeCount":95,"soonestReadout":560},[3626,3642],{"nctId":3627,"briefTitle":3628,"status":157,"phases":3629,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":3632,"interventions":3633},"NCT07567222","Clinical Study of Novel Therapeutic Vaccine for Advanced Solid Tumors",[87],"2026-05-15",54,[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],"YMN101","YMN102","YMN103","YMN104","YMN105","YMN106","YMN107","YMN108",{"nctId":3643,"briefTitle":3644,"status":314,"phases":3645,"primaryCompletion":3646,"completion":3646,"start":3647,"enrollment":3600,"conditions":3648,"interventions":3650},"NCT06200363","A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer",[87],"2024-11","2023-09-21",[3649],"Advanced Colorectal Cancer",[3651,3620],"T3011",{"trials":3653,"activeCount":99},[],{"trials":3655,"activeCount":99},[],{"trials":3657,"activeCount":99},[],{"trials":3659,"activeCount":99},[],{"intervention":3661,"totalTrials":95,"cells":3662},"NCP-CD47 siRNA intratumorally",{"EARLY_PHASE1":3663,"PHASE1":3665,"PHASE2":3676,"PHASE3":3678,"PHASE4":3680,"NA":3682},{"trials":3664,"activeCount":99},[],{"trials":3666,"activeCount":95,"soonestReadout":561},[3667],{"nctId":3668,"briefTitle":3669,"status":111,"phases":3670,"primaryCompletion":561,"completion":3671,"start":3238,"enrollment":25,"conditions":3672,"interventions":3675},"NCT07583914","Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors",[87],"2027-12-30",[3673,3674,1053],"Solid Tumor Cancer","Metastases",[3661],{"trials":3677,"activeCount":99},[],{"trials":3679,"activeCount":99},[],{"trials":3681,"activeCount":99},[],{"trials":3683,"activeCount":99},[],{"intervention":3685,"totalTrials":95,"cells":3686},"Low Dose PD-1 mRNA LNP Vaccine",{"EARLY_PHASE1":3687,"PHASE1":3689,"PHASE2":3699,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3688,"activeCount":99},[],{"trials":3690,"activeCount":95,"soonestReadout":2940},[3691],{"nctId":3692,"briefTitle":3693,"status":157,"phases":3694,"primaryCompletion":2940,"completion":449,"start":3695,"enrollment":25,"conditions":3696,"interventions":3697},"NCT07053072","PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.",[87],"2025-10-23",[27],[3685,3698],"High dose PD-1 mRNA LNP vaccines",{"trials":3700,"activeCount":99},[],{"trials":3702,"activeCount":99},[],{"trials":3704,"activeCount":99},[],{"trials":3706,"activeCount":99},[],{"intervention":3698,"totalTrials":95,"cells":3708},{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3723},{"trials":3710,"activeCount":99},[],{"trials":3712,"activeCount":95,"soonestReadout":2940},[3713],{"nctId":3692,"briefTitle":3693,"status":157,"phases":3714,"primaryCompletion":2940,"completion":449,"start":3695,"enrollment":25,"conditions":3715,"interventions":3716},[87],[27],[3685,3698],{"trials":3718,"activeCount":99},[],{"trials":3720,"activeCount":99},[],{"trials":3722,"activeCount":99},[],{"trials":3724,"activeCount":99},[],{"intervention":1024,"totalTrials":95,"cells":3726},{"EARLY_PHASE1":3727,"PHASE1":3729,"PHASE2":3735,"PHASE3":3737,"PHASE4":3739,"NA":3741},{"trials":3728,"activeCount":99},[],{"trials":3730,"activeCount":95,"soonestReadout":1018},[3731],{"nctId":1015,"briefTitle":1016,"status":157,"phases":3732,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":25,"conditions":3733,"interventions":3734},[87],[1022],[1024,1024,1024,1008],{"trials":3736,"activeCount":99},[],{"trials":3738,"activeCount":99},[],{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[],{"intervention":1033,"totalTrials":95,"cells":3744},{"EARLY_PHASE1":3745,"PHASE1":3747,"PHASE2":3753,"PHASE3":3755,"PHASE4":3757,"NA":3759},{"trials":3746,"activeCount":99},[],{"trials":3748,"activeCount":95,"soonestReadout":536},[3749],{"nctId":1026,"briefTitle":1027,"status":111,"phases":3750,"primaryCompletion":536,"completion":114,"start":1029,"enrollment":22,"conditions":3751,"interventions":3752},[87],[1031],[1033,1008],{"trials":3754,"activeCount":99},[],{"trials":3756,"activeCount":99},[],{"trials":3758,"activeCount":99},[],{"trials":3760,"activeCount":99},[],{"intervention":3762,"totalTrials":95,"cells":3763},"CP-IL22BP mRNA intratumorally",{"EARLY_PHASE1":3764,"PHASE1":3766,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":95,"soonestReadout":561},[3768],{"nctId":3769,"briefTitle":3770,"status":111,"phases":3771,"primaryCompletion":561,"completion":3671,"start":3238,"enrollment":3772,"conditions":3773,"interventions":3777},"NCT07583654","Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors",[87],18,[3774,3673,3775,3776],"mRNA Vaccine","Peptides","Cancer Metastatic",[3762],{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":99},[],{"trials":3783,"activeCount":99},[],{"trials":3785,"activeCount":99},[],{"intervention":3787,"totalTrials":95,"cells":3788},"Canagliflozin",{"EARLY_PHASE1":3789,"PHASE1":3791,"PHASE2":3800,"PHASE3":3802,"PHASE4":3804,"NA":3806},{"trials":3790,"activeCount":99},[],{"trials":3792,"activeCount":95,"soonestReadout":856},[3793],{"nctId":3794,"briefTitle":3795,"status":157,"phases":3796,"primaryCompletion":856,"completion":856,"start":249,"enrollment":3600,"conditions":3797,"interventions":3799},"NCT07076823","Safety and Efficacy of Canagliflozin in Patients With Metastatic High Microsatellite Instability (MSI-H) Colorectal Cancer",[87],[15,3798],"SGLT-2 Inhibitor",[3787],{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[],{"trials":3805,"activeCount":99},[],{"trials":3807,"activeCount":99},[],{"intervention":3809,"totalTrials":95,"cells":3810},"CD-001",{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3826,"PHASE3":3828,"PHASE4":3830,"NA":3832},{"trials":3812,"activeCount":99},[],{"trials":3814,"activeCount":95,"soonestReadout":1577},[3815],{"nctId":3816,"briefTitle":3817,"status":111,"phases":3818,"primaryCompletion":1577,"completion":3819,"start":3820,"enrollment":25,"conditions":3821,"interventions":3825},"NCT07072325","Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers",[87],"2028-08-31","2025-08-10",[3822,3823,1053,3824],"Malignant Neoplasm","Head &Amp; Neck Cancer","Advanced Head and Neck Carcinoma",[3809],{"trials":3827,"activeCount":99},[],{"trials":3829,"activeCount":99},[],{"trials":3831,"activeCount":99},[],{"trials":3833,"activeCount":99},[],{"intervention":3835,"totalTrials":95,"cells":3836},"Mechanobiologically Reprogrammed Macrophage-Derived Exosomes",{"EARLY_PHASE1":3837,"PHASE1":3839,"PHASE2":3850,"PHASE3":3852,"PHASE4":3854,"NA":3856},{"trials":3838,"activeCount":99},[],{"trials":3840,"activeCount":95,"soonestReadout":3091},[3841],{"nctId":3842,"briefTitle":3843,"status":157,"phases":3844,"primaryCompletion":3091,"completion":3845,"start":1020,"enrollment":25,"conditions":3846,"interventions":3849},"NCT07563972","Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors",[87],"2028-05",[3847,3848],"Advanced Solid Tumors","Neoplasm",[3835,3835,3835],{"trials":3851,"activeCount":99},[],{"trials":3853,"activeCount":99},[],{"trials":3855,"activeCount":99},[],{"trials":3857,"activeCount":99},[],{"intervention":3859,"totalTrials":95,"cells":3860},"Ta-NPs",{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3872,"PHASE3":3874,"PHASE4":3876,"NA":3878},{"trials":3862,"activeCount":99},[],{"trials":3864,"activeCount":95,"soonestReadout":560},[3865],{"nctId":3866,"briefTitle":3867,"status":111,"phases":3868,"primaryCompletion":560,"completion":1552,"start":3353,"enrollment":25,"conditions":3869,"interventions":3871},"NCT07578506","A Study of Ta-NPs Plus Radiotherapy for Locally Recurrent Retroperitoneal Sarcoma",[87],[3870],"Locally Recurrent Retroperitoneal Soft Tissue Sarcoma",[3859,3859,3859],{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[],{"trials":3877,"activeCount":99},[],{"trials":3879,"activeCount":99},[],{"intervention":3881,"totalTrials":95,"cells":3882},"JWK007 Single intravenous infusion administration",{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3896,"PHASE3":3898,"PHASE4":3900,"NA":3902},{"trials":3884,"activeCount":99},[],{"trials":3886,"activeCount":95,"soonestReadout":3891},[3887],{"nctId":3888,"briefTitle":3889,"status":200,"phases":3890,"primaryCompletion":3891,"completion":3891,"start":3892,"enrollment":1055,"conditions":3893,"interventions":3895},"NCT06114056","A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)",[87],"2029-11-13","2024-01-31",[3894],"Duchenne Muscular Dystrophy",[3881],{"trials":3897,"activeCount":99},[],{"trials":3899,"activeCount":99},[],{"trials":3901,"activeCount":99},[],{"trials":3903,"activeCount":99},[],{"intervention":3905,"totalTrials":95,"cells":3906},"Low Dose MSH2-\u002F- tumor cell vaccine",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3920,"PHASE3":3922,"PHASE4":3924,"NA":3926},{"trials":3908,"activeCount":99},[],{"trials":3910,"activeCount":95,"soonestReadout":1646},[3911],{"nctId":3912,"briefTitle":3913,"status":157,"phases":3914,"primaryCompletion":1646,"completion":369,"start":1264,"enrollment":25,"conditions":3915,"interventions":3917},"NCT07510308","Clinical Study of MSH2-\u002F- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients",[87],[3916],"pMMR\u002FMSS Advanced Colorectal Cancer",[3905,3918,3919],"Medium Dose MSH2-\u002F- tumor cell vaccine","High dose MSH2-\u002F- tumor cell vaccine",{"trials":3921,"activeCount":99},[],{"trials":3923,"activeCount":99},[],{"trials":3925,"activeCount":99},[],{"trials":3927,"activeCount":99},[],{"intervention":3918,"totalTrials":95,"cells":3929},{"EARLY_PHASE1":3930,"PHASE1":3932,"PHASE2":3938,"PHASE3":3940,"PHASE4":3942,"NA":3944},{"trials":3931,"activeCount":99},[],{"trials":3933,"activeCount":95,"soonestReadout":1646},[3934],{"nctId":3912,"briefTitle":3913,"status":157,"phases":3935,"primaryCompletion":1646,"completion":369,"start":1264,"enrollment":25,"conditions":3936,"interventions":3937},[87],[3916],[3905,3918,3919],{"trials":3939,"activeCount":99},[],{"trials":3941,"activeCount":99},[],{"trials":3943,"activeCount":99},[],{"trials":3945,"activeCount":99},[],{"intervention":3919,"totalTrials":95,"cells":3947},{"EARLY_PHASE1":3948,"PHASE1":3950,"PHASE2":3956,"PHASE3":3958,"PHASE4":3960,"NA":3962},{"trials":3949,"activeCount":99},[],{"trials":3951,"activeCount":95,"soonestReadout":1646},[3952],{"nctId":3912,"briefTitle":3913,"status":157,"phases":3953,"primaryCompletion":1646,"completion":369,"start":1264,"enrollment":25,"conditions":3954,"interventions":3955},[87],[3916],[3905,3918,3919],{"trials":3957,"activeCount":99},[],{"trials":3959,"activeCount":99},[],{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[],{"intervention":3965,"totalTrials":95,"cells":3966},"FAP mRNA vaccine (dose 1) + immune checkpoint inhibitors",{"EARLY_PHASE1":3967,"PHASE1":3969,"PHASE2":3982,"PHASE3":3984,"PHASE4":3986,"NA":3988},{"trials":3968,"activeCount":99},[],{"trials":3970,"activeCount":95,"soonestReadout":560},[3971],{"nctId":3972,"briefTitle":3973,"status":111,"phases":3974,"primaryCompletion":560,"completion":536,"start":3975,"enrollment":22,"conditions":3976,"interventions":3978},"NCT07363369","Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors",[87],"2026-01-25",[3977],"Advanced Malignant Solid Tumors",[3965,3979,3980,3981],"FAP mRNA vaccine (dose 2) + immune checkpoint inhibitors","FAP mRNA vaccine (dose 3) + immune checkpoint inhibitors","FAP mRNA vaccine (dose 4) + immune checkpoint inhibitors",{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"trials":3987,"activeCount":99},[],{"trials":3989,"activeCount":99},[],{"intervention":3979,"totalTrials":95,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":4000,"PHASE3":4002,"PHASE4":4004,"NA":4006},{"trials":3993,"activeCount":99},[],{"trials":3995,"activeCount":95,"soonestReadout":560},[3996],{"nctId":3972,"briefTitle":3973,"status":111,"phases":3997,"primaryCompletion":560,"completion":536,"start":3975,"enrollment":22,"conditions":3998,"interventions":3999},[87],[3977],[3965,3979,3980,3981],{"trials":4001,"activeCount":99},[],{"trials":4003,"activeCount":99},[],{"trials":4005,"activeCount":99},[],{"trials":4007,"activeCount":99},[],{"intervention":3980,"totalTrials":95,"cells":4009},{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4018,"PHASE3":4020,"PHASE4":4022,"NA":4024},{"trials":4011,"activeCount":99},[],{"trials":4013,"activeCount":95,"soonestReadout":560},[4014],{"nctId":3972,"briefTitle":3973,"status":111,"phases":4015,"primaryCompletion":560,"completion":536,"start":3975,"enrollment":22,"conditions":4016,"interventions":4017},[87],[3977],[3965,3979,3980,3981],{"trials":4019,"activeCount":99},[],{"trials":4021,"activeCount":99},[],{"trials":4023,"activeCount":99},[],{"trials":4025,"activeCount":99},[],{"intervention":3981,"totalTrials":95,"cells":4027},{"EARLY_PHASE1":4028,"PHASE1":4030,"PHASE2":4036,"PHASE3":4038,"PHASE4":4040,"NA":4042},{"trials":4029,"activeCount":99},[],{"trials":4031,"activeCount":95,"soonestReadout":560},[4032],{"nctId":3972,"briefTitle":3973,"status":111,"phases":4033,"primaryCompletion":560,"completion":536,"start":3975,"enrollment":22,"conditions":4034,"interventions":4035},[87],[3977],[3965,3979,3980,3981],{"trials":4037,"activeCount":99},[],{"trials":4039,"activeCount":99},[],{"trials":4041,"activeCount":99},[],{"trials":4043,"activeCount":99},[],{"intervention":4045,"totalTrials":95,"cells":4046},"Investigator-Selected Standard PD-1\u002FPD-L1 Inhibitor-Based Therapy",{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4062,"PHASE3":4064,"PHASE4":4066,"NA":4068},{"trials":4048,"activeCount":99},[],{"trials":4050,"activeCount":95,"soonestReadout":650},[4051],{"nctId":4052,"briefTitle":4053,"status":157,"phases":4054,"primaryCompletion":650,"completion":4055,"start":4056,"enrollment":4057,"conditions":4058,"interventions":4061},"NCT07538479","Controlled Cold Exposure Combined With PD-1\u002FPD-L1 Immunotherapy in Solid Tumors (NIVALIS)",[87],"2029-06-30","2026-04-20",24,[2989,4059,4060,30],"Solid Malignancies","Cold Exposure",[4045],{"trials":4063,"activeCount":99},[],{"trials":4065,"activeCount":99},[],{"trials":4067,"activeCount":99},[],{"trials":4069,"activeCount":99},[],{"intervention":4071,"totalTrials":95,"cells":4072},"IL-22BP",{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4086,"PHASE3":4088,"PHASE4":4090,"NA":4092},{"trials":4074,"activeCount":99},[],{"trials":4076,"activeCount":95,"soonestReadout":202},[4077],{"nctId":4078,"briefTitle":4079,"status":157,"phases":4080,"primaryCompletion":202,"completion":202,"start":4081,"enrollment":304,"conditions":4082,"interventions":4085},"NCT07040943","Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.",[87],"2025-06-29",[4083,3774,4084],"Refractory Malignant Solid Tumors","Interleukin",[4071],{"trials":4087,"activeCount":99},[],{"trials":4089,"activeCount":99},[],{"trials":4091,"activeCount":99},[],{"trials":4093,"activeCount":99},[],{"intervention":4095,"totalTrials":95,"cells":4096},"JWK008 Single intravenous infusion administration",{"EARLY_PHASE1":4097,"PHASE1":4099,"PHASE2":4111,"PHASE3":4113,"PHASE4":4115,"NA":4117},{"trials":4098,"activeCount":99},[],{"trials":4100,"activeCount":95,"soonestReadout":4105},[4101],{"nctId":4102,"briefTitle":4103,"status":157,"phases":4104,"primaryCompletion":4105,"completion":4106,"start":4107,"enrollment":304,"conditions":4108,"interventions":4110},"NCT06519552","A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type I",[87],"2026-06-22","2029-06-22","2024-07-22",[4109],"Mucopolysaccharidosis Type I",[4095],{"trials":4112,"activeCount":99},[],{"trials":4114,"activeCount":99},[],{"trials":4116,"activeCount":99},[],{"trials":4118,"activeCount":99},[],{"intervention":4120,"totalTrials":95,"cells":4121},"Tumor antigen-sensitized DC vaccine",{"EARLY_PHASE1":4122,"PHASE1":4124,"PHASE2":4136,"PHASE3":4138,"PHASE4":4140,"NA":4142},{"trials":4123,"activeCount":99},[],{"trials":4125,"activeCount":95,"soonestReadout":4130},[4126],{"nctId":4127,"briefTitle":4128,"status":157,"phases":4129,"primaryCompletion":4130,"completion":4131,"start":4132,"enrollment":22,"conditions":4133,"interventions":4135},"NCT06545630","Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases",[87],"2025-11","2026-05","2023-11-01",[4134,15],"Carcinoma",[4120],{"trials":4137,"activeCount":99},[],{"trials":4139,"activeCount":99},[],{"trials":4141,"activeCount":99},[],{"trials":4143,"activeCount":99},[],{"intervention":4145,"totalTrials":95,"cells":4146},"CFH Protein-loaded Ice Microneedles",{"EARLY_PHASE1":4147,"PHASE1":4149,"PHASE2":4160,"PHASE3":4162,"PHASE4":4164,"NA":4166},{"trials":4148,"activeCount":99},[],{"trials":4150,"activeCount":95,"soonestReadout":4155},[4151],{"nctId":4152,"briefTitle":4153,"status":157,"phases":4154,"primaryCompletion":4155,"completion":4155,"start":4156,"enrollment":25,"conditions":4157,"interventions":4159},"NCT07567235","Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis",[87],"2027-03-01","2026-05-20",[4158,18],"Radiation-Induced Skin Fibrosis",[4145,4145,4145],{"trials":4161,"activeCount":99},[],{"trials":4163,"activeCount":99},[],{"trials":4165,"activeCount":99},[],{"trials":4167,"activeCount":99},[],{"intervention":4169,"totalTrials":95,"cells":4170},"Chidamide",{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4182,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4172,"activeCount":99},[],{"trials":4174,"activeCount":95,"soonestReadout":1576},[4175],{"nctId":4176,"briefTitle":4177,"status":157,"phases":4178,"primaryCompletion":1576,"completion":1576,"start":4179,"enrollment":304,"conditions":4180,"interventions":4181},"NCT07545967","Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy",[87],"2026-04-23",[1266],[4169,4169],{"trials":4183,"activeCount":99},[],{"trials":4185,"activeCount":99},[],{"trials":4187,"activeCount":99},[],{"trials":4189,"activeCount":99},[],{"intervention":4191,"totalTrials":95,"cells":4192},"YMN-136 Vaccine",{"EARLY_PHASE1":4193,"PHASE1":4195,"PHASE2":4204,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4194,"activeCount":99},[],{"trials":4196,"activeCount":95,"soonestReadout":438},[4197],{"nctId":4198,"briefTitle":4199,"status":111,"phases":4200,"primaryCompletion":438,"completion":4201,"start":562,"enrollment":25,"conditions":4202,"interventions":4203},"NCT07409805","YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment",[87],"2028-03-01",[15],[4191],{"trials":4205,"activeCount":99},[],{"trials":4207,"activeCount":99},[],{"trials":4209,"activeCount":99},[],{"trials":4211,"activeCount":99},[],{"intervention":4213,"totalTrials":95,"cells":4214},"IMP3-saRNA (YMN-136) Vaccine",{"EARLY_PHASE1":4215,"PHASE1":4217,"PHASE2":4225,"PHASE3":4227,"PHASE4":4229,"NA":4231},{"trials":4216,"activeCount":99},[],{"trials":4218,"activeCount":95,"soonestReadout":301},[4219],{"nctId":4220,"briefTitle":4221,"status":157,"phases":4222,"primaryCompletion":301,"completion":302,"start":2315,"enrollment":25,"conditions":4223,"interventions":4224},"NCT07561723","IMP3-saRNA Vaccine in Advanced NSCLC",[87],[1773],[4213],{"trials":4226,"activeCount":99},[],{"trials":4228,"activeCount":99},[],{"trials":4230,"activeCount":99},[],{"trials":4232,"activeCount":99},[],{"intervention":308,"totalTrials":95,"cells":4234},{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4243,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4236,"activeCount":99},[],{"trials":4238,"activeCount":95,"soonestReadout":301},[4239],{"nctId":298,"briefTitle":299,"status":157,"phases":4240,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":4241,"interventions":4242},[87],[306],[308,290],{"trials":4244,"activeCount":99},[],{"trials":4246,"activeCount":99},[],{"trials":4248,"activeCount":99},[],{"trials":4250,"activeCount":99},[],{"intervention":3634,"totalTrials":95,"cells":4252},{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4254,"activeCount":99},[],{"trials":4256,"activeCount":95,"soonestReadout":560},[4257],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4258,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4259,"interventions":4260},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4262,"activeCount":99},[],{"trials":4264,"activeCount":99},[],{"trials":4266,"activeCount":99},[],{"trials":4268,"activeCount":99},[],{"intervention":3635,"totalTrials":95,"cells":4270},{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4279,"PHASE3":4281,"PHASE4":4283,"NA":4285},{"trials":4272,"activeCount":99},[],{"trials":4274,"activeCount":95,"soonestReadout":560},[4275],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4276,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4277,"interventions":4278},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4280,"activeCount":99},[],{"trials":4282,"activeCount":99},[],{"trials":4284,"activeCount":99},[],{"trials":4286,"activeCount":99},[],{"intervention":3636,"totalTrials":95,"cells":4288},{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4297,"PHASE3":4299,"PHASE4":4301,"NA":4303},{"trials":4290,"activeCount":99},[],{"trials":4292,"activeCount":95,"soonestReadout":560},[4293],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4294,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4295,"interventions":4296},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4298,"activeCount":99},[],{"trials":4300,"activeCount":99},[],{"trials":4302,"activeCount":99},[],{"trials":4304,"activeCount":99},[],{"intervention":3637,"totalTrials":95,"cells":4306},{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4315,"PHASE3":4317,"PHASE4":4319,"NA":4321},{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":95,"soonestReadout":560},[4311],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4312,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4313,"interventions":4314},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[],{"trials":4320,"activeCount":99},[],{"trials":4322,"activeCount":99},[],{"intervention":3638,"totalTrials":95,"cells":4324},{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4339},{"trials":4326,"activeCount":99},[],{"trials":4328,"activeCount":95,"soonestReadout":560},[4329],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4330,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4331,"interventions":4332},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[],{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[],{"intervention":3639,"totalTrials":95,"cells":4342},{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4351,"PHASE3":4353,"PHASE4":4355,"NA":4357},{"trials":4344,"activeCount":99},[],{"trials":4346,"activeCount":95,"soonestReadout":560},[4347],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4348,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4349,"interventions":4350},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4352,"activeCount":99},[],{"trials":4354,"activeCount":99},[],{"trials":4356,"activeCount":99},[],{"trials":4358,"activeCount":99},[],{"intervention":3640,"totalTrials":95,"cells":4360},{"EARLY_PHASE1":4361,"PHASE1":4363,"PHASE2":4369,"PHASE3":4371,"PHASE4":4373,"NA":4375},{"trials":4362,"activeCount":99},[],{"trials":4364,"activeCount":95,"soonestReadout":560},[4365],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4366,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4367,"interventions":4368},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4370,"activeCount":99},[],{"trials":4372,"activeCount":99},[],{"trials":4374,"activeCount":99},[],{"trials":4376,"activeCount":99},[],{"intervention":3641,"totalTrials":95,"cells":4378},{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4387,"PHASE3":4389,"PHASE4":4391,"NA":4393},{"trials":4380,"activeCount":99},[],{"trials":4382,"activeCount":95,"soonestReadout":560},[4383],{"nctId":3627,"briefTitle":3628,"status":157,"phases":4384,"primaryCompletion":560,"completion":561,"start":3630,"enrollment":3631,"conditions":4385,"interventions":4386},[87],[3524],[3634,3635,3636,3637,3638,3639,3640,3641,3620],{"trials":4388,"activeCount":99},[],{"trials":4390,"activeCount":99},[],{"trials":4392,"activeCount":99},[],{"trials":4394,"activeCount":99},[],{"intervention":4396,"totalTrials":95,"cells":4397},"25 μg NCP-IL-22BP mRNA",{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4413,"PHASE3":4415,"PHASE4":4417,"NA":4419},{"trials":4399,"activeCount":99},[],{"trials":4401,"activeCount":95,"soonestReadout":4406},[4402],{"nctId":4403,"briefTitle":4404,"status":111,"phases":4405,"primaryCompletion":4406,"completion":4407,"start":303,"enrollment":25,"conditions":4408,"interventions":4410},"NCT07562815","Safety and Tolerability of NCP-IL-22BP mRNA in Advanced Solid Tumors",[87],"2027-04-28","2027-12-28",[4409],"Cancer",[4396,4411,4412],"50 μg NCP-IL-22BP mRNA","100 μg NCP-IL-22BP mRNA",{"trials":4414,"activeCount":99},[],{"trials":4416,"activeCount":99},[],{"trials":4418,"activeCount":99},[],{"trials":4420,"activeCount":99},[],{"intervention":4411,"totalTrials":95,"cells":4422},{"EARLY_PHASE1":4423,"PHASE1":4425,"PHASE2":4431,"PHASE3":4433,"PHASE4":4435,"NA":4437},{"trials":4424,"activeCount":99},[],{"trials":4426,"activeCount":95,"soonestReadout":4406},[4427],{"nctId":4403,"briefTitle":4404,"status":111,"phases":4428,"primaryCompletion":4406,"completion":4407,"start":303,"enrollment":25,"conditions":4429,"interventions":4430},[87],[4409],[4396,4411,4412],{"trials":4432,"activeCount":99},[],{"trials":4434,"activeCount":99},[],{"trials":4436,"activeCount":99},[],{"trials":4438,"activeCount":99},[],{"intervention":4412,"totalTrials":95,"cells":4440},{"EARLY_PHASE1":4441,"PHASE1":4443,"PHASE2":4449,"PHASE3":4451,"PHASE4":4453,"NA":4455},{"trials":4442,"activeCount":99},[],{"trials":4444,"activeCount":95,"soonestReadout":4406},[4445],{"nctId":4403,"briefTitle":4404,"status":111,"phases":4446,"primaryCompletion":4406,"completion":4407,"start":303,"enrollment":25,"conditions":4447,"interventions":4448},[87],[4409],[4396,4411,4412],{"trials":4450,"activeCount":99},[],{"trials":4452,"activeCount":99},[],{"trials":4454,"activeCount":99},[],{"trials":4456,"activeCount":99},[],{"intervention":4458,"totalTrials":95,"cells":4459},"PAN-NeoVax",{"EARLY_PHASE1":4460,"PHASE1":4462,"PHASE2":4470,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4461,"activeCount":99},[],{"trials":4463,"activeCount":95,"soonestReadout":4406},[4464],{"nctId":4465,"briefTitle":4466,"status":157,"phases":4467,"primaryCompletion":4406,"completion":4407,"start":303,"enrollment":25,"conditions":4468,"interventions":4469},"NCT07560943","Safety and Tolerability of AI-Designed Pan-Cancer Neoantigen mRNA Vaccine (PAN-NeoVax) in Advanced Solid Tumors",[87],[4409],[4458,4458,4458],{"trials":4471,"activeCount":99},[],{"trials":4473,"activeCount":99},[],{"trials":4475,"activeCount":99},[],{"trials":4477,"activeCount":99},[],{"intervention":4479,"totalTrials":95,"cells":4480},"CD19\u002FBCMA in vivo CAR-T",{"EARLY_PHASE1":4481,"PHASE1":4492,"PHASE2":4494,"PHASE3":4496,"PHASE4":4498,"NA":4500},{"trials":4482,"activeCount":95,"soonestReadout":4487},[4483],{"nctId":4484,"briefTitle":4485,"status":111,"phases":4486,"primaryCompletion":4487,"completion":114,"start":4488,"enrollment":3532,"conditions":4489,"interventions":4491},"NCT07388212","Exploratory Study on LNP-mRNA Drugs Targeting CD19\u002FBCMA for the Treatment of Relapsed and Refractory Autoimmune Diseases",[86],"2028-01-01","2026-02-23",[4490],"Autoimmune Diseases",[4479],{"trials":4493,"activeCount":99},[],{"trials":4495,"activeCount":99},[],{"trials":4497,"activeCount":99},[],{"trials":4499,"activeCount":99},[],{"trials":4501,"activeCount":99},[],{"intervention":4503,"totalTrials":95,"cells":4504},"JWK010 gene therapy",{"EARLY_PHASE1":4505,"PHASE1":4515,"PHASE2":4517,"PHASE3":4519,"PHASE4":4521,"NA":4523},{"trials":4506,"activeCount":95,"soonestReadout":343},[4507],{"nctId":4508,"briefTitle":4509,"status":157,"phases":4510,"primaryCompletion":343,"completion":343,"start":4511,"enrollment":3772,"conditions":4512,"interventions":4514},"NCT07313618","Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1)",[86],"2025-12-22",[4513],"Oculocutaneous Albinism (OCA)",[4503],{"trials":4516,"activeCount":99},[],{"trials":4518,"activeCount":99},[],{"trials":4520,"activeCount":99},[],{"trials":4522,"activeCount":99},[],{"trials":4524,"activeCount":99},[],{"intervention":4526,"totalTrials":95,"cells":4527},"ICG-Cisplatin Nanoprobe",{"EARLY_PHASE1":4528,"PHASE1":4539,"PHASE2":4541,"PHASE3":4543,"PHASE4":4545,"NA":4547},{"trials":4529,"activeCount":95,"soonestReadout":4534},[4530],{"nctId":4531,"briefTitle":4532,"status":157,"phases":4533,"primaryCompletion":4534,"completion":625,"start":4535,"enrollment":410,"conditions":4536,"interventions":4538},"NCT07295262","NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC",[86],"2028-07-01","2026-01-01",[4537],"Liver Cancer, Adult",[4526],{"trials":4540,"activeCount":99},[],{"trials":4542,"activeCount":99},[],{"trials":4544,"activeCount":99},[],{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[],{"intervention":4550,"totalTrials":95,"cells":4551},"JWK002",{"EARLY_PHASE1":4552,"PHASE1":4563,"PHASE2":4565,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4553,"activeCount":95,"soonestReadout":4558},[4554],{"nctId":4555,"briefTitle":4556,"status":157,"phases":4557,"primaryCompletion":4558,"completion":4558,"start":4559,"enrollment":939,"conditions":4560,"interventions":4562},"NCT06345898","Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)",[86],"2033-11-30","2023-11-17",[4561],"X Linked Retinoschisis",[4550],{"trials":4564,"activeCount":99},[],{"trials":4566,"activeCount":99},[],{"trials":4568,"activeCount":99},[],{"trials":4570,"activeCount":99},[],{"trials":4572,"activeCount":99},[],{"intervention":4574,"totalTrials":95,"cells":4575},"WGb-0301",{"EARLY_PHASE1":4576,"PHASE1":4586,"PHASE2":4588,"PHASE3":4590,"PHASE4":4592,"NA":4594},{"trials":4577,"activeCount":95,"soonestReadout":536},[4578],{"nctId":4579,"briefTitle":4580,"status":111,"phases":4581,"primaryCompletion":536,"completion":114,"start":4582,"enrollment":4583,"conditions":4584,"interventions":4585},"NCT07349823","Exploratory Study on the Treatment of Relapsed and Refractory Immune Related Diseases With WGb-0301 Injection",[86],"2026-01-26",47,[4490],[4574],{"trials":4587,"activeCount":99},[],{"trials":4589,"activeCount":99},[],{"trials":4591,"activeCount":99},[],{"trials":4593,"activeCount":99},[],{"trials":4595,"activeCount":99},[],{"intervention":4597,"totalTrials":259,"cells":4598},"Tramadol",{"EARLY_PHASE1":4599,"PHASE1":4601,"PHASE2":4603,"PHASE3":4605,"PHASE4":4619,"NA":4621},{"trials":4600,"activeCount":99},[],{"trials":4602,"activeCount":99},[],{"trials":4604,"activeCount":99},[],{"trials":4606,"activeCount":99},[4607],{"nctId":4608,"briefTitle":4609,"status":280,"phases":4610,"primaryCompletion":4611,"completion":4612,"start":4613,"enrollment":1823,"conditions":4614,"interventions":4618},"NCT01721031","DPNB for Prevention of CRDB",[89],"2015-12-01","2015-12-15","2013-04-01",[4615,4616,4617],"Indwelling Urinary Catheter","Male Patients","General Anesthesia",[4597],{"trials":4620,"activeCount":99},[],{"trials":4622,"activeCount":95,"soonestReadout":1075},[4623],{"nctId":4624,"briefTitle":4625,"status":111,"phases":4626,"primaryCompletion":1075,"completion":536,"start":2126,"enrollment":345,"conditions":4627,"interventions":4631},"NCT06728033","Fascia Iliaca Compartment Block and Tramadol for Analgesia in Hip Fracture",[91],[4628,4629,4630],"Hip Fractures","Ultrasound-guided Nerve Block","Perioperative Analgesia",[4597],{"intervention":4633,"totalTrials":259,"cells":4634},"Ursodeoxycholic Acid",{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4639,"PHASE3":4641,"PHASE4":4643,"NA":4657},{"trials":4636,"activeCount":99},[],{"trials":4638,"activeCount":99},[],{"trials":4640,"activeCount":99},[],{"trials":4642,"activeCount":99},[],{"trials":4644,"activeCount":99},[4645],{"nctId":4646,"briefTitle":4647,"status":314,"phases":4648,"primaryCompletion":950,"completion":950,"start":4649,"enrollment":4650,"conditions":4651,"interventions":4654},"NCT04617561","Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II",[90],"2020-11-01",90,[4652,4653],"Hepatitis, Autoimmune","Primary Biliary Cholangitis",[4655,4656],"Ursodeoxycholic acid","Ursodeoxycholic acid+Low Dose Glucocorticoid",{"trials":4658,"activeCount":95,"soonestReadout":561},[4659],{"nctId":4660,"briefTitle":4661,"status":111,"phases":4662,"primaryCompletion":561,"completion":536,"start":4535,"enrollment":4663,"conditions":4664,"interventions":4667},"NCT07273734","UDCA to Prevent Post-TIPS Hepatic Encephalopathy",[91],270,[4665,4666],"Hepatic Encephalopathy (HE)","TIPS",[4633,4668],"Lactulose",{"intervention":70,"totalTrials":259,"cells":4670},{"EARLY_PHASE1":4671,"PHASE1":4673,"PHASE2":4675,"PHASE3":4677,"PHASE4":4679,"NA":4681},{"trials":4672,"activeCount":99},[],{"trials":4674,"activeCount":99},[],{"trials":4676,"activeCount":99},[],{"trials":4678,"activeCount":99},[],{"trials":4680,"activeCount":99},[],{"trials":4682,"activeCount":95,"soonestReadout":69},[4683,4693],{"nctId":4684,"briefTitle":4685,"status":280,"phases":4686,"primaryCompletion":4687,"completion":4688,"start":4689,"enrollment":4690,"conditions":4691,"interventions":4692},"NCT05920980","Effect of Lidocaine on Postoperative Pain in Elderlypatients Undergoing Colorectal Cancer Surgery",[91],"2025-01-13","2025-01-23","2023-06-05",276,[15],[70],{"nctId":67,"briefTitle":68,"status":157,"phases":4694,"primaryCompletion":69,"completion":2985,"start":4689,"enrollment":4690,"conditions":4695,"interventions":4696},[91],[15],[70],{"intervention":4698,"totalTrials":95,"cells":4699},"Disitamab vedotin + Sintilimab + Multimodality radiotherapy",{"EARLY_PHASE1":4700,"PHASE1":4702,"PHASE2":4704,"PHASE3":4706,"PHASE4":4708,"NA":4710},{"trials":4701,"activeCount":99},[],{"trials":4703,"activeCount":99},[],{"trials":4705,"activeCount":99},[],{"trials":4707,"activeCount":99},[],{"trials":4709,"activeCount":99},[],{"trials":4711,"activeCount":95,"soonestReadout":4716},[4712],{"nctId":4713,"briefTitle":4714,"status":111,"phases":4715,"primaryCompletion":4716,"completion":4717,"start":782,"enrollment":410,"conditions":4718,"interventions":4720},"NCT07490990","A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure",[],"2028-06","2028-12",[4719],"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",[4698],{"intervention":4722,"totalTrials":95,"cells":4723},"ROS-scavenging Nanoenzymes",{"EARLY_PHASE1":4724,"PHASE1":4726,"PHASE2":4728,"PHASE3":4730,"PHASE4":4732,"NA":4734},{"trials":4725,"activeCount":99},[],{"trials":4727,"activeCount":99},[],{"trials":4729,"activeCount":99},[],{"trials":4731,"activeCount":99},[],{"trials":4733,"activeCount":99},[],{"trials":4735,"activeCount":95,"soonestReadout":1406},[4736],{"nctId":4737,"briefTitle":4738,"status":157,"phases":4739,"primaryCompletion":1406,"completion":4740,"start":4741,"enrollment":410,"conditions":4742,"interventions":4744},"NCT07064577","Novel ROS-scavenging Nanoenzymes for the Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer",[91],"2025-10-15","2025-07-15",[4743],"Radiation Dermatitis",[4722],{"intervention":3383,"totalTrials":95,"cells":4746},{"EARLY_PHASE1":4747,"PHASE1":4749,"PHASE2":4751,"PHASE3":4753,"PHASE4":4755,"NA":4757},{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"trials":4752,"activeCount":99},[],{"trials":4754,"activeCount":99},[],{"trials":4756,"activeCount":99},[],{"trials":4758,"activeCount":95,"soonestReadout":560},[4759],{"nctId":3377,"briefTitle":3378,"status":111,"phases":4760,"primaryCompletion":560,"completion":536,"start":1029,"enrollment":319,"conditions":4761,"interventions":4762},[91],[3381],[3345,3383],{"intervention":4764,"totalTrials":95,"cells":4765},"Nonselective Beta-Blockers",{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4776},{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[],{"trials":4771,"activeCount":99},[],{"trials":4773,"activeCount":99},[],{"trials":4775,"activeCount":99},[],{"trials":4777,"activeCount":95,"soonestReadout":4782},[4778],{"nctId":4779,"briefTitle":4780,"status":111,"phases":4781,"primaryCompletion":4782,"completion":4783,"start":857,"enrollment":345,"conditions":4784,"interventions":4789},"NCT07587671","Underdilated VCX-TIPS Versus EVL Plus NSBB for Secondary Prophylaxis of Variceal Bleeding in Cirrhosis",[91],"2029-03-31","2030-07-30",[4785,21,4786,4787,4788],"Liver Cirrhosis","Gastroesophageal Varices Bleeding","Esophageal Varices","Hepatic Encephalopathy",[4764],{"intervention":4668,"totalTrials":95,"cells":4791},{"EARLY_PHASE1":4792,"PHASE1":4794,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4793,"activeCount":99},[],{"trials":4795,"activeCount":99},[],{"trials":4797,"activeCount":99},[],{"trials":4799,"activeCount":99},[],{"trials":4801,"activeCount":99},[],{"trials":4803,"activeCount":95,"soonestReadout":561},[4804],{"nctId":4660,"briefTitle":4661,"status":111,"phases":4805,"primaryCompletion":561,"completion":536,"start":4535,"enrollment":4663,"conditions":4806,"interventions":4807},[91],[4665,4666],[4633,4668],{"intervention":4809,"totalTrials":95,"cells":4810},"Photo-responsive nanozyme",{"EARLY_PHASE1":4811,"PHASE1":4813,"PHASE2":4815,"PHASE3":4817,"PHASE4":4819,"NA":4821},{"trials":4812,"activeCount":99},[],{"trials":4814,"activeCount":99},[],{"trials":4816,"activeCount":99},[],{"trials":4818,"activeCount":99},[],{"trials":4820,"activeCount":99},[],{"trials":4822,"activeCount":95,"soonestReadout":3238},[4823],{"nctId":4824,"briefTitle":4825,"status":157,"phases":4826,"primaryCompletion":3238,"completion":4827,"start":4828,"enrollment":1183,"conditions":4829,"interventions":4830},"NCT07086638","ROS-Scavenging Nanozyme Combined With Thermotherapy Alleviate Radiation Dermatitis in Patients With Head and Neck Cancer",[91],"2026-10-25","2025-07-25",[4743],[4809],{"intervention":4832,"totalTrials":95,"cells":4833},"Esketamine-lidocaine group",{"EARLY_PHASE1":4834,"PHASE1":4836,"PHASE2":4838,"PHASE3":4840,"PHASE4":4842,"NA":4844},{"trials":4835,"activeCount":99},[],{"trials":4837,"activeCount":99},[],{"trials":4839,"activeCount":99},[],{"trials":4841,"activeCount":99},[],{"trials":4843,"activeCount":99},[],{"trials":4845,"activeCount":95,"soonestReadout":4850},[4846],{"nctId":4847,"briefTitle":4848,"status":157,"phases":4849,"primaryCompletion":4850,"completion":4850,"start":4851,"enrollment":4852,"conditions":4853,"interventions":4855},"NCT06778460","Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy",[91],"2027-03-31","2023-05-05",304,[4854],"Postoperative Chronic Pain",[4832],{"intervention":4857,"totalTrials":95,"cells":4858},"Amino acid-derived lipids",{"EARLY_PHASE1":4859,"PHASE1":4861,"PHASE2":4863,"PHASE3":4865,"PHASE4":4867,"NA":4869},{"trials":4860,"activeCount":99},[],{"trials":4862,"activeCount":99},[],{"trials":4864,"activeCount":99},[],{"trials":4866,"activeCount":99},[],{"trials":4868,"activeCount":99},[],{"trials":4870,"activeCount":95,"soonestReadout":4875},[4871],{"nctId":4872,"briefTitle":4873,"status":157,"phases":4874,"primaryCompletion":4875,"completion":4876,"start":4877,"enrollment":319,"conditions":4878,"interventions":4879},"NCT07081074","ROS-scavenging Amino Acid-derived Lipids for the Prevention and Treatment of Radiation Dermatitis in Patients With Head and Neck Cancer",[91],"2026-05-23","2026-12-23","2025-07-23",[4743],[4857],{"intervention":4881,"totalTrials":95,"cells":4882},"Desflurane",{"EARLY_PHASE1":4883,"PHASE1":4885,"PHASE2":4887,"PHASE3":4889,"PHASE4":4891,"NA":4893},{"trials":4884,"activeCount":99},[],{"trials":4886,"activeCount":99},[],{"trials":4888,"activeCount":99},[],{"trials":4890,"activeCount":99},[],{"trials":4892,"activeCount":99},[],{"trials":4894,"activeCount":95,"soonestReadout":4899},[4895],{"nctId":4896,"briefTitle":4897,"status":157,"phases":4898,"primaryCompletion":4899,"completion":1454,"start":4900,"enrollment":4901,"conditions":4902,"interventions":4905},"NCT06176144","Impact of Desflurane and Sevoflurane on Postoperative Delirium in Elderly Patients",[91],"2025-07","2023-09-10",890,[4903,4904],"Delirium","Postoperative Cognitive Dysfunction",[4881,4906],"Sevoflurane",{"intervention":4906,"totalTrials":95,"cells":4908},{"EARLY_PHASE1":4909,"PHASE1":4911,"PHASE2":4913,"PHASE3":4915,"PHASE4":4917,"NA":4919},{"trials":4910,"activeCount":99},[],{"trials":4912,"activeCount":99},[],{"trials":4914,"activeCount":99},[],{"trials":4916,"activeCount":99},[],{"trials":4918,"activeCount":99},[],{"trials":4920,"activeCount":95,"soonestReadout":4899},[4921],{"nctId":4896,"briefTitle":4897,"status":157,"phases":4922,"primaryCompletion":4899,"completion":1454,"start":4900,"enrollment":4901,"conditions":4923,"interventions":4924},[91],[4903,4904],[4881,4906],{"intervention":4926,"totalTrials":95,"cells":4927},"Standard of Care",{"EARLY_PHASE1":4928,"PHASE1":4930,"PHASE2":4932,"PHASE3":4934,"PHASE4":4936,"NA":4938},{"trials":4929,"activeCount":99},[],{"trials":4931,"activeCount":99},[],{"trials":4933,"activeCount":99},[],{"trials":4935,"activeCount":99},[],{"trials":4937,"activeCount":99},[],{"trials":4939,"activeCount":95,"soonestReadout":536},[4940],{"nctId":4941,"briefTitle":4942,"status":111,"phases":4943,"primaryCompletion":536,"completion":985,"start":4944,"enrollment":385,"conditions":4945,"interventions":4947},"NCT07402252","Effectiveness and Safety of a Type A Dissection Total Endovascular Reconstruction System in Promoting Favorable Distal Aortic Remodeling",[91],"2026-02-09",[4946],"Residual Dissection After Repair for Type A Aortic Dissection",[4926],{"intervention":4949,"totalTrials":95,"cells":4950},"Different categories of antibiotics",{"EARLY_PHASE1":4951,"PHASE1":4953,"PHASE2":4955,"PHASE3":4957,"PHASE4":4959,"NA":4961},{"trials":4952,"activeCount":99},[],{"trials":4954,"activeCount":99},[],{"trials":4956,"activeCount":99},[],{"trials":4958,"activeCount":99},[],{"trials":4960,"activeCount":99},[],{"trials":4962,"activeCount":95,"soonestReadout":4967},[4963],{"nctId":4964,"briefTitle":4965,"status":200,"phases":4966,"primaryCompletion":4967,"completion":856,"start":69,"enrollment":4968,"conditions":4969,"interventions":4971},"NCT06770465","Maternal Use of Antibiotics and the Risk of Congenital Malformations",[],"2025-06-30",850000,[4970],"Congenital Malformations",[4949],{"intervention":4973,"totalTrials":95,"cells":4974},"PCSK9 inhibitor",{"EARLY_PHASE1":4975,"PHASE1":4977,"PHASE2":4979,"PHASE3":4981,"PHASE4":4983,"NA":4985},{"trials":4976,"activeCount":99},[],{"trials":4978,"activeCount":99},[],{"trials":4980,"activeCount":99},[],{"trials":4982,"activeCount":99},[],{"trials":4984,"activeCount":99},[],{"trials":4986,"activeCount":95,"soonestReadout":963},[4987],{"nctId":4988,"briefTitle":4989,"status":111,"phases":4990,"primaryCompletion":963,"completion":4716,"start":965,"enrollment":4991,"conditions":4992,"interventions":4993},"NCT06791031","PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)",[91],212,[164],[4973],{"intervention":4995,"totalTrials":95,"cells":4996},"surufatinib",{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5001,"PHASE3":5003,"PHASE4":5005,"NA":5007},{"trials":4998,"activeCount":99},[],{"trials":5000,"activeCount":99},[],{"trials":5002,"activeCount":99},[],{"trials":5004,"activeCount":99},[],{"trials":5006,"activeCount":99},[],{"trials":5008,"activeCount":95,"soonestReadout":5013},[5009],{"nctId":5010,"briefTitle":5011,"status":200,"phases":5012,"primaryCompletion":5013,"completion":5013,"start":5014,"enrollment":5015,"conditions":5016,"interventions":5018},"NCT07534371","Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study",[],"2026-07","2026-03-06",500,[5017],"Neuroendocrine Tumors",[4995,5019],"Somatostatin Analogs",{"intervention":5019,"totalTrials":95,"cells":5021},{"EARLY_PHASE1":5022,"PHASE1":5024,"PHASE2":5026,"PHASE3":5028,"PHASE4":5030,"NA":5032},{"trials":5023,"activeCount":99},[],{"trials":5025,"activeCount":99},[],{"trials":5027,"activeCount":99},[],{"trials":5029,"activeCount":99},[],{"trials":5031,"activeCount":99},[],{"trials":5033,"activeCount":95,"soonestReadout":5013},[5034],{"nctId":5010,"briefTitle":5011,"status":200,"phases":5035,"primaryCompletion":5013,"completion":5013,"start":5014,"enrollment":5015,"conditions":5036,"interventions":5037},[],[5017],[4995,5019],{"intervention":5039,"totalTrials":95,"cells":5040},"Intravenous iron isomaltose anhydride",{"EARLY_PHASE1":5041,"PHASE1":5043,"PHASE2":5045,"PHASE3":5047,"PHASE4":5049,"NA":5051},{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[],{"trials":5046,"activeCount":99},[],{"trials":5048,"activeCount":99},[],{"trials":5050,"activeCount":99},[],{"trials":5052,"activeCount":95,"soonestReadout":5057},[5053],{"nctId":5054,"briefTitle":5055,"status":111,"phases":5056,"primaryCompletion":5057,"completion":5058,"start":5059,"enrollment":5060,"conditions":5061,"interventions":5063},"NCT03915327","Short-term Intravenous Iron Isomaltose Anhydride for IDA",[91],"2028-05-31","2029-05-31","2024-07-05",1600,[5062],"Iron Deficiency Anemia",[5039],{"intervention":5065,"totalTrials":259,"cells":5066},"Hydrochlorothiazide",{"EARLY_PHASE1":5067,"PHASE1":5069,"PHASE2":5071,"PHASE3":5073,"PHASE4":5075,"NA":5102},{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"trials":5072,"activeCount":99},[],{"trials":5074,"activeCount":99},[],{"trials":5076,"activeCount":99},[5077,5089],{"nctId":5078,"briefTitle":5079,"status":280,"phases":5080,"primaryCompletion":5081,"completion":5082,"start":5083,"enrollment":345,"conditions":5084,"interventions":5087},"NCT01172431","Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency",[90],"2012-03","2013-12","2010-09",[5085,5086],"Hypertension","Renal Insufficiency",[5088,5065],"Indapamide",{"nctId":5090,"briefTitle":5091,"status":314,"phases":5092,"primaryCompletion":5093,"completion":5094,"start":5095,"enrollment":5096,"conditions":5097,"interventions":5098},"NCT02217852","Treatment of Hypertension in Tibetan Adult Population",[90],"2016-01","2016-07","2014-08",800,[5085],[5099,5065,5100,5101],"Nitrendipine","Captopril,Hydrochlorothiazide","Beijing hypotensive No.0",{"trials":5103,"activeCount":99},[],{"intervention":5088,"totalTrials":95,"cells":5105},{"EARLY_PHASE1":5106,"PHASE1":5108,"PHASE2":5110,"PHASE3":5112,"PHASE4":5114,"NA":5120},{"trials":5107,"activeCount":99},[],{"trials":5109,"activeCount":99},[],{"trials":5111,"activeCount":99},[],{"trials":5113,"activeCount":99},[],{"trials":5115,"activeCount":99},[5116],{"nctId":5078,"briefTitle":5079,"status":280,"phases":5117,"primaryCompletion":5081,"completion":5082,"start":5083,"enrollment":345,"conditions":5118,"interventions":5119},[90],[5085,5086],[5088,5065],{"trials":5121,"activeCount":99},[],{"intervention":5123,"totalTrials":95,"cells":5124},"18-22mg\u002Fkg\u002Fd Ursodeoxycholic",{"EARLY_PHASE1":5125,"PHASE1":5127,"PHASE2":5129,"PHASE3":5131,"PHASE4":5133,"NA":5144},{"trials":5126,"activeCount":99},[],{"trials":5128,"activeCount":99},[],{"trials":5130,"activeCount":99},[],{"trials":5132,"activeCount":99},[],{"trials":5134,"activeCount":99},[5135],{"nctId":5136,"briefTitle":5137,"status":314,"phases":5138,"primaryCompletion":250,"completion":5139,"start":5140,"enrollment":319,"conditions":5141,"interventions":5142},"NCT03345589","A Trial of 18-22mg\u002Fkg\u002Fd Ursodeoxycholic in Refractory Primary Biliary Cholangitis",[90],"2019-01-01","2018-01-30",[4653],[5123,5143],"13-15mg\u002Fkg\u002Fd Ursodeoxycholic",{"trials":5145,"activeCount":99},[],{"intervention":5143,"totalTrials":95,"cells":5147},{"EARLY_PHASE1":5148,"PHASE1":5150,"PHASE2":5152,"PHASE3":5154,"PHASE4":5156,"NA":5162},{"trials":5149,"activeCount":99},[],{"trials":5151,"activeCount":99},[],{"trials":5153,"activeCount":99},[],{"trials":5155,"activeCount":99},[],{"trials":5157,"activeCount":99},[5158],{"nctId":5136,"briefTitle":5137,"status":314,"phases":5159,"primaryCompletion":250,"completion":5139,"start":5140,"enrollment":319,"conditions":5160,"interventions":5161},[90],[4653],[5123,5143],{"trials":5163,"activeCount":99},[],{"intervention":5165,"totalTrials":95,"cells":5166},"midazolam",{"EARLY_PHASE1":5167,"PHASE1":5169,"PHASE2":5171,"PHASE3":5173,"PHASE4":5175,"NA":5191},{"trials":5168,"activeCount":99},[],{"trials":5170,"activeCount":99},[],{"trials":5172,"activeCount":99},[],{"trials":5174,"activeCount":99},[],{"trials":5176,"activeCount":99},[5177],{"nctId":5178,"briefTitle":5179,"status":314,"phases":5180,"primaryCompletion":5181,"completion":5182,"start":5183,"enrollment":345,"conditions":5184,"interventions":5187},"NCT02528513","Midazolam Used Alone or Sequential Use of Midazolam and Propofol\u002FDexmedetomidine in Mechanically Ventilated Patients",[90],"2016-12","2017-02","2015-12",[5185,5186,4903],"Mechanical Ventilation","Complication",[5165,5188,5189,5190,5165],"Fentanyl","propofol","Dexmedetomidine",{"trials":5192,"activeCount":99},[],{"intervention":5188,"totalTrials":95,"cells":5194},{"EARLY_PHASE1":5195,"PHASE1":5197,"PHASE2":5199,"PHASE3":5201,"PHASE4":5203,"NA":5209},{"trials":5196,"activeCount":99},[],{"trials":5198,"activeCount":99},[],{"trials":5200,"activeCount":99},[],{"trials":5202,"activeCount":99},[],{"trials":5204,"activeCount":99},[5205],{"nctId":5178,"briefTitle":5179,"status":314,"phases":5206,"primaryCompletion":5181,"completion":5182,"start":5183,"enrollment":345,"conditions":5207,"interventions":5208},[90],[5185,5186,4903],[5165,5188,5189,5190,5165],{"trials":5210,"activeCount":99},[],{"intervention":5099,"totalTrials":95,"cells":5212},{"EARLY_PHASE1":5213,"PHASE1":5215,"PHASE2":5217,"PHASE3":5219,"PHASE4":5221,"NA":5227},{"trials":5214,"activeCount":99},[],{"trials":5216,"activeCount":99},[],{"trials":5218,"activeCount":99},[],{"trials":5220,"activeCount":99},[],{"trials":5222,"activeCount":99},[5223],{"nctId":5090,"briefTitle":5091,"status":314,"phases":5224,"primaryCompletion":5093,"completion":5094,"start":5095,"enrollment":5096,"conditions":5225,"interventions":5226},[90],[5085],[5099,5065,5100,5101],{"trials":5228,"activeCount":99},[],{"intervention":5100,"totalTrials":95,"cells":5230},{"EARLY_PHASE1":5231,"PHASE1":5233,"PHASE2":5235,"PHASE3":5237,"PHASE4":5239,"NA":5245},{"trials":5232,"activeCount":99},[],{"trials":5234,"activeCount":99},[],{"trials":5236,"activeCount":99},[],{"trials":5238,"activeCount":99},[],{"trials":5240,"activeCount":99},[5241],{"nctId":5090,"briefTitle":5091,"status":314,"phases":5242,"primaryCompletion":5093,"completion":5094,"start":5095,"enrollment":5096,"conditions":5243,"interventions":5244},[90],[5085],[5099,5065,5100,5101],{"trials":5246,"activeCount":99},[],{"intervention":5101,"totalTrials":95,"cells":5248},{"EARLY_PHASE1":5249,"PHASE1":5251,"PHASE2":5253,"PHASE3":5255,"PHASE4":5257,"NA":5263},{"trials":5250,"activeCount":99},[],{"trials":5252,"activeCount":99},[],{"trials":5254,"activeCount":99},[],{"trials":5256,"activeCount":99},[],{"trials":5258,"activeCount":99},[5259],{"nctId":5090,"briefTitle":5091,"status":314,"phases":5260,"primaryCompletion":5093,"completion":5094,"start":5095,"enrollment":5096,"conditions":5261,"interventions":5262},[90],[5085],[5099,5065,5100,5101],{"trials":5264,"activeCount":99},[],{"intervention":4656,"totalTrials":95,"cells":5266},{"EARLY_PHASE1":5267,"PHASE1":5269,"PHASE2":5271,"PHASE3":5273,"PHASE4":5275,"NA":5281},{"trials":5268,"activeCount":99},[],{"trials":5270,"activeCount":99},[],{"trials":5272,"activeCount":99},[],{"trials":5274,"activeCount":99},[],{"trials":5276,"activeCount":99},[5277],{"nctId":4646,"briefTitle":4647,"status":314,"phases":5278,"primaryCompletion":950,"completion":950,"start":4649,"enrollment":4650,"conditions":5279,"interventions":5280},[90],[4652,4653],[4655,4656],{"trials":5282,"activeCount":99},[],{"intervention":5284,"totalTrials":95,"cells":5285},"danshen dripping pill",{"EARLY_PHASE1":5286,"PHASE1":5288,"PHASE2":5290,"PHASE3":5292,"PHASE4":5294,"NA":5306},{"trials":5287,"activeCount":99},[],{"trials":5289,"activeCount":99},[],{"trials":5291,"activeCount":99},[],{"trials":5293,"activeCount":99},[],{"trials":5295,"activeCount":99},[5296],{"nctId":5297,"briefTitle":5298,"status":314,"phases":5299,"primaryCompletion":5300,"completion":5300,"start":5301,"enrollment":2205,"conditions":5302,"interventions":5305},"NCT01825759","Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function",[90],"2014-12","2013-01",[5303,5304],"Coronary Heart Disease","Essential Hypertension",[5284],{"trials":5307,"activeCount":99},[],{"intervention":5309,"totalTrials":95,"cells":5310},"Hydrocortisone",{"EARLY_PHASE1":5311,"PHASE1":5313,"PHASE2":5315,"PHASE3":5317,"PHASE4":5319,"NA":5331},{"trials":5312,"activeCount":99},[],{"trials":5314,"activeCount":99},[],{"trials":5316,"activeCount":99},[],{"trials":5318,"activeCount":99},[],{"trials":5320,"activeCount":99},[5321],{"nctId":5322,"briefTitle":5323,"status":314,"phases":5324,"primaryCompletion":5095,"completion":5300,"start":5325,"enrollment":284,"conditions":5326,"interventions":5329},"NCT02190994","Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions",[90],"2013-08",[5327,5328],"Pituitary Neoplasms","Craniopharyngiomas",[5309,5330],"Prednisone",{"trials":5332,"activeCount":99},[],{"intervention":5330,"totalTrials":95,"cells":5334},{"EARLY_PHASE1":5335,"PHASE1":5337,"PHASE2":5339,"PHASE3":5341,"PHASE4":5343,"NA":5349},{"trials":5336,"activeCount":99},[],{"trials":5338,"activeCount":99},[],{"trials":5340,"activeCount":99},[],{"trials":5342,"activeCount":99},[],{"trials":5344,"activeCount":99},[5345],{"nctId":5322,"briefTitle":5323,"status":314,"phases":5346,"primaryCompletion":5095,"completion":5300,"start":5325,"enrollment":284,"conditions":5347,"interventions":5348},[90],[5327,5328],[5309,5330],{"trials":5350,"activeCount":99},[],{"intervention":5352,"totalTrials":95,"cells":5353},"Cyclosporin A",{"EARLY_PHASE1":5354,"PHASE1":5356,"PHASE2":5358,"PHASE3":5360,"PHASE4":5362,"NA":5375},{"trials":5355,"activeCount":99},[],{"trials":5357,"activeCount":99},[],{"trials":5359,"activeCount":99},[],{"trials":5361,"activeCount":99},[],{"trials":5363,"activeCount":99},[5364],{"nctId":5365,"briefTitle":5366,"status":314,"phases":5367,"primaryCompletion":5368,"completion":5368,"start":5369,"enrollment":5370,"conditions":5371,"interventions":5373},"NCT04376528","Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy",[90],"2021-12-30","2021-06-16",89,[4652,4653,5372],"Immunosuppression",[5352,5374],"Mycophenolate Mofetil",{"trials":5376,"activeCount":99},[],{"intervention":5374,"totalTrials":95,"cells":5378},{"EARLY_PHASE1":5379,"PHASE1":5381,"PHASE2":5383,"PHASE3":5385,"PHASE4":5387,"NA":5393},{"trials":5380,"activeCount":99},[],{"trials":5382,"activeCount":99},[],{"trials":5384,"activeCount":99},[],{"trials":5386,"activeCount":99},[],{"trials":5388,"activeCount":99},[5389],{"nctId":5365,"briefTitle":5366,"status":314,"phases":5390,"primaryCompletion":5368,"completion":5368,"start":5369,"enrollment":5370,"conditions":5391,"interventions":5392},[90],[4652,4653,5372],[5352,5374],{"trials":5394,"activeCount":99},[],{"intervention":5396,"totalTrials":95,"cells":5397},"aspirin",{"EARLY_PHASE1":5398,"PHASE1":5400,"PHASE2":5402,"PHASE3":5404,"PHASE4":5406,"NA":5419},{"trials":5399,"activeCount":99},[],{"trials":5401,"activeCount":99},[],{"trials":5403,"activeCount":99},[],{"trials":5405,"activeCount":99},[],{"trials":5407,"activeCount":99},[5408],{"nctId":5409,"briefTitle":5410,"status":314,"phases":5411,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":284,"conditions":5415,"interventions":5417},"NCT02757365","Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer",[90],"2018-04","2019-04","2014-04",[5416],"Prostate Cancer",[5396,5418],"Levofloxacin",{"trials":5420,"activeCount":99},[],{"intervention":5418,"totalTrials":95,"cells":5422},{"EARLY_PHASE1":5423,"PHASE1":5425,"PHASE2":5427,"PHASE3":5429,"PHASE4":5431,"NA":5437},{"trials":5424,"activeCount":99},[],{"trials":5426,"activeCount":99},[],{"trials":5428,"activeCount":99},[],{"trials":5430,"activeCount":99},[],{"trials":5432,"activeCount":99},[5433],{"nctId":5409,"briefTitle":5410,"status":314,"phases":5434,"primaryCompletion":5412,"completion":5413,"start":5414,"enrollment":284,"conditions":5435,"interventions":5436},[90],[5416],[5396,5418],{"trials":5438,"activeCount":99},[],{"intervention":5440,"totalTrials":95,"cells":5441},"Deep sedation",{"EARLY_PHASE1":5442,"PHASE1":5444,"PHASE2":5446,"PHASE3":5448,"PHASE4":5450,"NA":5462},{"trials":5443,"activeCount":99},[],{"trials":5445,"activeCount":99},[],{"trials":5447,"activeCount":99},[],{"trials":5449,"activeCount":99},[],{"trials":5451,"activeCount":99},[5452],{"nctId":5453,"briefTitle":5454,"status":314,"phases":5455,"primaryCompletion":5456,"completion":5183,"start":5414,"enrollment":451,"conditions":5457,"interventions":5459},"NCT02123589","The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill Adults.",[90],"2015-05",[5458],"Sedative Withdrawal Delirium",[5440,5460,5461],"Deep and daily interruption of sedation","Light sedation",{"trials":5463,"activeCount":99},[],{"intervention":5460,"totalTrials":95,"cells":5465},{"EARLY_PHASE1":5466,"PHASE1":5468,"PHASE2":5470,"PHASE3":5472,"PHASE4":5474,"NA":5480},{"trials":5467,"activeCount":99},[],{"trials":5469,"activeCount":99},[],{"trials":5471,"activeCount":99},[],{"trials":5473,"activeCount":99},[],{"trials":5475,"activeCount":99},[5476],{"nctId":5453,"briefTitle":5454,"status":314,"phases":5477,"primaryCompletion":5456,"completion":5183,"start":5414,"enrollment":451,"conditions":5478,"interventions":5479},[90],[5458],[5440,5460,5461],{"trials":5481,"activeCount":99},[],{"intervention":5461,"totalTrials":95,"cells":5483},{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5488,"PHASE3":5490,"PHASE4":5492,"NA":5498},{"trials":5485,"activeCount":99},[],{"trials":5487,"activeCount":99},[],{"trials":5489,"activeCount":99},[],{"trials":5491,"activeCount":99},[],{"trials":5493,"activeCount":99},[5494],{"nctId":5453,"briefTitle":5454,"status":314,"phases":5495,"primaryCompletion":5456,"completion":5183,"start":5414,"enrollment":451,"conditions":5496,"interventions":5497},[90],[5458],[5440,5460,5461],{"trials":5499,"activeCount":99},[],{"intervention":5501,"totalTrials":95,"cells":5502},"Ursodeoxycholic acid combined with total glucosides of paeony",{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5507,"PHASE3":5509,"PHASE4":5511,"NA":5525},{"trials":5504,"activeCount":99},[],{"trials":5506,"activeCount":99},[],{"trials":5508,"activeCount":99},[],{"trials":5510,"activeCount":99},[],{"trials":5512,"activeCount":99},[5513],{"nctId":5514,"briefTitle":5515,"status":314,"phases":5516,"primaryCompletion":5517,"completion":5517,"start":5518,"enrollment":5519,"conditions":5520,"interventions":5523},"NCT04618575","Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1",[90],"2022-11-05","2021-03-17",137,[5521,4653,5522],"Hepatitis","Autoimmune",[5501,5524],"Ursodeoxycholic acid only",{"trials":5526,"activeCount":99},[],{"intervention":5524,"totalTrials":95,"cells":5528},{"EARLY_PHASE1":5529,"PHASE1":5531,"PHASE2":5533,"PHASE3":5535,"PHASE4":5537,"NA":5543},{"trials":5530,"activeCount":99},[],{"trials":5532,"activeCount":99},[],{"trials":5534,"activeCount":99},[],{"trials":5536,"activeCount":99},[],{"trials":5538,"activeCount":99},[5539],{"nctId":5514,"briefTitle":5515,"status":314,"phases":5540,"primaryCompletion":5517,"completion":5517,"start":5518,"enrollment":5519,"conditions":5541,"interventions":5542},[90],[5521,4653,5522],[5501,5524],{"trials":5544,"activeCount":99},[],{"intervention":5546,"totalTrials":95,"cells":5547},"Lipo-PGE1",{"EARLY_PHASE1":5548,"PHASE1":5550,"PHASE2":5552,"PHASE3":5554,"PHASE4":5556,"NA":5566},{"trials":5549,"activeCount":99},[],{"trials":5551,"activeCount":99},[],{"trials":5553,"activeCount":99},[],{"trials":5555,"activeCount":99},[],{"trials":5557,"activeCount":99},[5558],{"nctId":5559,"briefTitle":5560,"status":280,"phases":5561,"primaryCompletion":5093,"completion":5562,"start":5183,"enrollment":997,"conditions":5563,"interventions":5565},"NCT02628106","Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy",[90],"2016-02",[5564],"Diabetic Nephropathy",[5546],{"trials":5567,"activeCount":99},[],{"intervention":5569,"totalTrials":259,"cells":5570},"Capecitabine",{"EARLY_PHASE1":5571,"PHASE1":5573,"PHASE2":5575,"PHASE3":5593,"PHASE4":5606,"NA":5608},{"trials":5572,"activeCount":99},[],{"trials":5574,"activeCount":99},[],{"trials":5576,"activeCount":99},[5577],{"nctId":5578,"briefTitle":5579,"status":314,"phases":5580,"primaryCompletion":5581,"completion":5582,"start":5583,"enrollment":5584,"conditions":5585,"interventions":5588},"NCT05018182","FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer",[88],"2022-04","2022-08-02","2021-08-02",69,[5586,515,5587],"High-risk Locally Advanced Colorectal Cancer","FOLFOXIRI Regimen",[5589,5590,5591,5592,5569],"Oxaliplatin","Irinotecan","Folinic Acid","5FU",{"trials":5594,"activeCount":99},[5595],{"nctId":5596,"briefTitle":5597,"status":314,"phases":5598,"primaryCompletion":5599,"completion":5600,"start":5601,"enrollment":5602,"conditions":5603,"interventions":5605},"NCT02316535","Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II\u002FIII Colorectal Cancer",[89],"2017-12","2018-05","2014-11",710,[5604],"Colorectal Neoplasms",[5569],{"trials":5607,"activeCount":99},[],{"trials":5609,"activeCount":99},[],{"intervention":5611,"totalTrials":95,"cells":5612},"Adjuvant chemotherapy",{"EARLY_PHASE1":5613,"PHASE1":5615,"PHASE2":5617,"PHASE3":5619,"PHASE4":5635,"NA":5637},{"trials":5614,"activeCount":99},[],{"trials":5616,"activeCount":99},[],{"trials":5618,"activeCount":99},[],{"trials":5620,"activeCount":99},[5621],{"nctId":5622,"briefTitle":5623,"status":314,"phases":5624,"primaryCompletion":5625,"completion":5626,"start":5627,"enrollment":5628,"conditions":5629,"interventions":5634},"NCT03177382","Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors",[89],"2021-05-30","2023-05-30","2017-06-15",458,[5630,5631,5632,5633],"Total Neoadjuvant Treatment","Chemoradiotherapy","Local Advanced Rectal Cancer","High Risk Factors",[5611],{"trials":5636,"activeCount":99},[],{"trials":5638,"activeCount":99},[],{"intervention":851,"totalTrials":95,"cells":5640},{"EARLY_PHASE1":5641,"PHASE1":5643,"PHASE2":5645,"PHASE3":5647,"PHASE4":5653,"NA":5655},{"trials":5642,"activeCount":99},[],{"trials":5644,"activeCount":99},[],{"trials":5646,"activeCount":99},[],{"trials":5648,"activeCount":99},[5649],{"nctId":842,"briefTitle":843,"status":280,"phases":5650,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":5651,"interventions":5652},[89],[849],[831,851],{"trials":5654,"activeCount":99},[],{"trials":5656,"activeCount":99},[],{"intervention":5658,"totalTrials":95,"cells":5659},"Interferon",{"EARLY_PHASE1":5660,"PHASE1":5662,"PHASE2":5664,"PHASE3":5666,"PHASE4":5679,"NA":5681},{"trials":5661,"activeCount":99},[],{"trials":5663,"activeCount":99},[],{"trials":5665,"activeCount":99},[],{"trials":5667,"activeCount":99},[5668],{"nctId":5669,"briefTitle":5670,"status":314,"phases":5671,"primaryCompletion":1288,"completion":1288,"start":5672,"enrollment":5673,"conditions":5674,"interventions":5676},"NCT05912946","Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis",[88,89],"2023-10-15",129,[5675],"Interstitial Cystitis",[5658,5677,5678],"Sodium Hyaluronate","Sodium Chloride",{"trials":5680,"activeCount":99},[],{"trials":5682,"activeCount":99},[],{"intervention":5677,"totalTrials":95,"cells":5684},{"EARLY_PHASE1":5685,"PHASE1":5687,"PHASE2":5689,"PHASE3":5691,"PHASE4":5697,"NA":5699},{"trials":5686,"activeCount":99},[],{"trials":5688,"activeCount":99},[],{"trials":5690,"activeCount":99},[],{"trials":5692,"activeCount":99},[5693],{"nctId":5669,"briefTitle":5670,"status":314,"phases":5694,"primaryCompletion":1288,"completion":1288,"start":5672,"enrollment":5673,"conditions":5695,"interventions":5696},[88,89],[5675],[5658,5677,5678],{"trials":5698,"activeCount":99},[],{"trials":5700,"activeCount":99},[],{"intervention":5678,"totalTrials":95,"cells":5702},{"EARLY_PHASE1":5703,"PHASE1":5705,"PHASE2":5707,"PHASE3":5709,"PHASE4":5715,"NA":5717},{"trials":5704,"activeCount":99},[],{"trials":5706,"activeCount":99},[],{"trials":5708,"activeCount":99},[],{"trials":5710,"activeCount":99},[5711],{"nctId":5669,"briefTitle":5670,"status":314,"phases":5712,"primaryCompletion":1288,"completion":1288,"start":5672,"enrollment":5673,"conditions":5713,"interventions":5714},[88,89],[5675],[5658,5677,5678],{"trials":5716,"activeCount":99},[],{"trials":5718,"activeCount":99},[],{"intervention":5720,"totalTrials":95,"cells":5721},"gemcitabine and cisplatin; docetaxel, cisplatin and fluorouracil",{"EARLY_PHASE1":5722,"PHASE1":5724,"PHASE2":5726,"PHASE3":5728,"PHASE4":5740,"NA":5742},{"trials":5723,"activeCount":99},[],{"trials":5725,"activeCount":99},[],{"trials":5727,"activeCount":99},[],{"trials":5729,"activeCount":99},[5730],{"nctId":5731,"briefTitle":5732,"status":314,"phases":5733,"primaryCompletion":5734,"completion":5735,"start":976,"enrollment":5736,"conditions":5737,"interventions":5739},"NCT04414566","Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma",[89],"2022-05-30","2025-05-30",562,[5738],"Nasopharyngeal Carcinoma",[5720],{"trials":5741,"activeCount":99},[],{"trials":5743,"activeCount":99},[],{"intervention":5745,"totalTrials":95,"cells":5746},"Live Combined Bifidobacterium and Lactobacillus Tablets、Compound Glutamine Entersoluble",{"EARLY_PHASE1":5747,"PHASE1":5749,"PHASE2":5751,"PHASE3":5753,"PHASE4":5770,"NA":5772},{"trials":5748,"activeCount":99},[],{"trials":5750,"activeCount":99},[],{"trials":5752,"activeCount":99},[],{"trials":5754,"activeCount":99},[5755],{"nctId":5756,"briefTitle":5757,"status":314,"phases":5758,"primaryCompletion":5759,"completion":5760,"start":5761,"enrollment":5762,"conditions":5763,"interventions":5769},"NCT05406882","The Effects of Probiotics Combined With Glutamine in the Prevention and Treatment of Radiation Proctitis",[88,89],"2024-04-15","2024-09-30","2022-04-15",176,[5764,5765,5766,5767,5768],"Radiation Proctitis","Probiotics","Glutamine","Gut Microbiota","Bifidobacterium",[5745],{"trials":5771,"activeCount":99},[],{"trials":5773,"activeCount":99},[],{"intervention":5775,"totalTrials":95,"cells":5776},"administering RASI (the trade name or universal name will not be stipulated) before stenting",{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5783,"PHASE4":5795,"NA":5797},{"trials":5778,"activeCount":99},[],{"trials":5780,"activeCount":99},[],{"trials":5782,"activeCount":99},[],{"trials":5784,"activeCount":99},[5785],{"nctId":5786,"briefTitle":5787,"status":314,"phases":5788,"primaryCompletion":975,"completion":249,"start":5789,"enrollment":5790,"conditions":5791,"interventions":5793},"NCT05905848","Pre-operative Antihypertension Strategies-Carotid Artery Stenting",[89],"2023-06-15",560,[5792],"Carotid Stenosis",[5775,5794],"administering CCB (the trade name or universal name will not be stipulated) before stenting",{"trials":5796,"activeCount":99},[],{"trials":5798,"activeCount":99},[],{"intervention":5794,"totalTrials":95,"cells":5800},{"EARLY_PHASE1":5801,"PHASE1":5803,"PHASE2":5805,"PHASE3":5807,"PHASE4":5813,"NA":5815},{"trials":5802,"activeCount":99},[],{"trials":5804,"activeCount":99},[],{"trials":5806,"activeCount":99},[],{"trials":5808,"activeCount":99},[5809],{"nctId":5786,"briefTitle":5787,"status":314,"phases":5810,"primaryCompletion":975,"completion":249,"start":5789,"enrollment":5790,"conditions":5811,"interventions":5812},[89],[5792],[5775,5794],{"trials":5814,"activeCount":99},[],{"trials":5816,"activeCount":99},[],{"intervention":5818,"totalTrials":259,"cells":5819},"Abiraterone acetate",{"EARLY_PHASE1":5820,"PHASE1":5822,"PHASE2":5824,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5821,"activeCount":99},[],{"trials":5823,"activeCount":99},[],{"trials":5825,"activeCount":99},[5826,5835],{"nctId":5827,"briefTitle":5828,"status":314,"phases":5829,"primaryCompletion":5830,"completion":882,"start":5831,"enrollment":2127,"conditions":5832,"interventions":5833},"NCT04736108","Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate",[88],"2022-10","2021-05",[5416],[5818,424,5834],"Goserelin",{"nctId":5836,"briefTitle":5837,"status":314,"phases":5838,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":5841,"conditions":5842,"interventions":5845},"NCT03356444","Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate",[88],"2020-12","2017-11",140,[5416,5843,5844],"Castration-resistant Prostate Cancer","Drug",[5846,5847],"Abiraterone Acetate","Docetaxel",{"trials":5849,"activeCount":99},[],{"trials":5851,"activeCount":99},[],{"trials":5853,"activeCount":99},[],{"intervention":424,"totalTrials":259,"cells":5855},{"EARLY_PHASE1":5856,"PHASE1":5858,"PHASE2":5860,"PHASE3":5870,"PHASE4":5872,"NA":5874},{"trials":5857,"activeCount":99},[],{"trials":5859,"activeCount":99},[],{"trials":5861,"activeCount":99},[5862,5866],{"nctId":5827,"briefTitle":5828,"status":314,"phases":5863,"primaryCompletion":5830,"completion":882,"start":5831,"enrollment":2127,"conditions":5864,"interventions":5865},[88],[5416],[5818,424,5834],{"nctId":415,"briefTitle":416,"status":280,"phases":5867,"primaryCompletion":418,"completion":418,"start":419,"enrollment":410,"conditions":5868,"interventions":5869},[88],[421,422],[395,424],{"trials":5871,"activeCount":99},[],{"trials":5873,"activeCount":99},[],{"trials":5875,"activeCount":99},[],{"intervention":5877,"totalTrials":95,"cells":5878},"TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone",{"EARLY_PHASE1":5879,"PHASE1":5881,"PHASE2":5883,"PHASE3":5893,"PHASE4":5895,"NA":5897},{"trials":5880,"activeCount":99},[],{"trials":5882,"activeCount":99},[],{"trials":5884,"activeCount":99},[5885],{"nctId":5886,"briefTitle":5887,"status":314,"phases":5888,"primaryCompletion":115,"completion":3607,"start":1747,"enrollment":410,"conditions":5889,"interventions":5892},"NCT05156450","TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer",[88],[5890,5891],"Prostatic Neoplasms, Castration-Resistant","Drug Therapy, Combination",[5877],{"trials":5894,"activeCount":99},[],{"trials":5896,"activeCount":99},[],{"trials":5898,"activeCount":99},[],{"intervention":325,"totalTrials":95,"cells":5900},{"EARLY_PHASE1":5901,"PHASE1":5903,"PHASE2":5905,"PHASE3":5911,"PHASE4":5913,"NA":5915},{"trials":5902,"activeCount":99},[],{"trials":5904,"activeCount":99},[],{"trials":5906,"activeCount":99},[5907],{"nctId":312,"briefTitle":313,"status":314,"phases":5908,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":5909,"interventions":5910},[88],[321,322,323],[290,325],{"trials":5912,"activeCount":99},[],{"trials":5914,"activeCount":99},[],{"trials":5916,"activeCount":99},[],{"intervention":5918,"totalTrials":95,"cells":5919},"Tacrolimus ointment",{"EARLY_PHASE1":5920,"PHASE1":5922,"PHASE2":5924,"PHASE3":5935,"PHASE4":5937,"NA":5939},{"trials":5921,"activeCount":99},[],{"trials":5923,"activeCount":99},[],{"trials":5925,"activeCount":99},[5926],{"nctId":5927,"briefTitle":5928,"status":314,"phases":5929,"primaryCompletion":2898,"completion":5930,"start":5931,"enrollment":2127,"conditions":5932,"interventions":5934},"NCT04056962","Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma",[88],"2024-10-28","2019-09-01",[5933],"Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma",[5918],{"trials":5936,"activeCount":99},[],{"trials":5938,"activeCount":99},[],{"trials":5940,"activeCount":99},[],{"intervention":5942,"totalTrials":95,"cells":5943},"Lactobacillus reuteri",{"EARLY_PHASE1":5944,"PHASE1":5946,"PHASE2":5948,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5945,"activeCount":99},[],{"trials":5947,"activeCount":99},[],{"trials":5949,"activeCount":99},[5950],{"nctId":5951,"briefTitle":5952,"status":280,"phases":5953,"primaryCompletion":2126,"completion":2126,"start":5954,"enrollment":884,"conditions":5955,"interventions":5957},"NCT06285591","Lactobacillus Reuteri Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors",[88],"2024-03-01",[5956],"Head and Neck Malignant Tumors",[5942],{"trials":5959,"activeCount":99},[],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[],{"intervention":5834,"totalTrials":95,"cells":5965},{"EARLY_PHASE1":5966,"PHASE1":5968,"PHASE2":5970,"PHASE3":5976,"PHASE4":5978,"NA":5980},{"trials":5967,"activeCount":99},[],{"trials":5969,"activeCount":99},[],{"trials":5971,"activeCount":99},[5972],{"nctId":5827,"briefTitle":5828,"status":314,"phases":5973,"primaryCompletion":5830,"completion":882,"start":5831,"enrollment":2127,"conditions":5974,"interventions":5975},[88],[5416],[5818,424,5834],{"trials":5977,"activeCount":99},[],{"trials":5979,"activeCount":99},[],{"trials":5981,"activeCount":99},[],{"intervention":335,"totalTrials":95,"cells":5983},{"EARLY_PHASE1":5984,"PHASE1":5986,"PHASE2":5988,"PHASE3":5994,"PHASE4":5996,"NA":5998},{"trials":5985,"activeCount":99},[],{"trials":5987,"activeCount":99},[],{"trials":5989,"activeCount":99},[5990],{"nctId":327,"briefTitle":328,"status":314,"phases":5991,"primaryCompletion":74,"completion":330,"start":331,"enrollment":332,"conditions":5992,"interventions":5993},[88],[24],[335,290],{"trials":5995,"activeCount":99},[],{"trials":5997,"activeCount":99},[],{"trials":5999,"activeCount":99},[],{"intervention":6001,"totalTrials":95,"cells":6002},"lithium-containing mouthwash",{"EARLY_PHASE1":6003,"PHASE1":6005,"PHASE2":6007,"PHASE3":6019,"PHASE4":6021,"NA":6023},{"trials":6004,"activeCount":99},[],{"trials":6006,"activeCount":99},[],{"trials":6008,"activeCount":99},[6009],{"nctId":6010,"briefTitle":6011,"status":280,"phases":6012,"primaryCompletion":1494,"completion":6013,"start":5954,"enrollment":6014,"conditions":6015,"interventions":6017},"NCT06251050","A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy",[87,88],"2025-05-01",175,[18,6016],"Malignant Head and Neck Tumors",[6001,6018,6001],"Plcacebo mouthwash",{"trials":6020,"activeCount":99},[],{"trials":6022,"activeCount":99},[],{"trials":6024,"activeCount":99},[],{"intervention":6018,"totalTrials":95,"cells":6026},{"EARLY_PHASE1":6027,"PHASE1":6029,"PHASE2":6031,"PHASE3":6037,"PHASE4":6039,"NA":6041},{"trials":6028,"activeCount":99},[],{"trials":6030,"activeCount":99},[],{"trials":6032,"activeCount":99},[6033],{"nctId":6010,"briefTitle":6011,"status":280,"phases":6034,"primaryCompletion":1494,"completion":6013,"start":5954,"enrollment":6014,"conditions":6035,"interventions":6036},[87,88],[18,6016],[6001,6018,6001],{"trials":6038,"activeCount":99},[],{"trials":6040,"activeCount":99},[],{"trials":6042,"activeCount":99},[],{"intervention":6044,"totalTrials":95,"cells":6045},"Heparin",{"EARLY_PHASE1":6046,"PHASE1":6048,"PHASE2":6050,"PHASE3":6063,"PHASE4":6065,"NA":6067},{"trials":6047,"activeCount":99},[],{"trials":6049,"activeCount":99},[],{"trials":6051,"activeCount":99},[6052],{"nctId":6053,"briefTitle":6054,"status":314,"phases":6055,"primaryCompletion":6056,"completion":6056,"start":6057,"enrollment":6058,"conditions":6059,"interventions":6062},"NCT02940444","Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery",[87,88],"2018-06","2016-06",2000,[6060,6061],"Thromboprophylaxis","Thoracic Surgery",[6044],{"trials":6064,"activeCount":99},[],{"trials":6066,"activeCount":99},[],{"trials":6068,"activeCount":99},[],{"intervention":5589,"totalTrials":95,"cells":6070},{"EARLY_PHASE1":6071,"PHASE1":6073,"PHASE2":6075,"PHASE3":6081,"PHASE4":6083,"NA":6085},{"trials":6072,"activeCount":99},[],{"trials":6074,"activeCount":99},[],{"trials":6076,"activeCount":99},[6077],{"nctId":5578,"briefTitle":5579,"status":314,"phases":6078,"primaryCompletion":5581,"completion":5582,"start":5583,"enrollment":5584,"conditions":6079,"interventions":6080},[88],[5586,515,5587],[5589,5590,5591,5592,5569],{"trials":6082,"activeCount":99},[],{"trials":6084,"activeCount":99},[],{"trials":6086,"activeCount":99},[],{"intervention":5590,"totalTrials":95,"cells":6088},{"EARLY_PHASE1":6089,"PHASE1":6091,"PHASE2":6093,"PHASE3":6099,"PHASE4":6101,"NA":6103},{"trials":6090,"activeCount":99},[],{"trials":6092,"activeCount":99},[],{"trials":6094,"activeCount":99},[6095],{"nctId":5578,"briefTitle":5579,"status":314,"phases":6096,"primaryCompletion":5581,"completion":5582,"start":5583,"enrollment":5584,"conditions":6097,"interventions":6098},[88],[5586,515,5587],[5589,5590,5591,5592,5569],{"trials":6100,"activeCount":99},[],{"trials":6102,"activeCount":99},[],{"trials":6104,"activeCount":99},[],{"intervention":5591,"totalTrials":95,"cells":6106},{"EARLY_PHASE1":6107,"PHASE1":6109,"PHASE2":6111,"PHASE3":6117,"PHASE4":6119,"NA":6121},{"trials":6108,"activeCount":99},[],{"trials":6110,"activeCount":99},[],{"trials":6112,"activeCount":99},[6113],{"nctId":5578,"briefTitle":5579,"status":314,"phases":6114,"primaryCompletion":5581,"completion":5582,"start":5583,"enrollment":5584,"conditions":6115,"interventions":6116},[88],[5586,515,5587],[5589,5590,5591,5592,5569],{"trials":6118,"activeCount":99},[],{"trials":6120,"activeCount":99},[],{"trials":6122,"activeCount":99},[],{"intervention":5592,"totalTrials":95,"cells":6124},{"EARLY_PHASE1":6125,"PHASE1":6127,"PHASE2":6129,"PHASE3":6135,"PHASE4":6137,"NA":6139},{"trials":6126,"activeCount":99},[],{"trials":6128,"activeCount":99},[],{"trials":6130,"activeCount":99},[6131],{"nctId":5578,"briefTitle":5579,"status":314,"phases":6132,"primaryCompletion":5581,"completion":5582,"start":5583,"enrollment":5584,"conditions":6133,"interventions":6134},[88],[5586,515,5587],[5589,5590,5591,5592,5569],{"trials":6136,"activeCount":99},[],{"trials":6138,"activeCount":99},[],{"trials":6140,"activeCount":99},[],{"intervention":6142,"totalTrials":95,"cells":6143},"Streptococcus salivarius K12",{"EARLY_PHASE1":6144,"PHASE1":6146,"PHASE2":6148,"PHASE3":6158,"PHASE4":6160,"NA":6162},{"trials":6145,"activeCount":99},[],{"trials":6147,"activeCount":99},[],{"trials":6149,"activeCount":99},[6150],{"nctId":6151,"briefTitle":6152,"status":280,"phases":6153,"primaryCompletion":6154,"completion":6154,"start":1747,"enrollment":884,"conditions":6155,"interventions":6156},"NCT05918224","Streptococcus Salivarius K12 for Prevention and Treatment of Oral Mucositis in Patients Undergoing Radiotherapy",[88],"2022-11-30",[18],[6142,6157],"Streptococcus salivarius K12 simulants",{"trials":6159,"activeCount":99},[],{"trials":6161,"activeCount":99},[],{"trials":6163,"activeCount":99},[],{"intervention":6157,"totalTrials":95,"cells":6165},{"EARLY_PHASE1":6166,"PHASE1":6168,"PHASE2":6170,"PHASE3":6176,"PHASE4":6178,"NA":6180},{"trials":6167,"activeCount":99},[],{"trials":6169,"activeCount":99},[],{"trials":6171,"activeCount":99},[6172],{"nctId":6151,"briefTitle":6152,"status":280,"phases":6173,"primaryCompletion":6154,"completion":6154,"start":1747,"enrollment":884,"conditions":6174,"interventions":6175},[88],[18],[6142,6157],{"trials":6177,"activeCount":99},[],{"trials":6179,"activeCount":99},[],{"trials":6181,"activeCount":99},[],{"intervention":6183,"totalTrials":95,"cells":6184},"Foeniculum Vulgare Seed Ironing",{"EARLY_PHASE1":6185,"PHASE1":6187,"PHASE2":6189,"PHASE3":6204,"PHASE4":6206,"NA":6208},{"trials":6186,"activeCount":99},[],{"trials":6188,"activeCount":99},[],{"trials":6190,"activeCount":99},[6191],{"nctId":6192,"briefTitle":6193,"status":280,"phases":6194,"primaryCompletion":6195,"completion":6196,"start":6197,"enrollment":6198,"conditions":6199,"interventions":6203},"NCT03711487","The Effect of Foeniculum Vulgare Ironing on Gastrointestinal Recovery After Colorectal Resection",[88],"2019-06-15","2019-07-15","2018-10-20",300,[6200,6201,6202],"Colorectal Surgery","Foeniculum","Ileus",[6183],{"trials":6205,"activeCount":99},[],{"trials":6207,"activeCount":99},[],{"trials":6209,"activeCount":99},[],{"intervention":5847,"totalTrials":95,"cells":6211},{"EARLY_PHASE1":6212,"PHASE1":6214,"PHASE2":6216,"PHASE3":6222,"PHASE4":6224,"NA":6226},{"trials":6213,"activeCount":99},[],{"trials":6215,"activeCount":99},[],{"trials":6217,"activeCount":99},[6218],{"nctId":5836,"briefTitle":5837,"status":314,"phases":6219,"primaryCompletion":5839,"completion":5839,"start":5840,"enrollment":5841,"conditions":6220,"interventions":6221},[88],[5416,5843,5844],[5846,5847],{"trials":6223,"activeCount":99},[],{"trials":6225,"activeCount":99},[],{"trials":6227,"activeCount":99},[],{"intervention":6229,"totalTrials":95,"cells":6230},"Sintilimab injection plus Inlyta treatment",{"EARLY_PHASE1":6231,"PHASE1":6233,"PHASE2":6235,"PHASE3":6246,"PHASE4":6248,"NA":6250},{"trials":6232,"activeCount":99},[],{"trials":6234,"activeCount":99},[],{"trials":6236,"activeCount":99},[6237],{"nctId":6238,"briefTitle":6239,"status":314,"phases":6240,"primaryCompletion":1494,"completion":4535,"start":6241,"enrollment":966,"conditions":6242,"interventions":6245},"NCT04387500","Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma",[88],"2021-07-01",[6243,6244,30],"Carcinoma, Renal Cell","Fumarate Hydratase Deficiency",[6229],{"trials":6247,"activeCount":99},[],{"trials":6249,"activeCount":99},[],{"trials":6251,"activeCount":99},[],{"intervention":1237,"totalTrials":95,"cells":6253},{"EARLY_PHASE1":6254,"PHASE1":6256,"PHASE2":6258,"PHASE3":6264,"PHASE4":6266,"NA":6268},{"trials":6255,"activeCount":99},[],{"trials":6257,"activeCount":99},[],{"trials":6259,"activeCount":99},[6260],{"nctId":1226,"briefTitle":1227,"status":314,"phases":6261,"primaryCompletion":1229,"completion":1200,"start":1230,"enrollment":1231,"conditions":6262,"interventions":6263},[87,88],[1233,1234,1235,955],[955,1237,1238,1239,1240],{"trials":6265,"activeCount":99},[],{"trials":6267,"activeCount":99},[],{"trials":6269,"activeCount":99},[],{"intervention":1238,"totalTrials":95,"cells":6271},{"EARLY_PHASE1":6272,"PHASE1":6274,"PHASE2":6276,"PHASE3":6282,"PHASE4":6284,"NA":6286},{"trials":6273,"activeCount":99},[],{"trials":6275,"activeCount":99},[],{"trials":6277,"activeCount":99},[6278],{"nctId":1226,"briefTitle":1227,"status":314,"phases":6279,"primaryCompletion":1229,"completion":1200,"start":1230,"enrollment":1231,"conditions":6280,"interventions":6281},[87,88],[1233,1234,1235,955],[955,1237,1238,1239,1240],{"trials":6283,"activeCount":99},[],{"trials":6285,"activeCount":99},[],{"trials":6287,"activeCount":99},[],{"intervention":1239,"totalTrials":95,"cells":6289},{"EARLY_PHASE1":6290,"PHASE1":6292,"PHASE2":6294,"PHASE3":6300,"PHASE4":6302,"NA":6304},{"trials":6291,"activeCount":99},[],{"trials":6293,"activeCount":99},[],{"trials":6295,"activeCount":99},[6296],{"nctId":1226,"briefTitle":1227,"status":314,"phases":6297,"primaryCompletion":1229,"completion":1200,"start":1230,"enrollment":1231,"conditions":6298,"interventions":6299},[87,88],[1233,1234,1235,955],[955,1237,1238,1239,1240],{"trials":6301,"activeCount":99},[],{"trials":6303,"activeCount":99},[],{"trials":6305,"activeCount":99},[],{"intervention":1240,"totalTrials":95,"cells":6307},{"EARLY_PHASE1":6308,"PHASE1":6310,"PHASE2":6312,"PHASE3":6318,"PHASE4":6320,"NA":6322},{"trials":6309,"activeCount":99},[],{"trials":6311,"activeCount":99},[],{"trials":6313,"activeCount":99},[6314],{"nctId":1226,"briefTitle":1227,"status":314,"phases":6315,"primaryCompletion":1229,"completion":1200,"start":1230,"enrollment":1231,"conditions":6316,"interventions":6317},[87,88],[1233,1234,1235,955],[955,1237,1238,1239,1240],{"trials":6319,"activeCount":99},[],{"trials":6321,"activeCount":99},[],{"trials":6323,"activeCount":99},[],{"intervention":6325,"totalTrials":95,"cells":6326},"Sintilimab in combination with Multimodality Radiotherapy",{"EARLY_PHASE1":6327,"PHASE1":6329,"PHASE2":6331,"PHASE3":6341,"PHASE4":6343,"NA":6345},{"trials":6328,"activeCount":99},[],{"trials":6330,"activeCount":99},[],{"trials":6332,"activeCount":99},[6333],{"nctId":6334,"briefTitle":6335,"status":314,"phases":6336,"primaryCompletion":6337,"completion":1342,"start":6338,"enrollment":987,"conditions":6339,"interventions":6340},"NCT04917770","The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma",[88],"2022-06-30","2021-06-30",[5738],[6325],{"trials":6342,"activeCount":99},[],{"trials":6344,"activeCount":99},[],{"trials":6346,"activeCount":99},[],{"intervention":6348,"totalTrials":95,"cells":6349},"Pyrotinib Maleate",{"EARLY_PHASE1":6350,"PHASE1":6352,"PHASE2":6354,"PHASE3":6368,"PHASE4":6370,"NA":6372},{"trials":6351,"activeCount":99},[],{"trials":6353,"activeCount":99},[],{"trials":6355,"activeCount":99},[6356],{"nctId":6357,"briefTitle":6358,"status":314,"phases":6359,"primaryCompletion":6360,"completion":6361,"start":6362,"enrollment":484,"conditions":6363,"interventions":6365},"NCT04152057","Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer",[87,88],"2020-04","2021-04","2019-11",[486,6364,1235],"HER2 Positive",[6348,6366,6367],"Albumin Paclitaxel","Trastuzumab",{"trials":6369,"activeCount":99},[],{"trials":6371,"activeCount":99},[],{"trials":6373,"activeCount":99},[],{"intervention":6366,"totalTrials":95,"cells":6375},{"EARLY_PHASE1":6376,"PHASE1":6378,"PHASE2":6380,"PHASE3":6386,"PHASE4":6388,"NA":6390},{"trials":6377,"activeCount":99},[],{"trials":6379,"activeCount":99},[],{"trials":6381,"activeCount":99},[6382],{"nctId":6357,"briefTitle":6358,"status":314,"phases":6383,"primaryCompletion":6360,"completion":6361,"start":6362,"enrollment":484,"conditions":6384,"interventions":6385},[87,88],[486,6364,1235],[6348,6366,6367],{"trials":6387,"activeCount":99},[],{"trials":6389,"activeCount":99},[],{"trials":6391,"activeCount":99},[],{"intervention":6367,"totalTrials":95,"cells":6393},{"EARLY_PHASE1":6394,"PHASE1":6396,"PHASE2":6398,"PHASE3":6404,"PHASE4":6406,"NA":6408},{"trials":6395,"activeCount":99},[],{"trials":6397,"activeCount":99},[],{"trials":6399,"activeCount":99},[6400],{"nctId":6357,"briefTitle":6358,"status":314,"phases":6401,"primaryCompletion":6360,"completion":6361,"start":6362,"enrollment":484,"conditions":6402,"interventions":6403},[87,88],[486,6364,1235],[6348,6366,6367],{"trials":6405,"activeCount":99},[],{"trials":6407,"activeCount":99},[],{"trials":6409,"activeCount":99},[],{"intervention":6411,"totalTrials":95,"cells":6412},"Pyrotinib combined with albumin-bound paclitaxel and trastuzumab",{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6428,"PHASE4":6430,"NA":6432},{"trials":6414,"activeCount":99},[],{"trials":6416,"activeCount":99},[],{"trials":6418,"activeCount":99},[6419],{"nctId":6420,"briefTitle":6421,"status":314,"phases":6422,"primaryCompletion":6423,"completion":60,"start":6424,"enrollment":6425,"conditions":6426,"interventions":6427},"NCT04917900","Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer",[88],"2023-08-30","2020-12-01",216,[486],[6411],{"trials":6429,"activeCount":99},[],{"trials":6431,"activeCount":99},[],{"trials":6433,"activeCount":99},[],{"intervention":6435,"totalTrials":95,"cells":6436},"mCapOX plus cetuximab",{"EARLY_PHASE1":6437,"PHASE1":6439,"PHASE2":6441,"PHASE3":6454,"PHASE4":6456,"NA":6458},{"trials":6438,"activeCount":99},[],{"trials":6440,"activeCount":99},[],{"trials":6442,"activeCount":99},[6443],{"nctId":6444,"briefTitle":6445,"status":314,"phases":6446,"primaryCompletion":2941,"completion":6447,"start":6448,"enrollment":451,"conditions":6449,"interventions":6452},"NCT05022030","First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS\u002FBRAF Genes",[88],"2026-06-01","2021-07-21",[6450,5569,6451],"Colo-rectal Cancer","Cetuximab",[6435,6453],"mFOLFOX6 plus cetuximab",{"trials":6455,"activeCount":99},[],{"trials":6457,"activeCount":99},[],{"trials":6459,"activeCount":99},[],{"intervention":6453,"totalTrials":95,"cells":6461},{"EARLY_PHASE1":6462,"PHASE1":6464,"PHASE2":6466,"PHASE3":6472,"PHASE4":6474,"NA":6476},{"trials":6463,"activeCount":99},[],{"trials":6465,"activeCount":99},[],{"trials":6467,"activeCount":99},[6468],{"nctId":6444,"briefTitle":6445,"status":314,"phases":6469,"primaryCompletion":2941,"completion":6447,"start":6448,"enrollment":451,"conditions":6470,"interventions":6471},[88],[6450,5569,6451],[6435,6453],{"trials":6473,"activeCount":99},[],{"trials":6475,"activeCount":99},[],{"trials":6477,"activeCount":99},[],{"intervention":6479,"totalTrials":95,"cells":6480},"Almonertinib",{"EARLY_PHASE1":6481,"PHASE1":6483,"PHASE2":6485,"PHASE3":6495,"PHASE4":6497,"NA":6499},{"trials":6482,"activeCount":99},[],{"trials":6484,"activeCount":99},[],{"trials":6486,"activeCount":99},[6487],{"nctId":6488,"briefTitle":6489,"status":314,"phases":6490,"primaryCompletion":6491,"completion":4967,"start":6492,"enrollment":1455,"conditions":6493,"interventions":6494},"NCT05662813","Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy",[88],"2023-12-30","2022-11-09",[1068],[6479],{"trials":6496,"activeCount":99},[],{"trials":6498,"activeCount":99},[],{"trials":6500,"activeCount":99},[],{"intervention":6502,"totalTrials":95,"cells":6503},"Anti-PD-1 antibody drug named Sintilimab",{"EARLY_PHASE1":6504,"PHASE1":6506,"PHASE2":6508,"PHASE3":6518,"PHASE4":6520,"NA":6522},{"trials":6505,"activeCount":99},[],{"trials":6507,"activeCount":99},[],{"trials":6509,"activeCount":99},[6510],{"nctId":6511,"briefTitle":6512,"status":314,"phases":6513,"primaryCompletion":45,"completion":1608,"start":1229,"enrollment":1395,"conditions":6514,"interventions":6517},"NCT04547452","Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC",[88],[6515,30,6516],"Stage IV HCC","SBRT",[6502],{"trials":6519,"activeCount":99},[],{"trials":6521,"activeCount":99},[],{"trials":6523,"activeCount":99},[],{"intervention":3651,"totalTrials":259,"cells":6525},{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6542,"PHASE3":6544,"PHASE4":6546,"NA":6548},{"trials":6527,"activeCount":99},[],{"trials":6529,"activeCount":99},[6530,6538],{"nctId":6531,"briefTitle":6532,"status":314,"phases":6533,"primaryCompletion":882,"completion":882,"start":6534,"enrollment":22,"conditions":6535,"interventions":6537},"NCT06200376","A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer",[87],"2023-09-28",[6536],"Malignant Ascites",[3651],{"nctId":3643,"briefTitle":3644,"status":314,"phases":6539,"primaryCompletion":3646,"completion":3646,"start":3647,"enrollment":3600,"conditions":6540,"interventions":6541},[87],[3649],[3651,3620],{"trials":6543,"activeCount":99},[],{"trials":6545,"activeCount":99},[],{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[],{"intervention":6551,"totalTrials":95,"cells":6552},"Sapropterin dihydrochloride",{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6566,"PHASE3":6568,"PHASE4":6570,"NA":6572},{"trials":6554,"activeCount":99},[],{"trials":6556,"activeCount":99},[6557],{"nctId":6558,"briefTitle":6559,"status":314,"phases":6560,"primaryCompletion":6561,"completion":6562,"start":6563,"enrollment":3772,"conditions":6564,"interventions":6565},"NCT05299203","BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)",[87],"2022-12","2023-05","2022-05",[18],[6551],{"trials":6567,"activeCount":99},[],{"trials":6569,"activeCount":99},[],{"trials":6571,"activeCount":99},[],{"trials":6573,"activeCount":99},[],{"intervention":6575,"totalTrials":95,"cells":6576},"Lidocaine 1mg\u002Fkg",{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6594,"PHASE3":6596,"PHASE4":6598,"NA":6600},{"trials":6578,"activeCount":99},[],{"trials":6580,"activeCount":99},[6581],{"nctId":6582,"briefTitle":6583,"status":280,"phases":6584,"primaryCompletion":6585,"completion":6586,"start":6587,"enrollment":284,"conditions":6588,"interventions":6590},"NCT01916642","A Dose-response Study of Lidocaine and Etomidate",[87],"2013-06","2013-07","2013-04",[6589],"Etomidate Overdose of Undetermined Intent",[6575,6591,6592,6593],"Lidocaine 1.5mg\u002Fkg","Lidocaine 2mg\u002Fkg","Lidocaine 2.5mg\u002Fkg",{"trials":6595,"activeCount":99},[],{"trials":6597,"activeCount":99},[],{"trials":6599,"activeCount":99},[],{"trials":6601,"activeCount":99},[],{"intervention":6591,"totalTrials":95,"cells":6603},{"EARLY_PHASE1":6604,"PHASE1":6606,"PHASE2":6612,"PHASE3":6614,"PHASE4":6616,"NA":6618},{"trials":6605,"activeCount":99},[],{"trials":6607,"activeCount":99},[6608],{"nctId":6582,"briefTitle":6583,"status":280,"phases":6609,"primaryCompletion":6585,"completion":6586,"start":6587,"enrollment":284,"conditions":6610,"interventions":6611},[87],[6589],[6575,6591,6592,6593],{"trials":6613,"activeCount":99},[],{"trials":6615,"activeCount":99},[],{"trials":6617,"activeCount":99},[],{"trials":6619,"activeCount":99},[],{"intervention":6592,"totalTrials":95,"cells":6621},{"EARLY_PHASE1":6622,"PHASE1":6624,"PHASE2":6630,"PHASE3":6632,"PHASE4":6634,"NA":6636},{"trials":6623,"activeCount":99},[],{"trials":6625,"activeCount":99},[6626],{"nctId":6582,"briefTitle":6583,"status":280,"phases":6627,"primaryCompletion":6585,"completion":6586,"start":6587,"enrollment":284,"conditions":6628,"interventions":6629},[87],[6589],[6575,6591,6592,6593],{"trials":6631,"activeCount":99},[],{"trials":6633,"activeCount":99},[],{"trials":6635,"activeCount":99},[],{"trials":6637,"activeCount":99},[],{"intervention":6593,"totalTrials":95,"cells":6639},{"EARLY_PHASE1":6640,"PHASE1":6642,"PHASE2":6648,"PHASE3":6650,"PHASE4":6652,"NA":6654},{"trials":6641,"activeCount":99},[],{"trials":6643,"activeCount":99},[6644],{"nctId":6582,"briefTitle":6583,"status":280,"phases":6645,"primaryCompletion":6585,"completion":6586,"start":6587,"enrollment":284,"conditions":6646,"interventions":6647},[87],[6589],[6575,6591,6592,6593],{"trials":6649,"activeCount":99},[],{"trials":6651,"activeCount":99},[],{"trials":6653,"activeCount":99},[],{"trials":6655,"activeCount":99},[],{"intervention":944,"totalTrials":95,"cells":6657},{"EARLY_PHASE1":6658,"PHASE1":6660,"PHASE2":6666,"PHASE3":6668,"PHASE4":6670,"NA":6672},{"trials":6659,"activeCount":99},[],{"trials":6661,"activeCount":99},[6662],{"nctId":933,"briefTitle":934,"status":314,"phases":6663,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":6664,"interventions":6665},[87],[941,942],[944,945,56],{"trials":6667,"activeCount":99},[],{"trials":6669,"activeCount":99},[],{"trials":6671,"activeCount":99},[],{"trials":6673,"activeCount":99},[],{"intervention":945,"totalTrials":95,"cells":6675},{"EARLY_PHASE1":6676,"PHASE1":6678,"PHASE2":6684,"PHASE3":6686,"PHASE4":6688,"NA":6690},{"trials":6677,"activeCount":99},[],{"trials":6679,"activeCount":99},[6680],{"nctId":933,"briefTitle":934,"status":314,"phases":6681,"primaryCompletion":936,"completion":937,"start":938,"enrollment":939,"conditions":6682,"interventions":6683},[87],[941,942],[944,945,56],{"trials":6685,"activeCount":99},[],{"trials":6687,"activeCount":99},[],{"trials":6689,"activeCount":99},[],{"trials":6691,"activeCount":99},[],{"intervention":6693,"totalTrials":95,"cells":6694},"Fospropofol disodium",{"EARLY_PHASE1":6695,"PHASE1":6697,"PHASE2":6709,"PHASE3":6711,"PHASE4":6713,"NA":6715},{"trials":6696,"activeCount":99},[],{"trials":6698,"activeCount":99},[6699],{"nctId":6700,"briefTitle":6701,"status":280,"phases":6702,"primaryCompletion":5083,"completion":6703,"start":6704,"enrollment":6705,"conditions":6706,"interventions":6708},"NCT01271569","A Study to Assess the Efficacy and Safety of Fospropofol Disodium",[87],"2011-01","2010-03",80,[6707],"Drug Safety",[6693],{"trials":6710,"activeCount":99},[],{"trials":6712,"activeCount":99},[],{"trials":6714,"activeCount":99},[],{"trials":6716,"activeCount":99},[],{"intervention":6718,"totalTrials":95,"cells":6719},"Oncolytic Virus SDJ001",{"EARLY_PHASE1":6720,"PHASE1":6722,"PHASE2":6731,"PHASE3":6733,"PHASE4":6735,"NA":6737},{"trials":6721,"activeCount":99},[],{"trials":6723,"activeCount":99},[6724],{"nctId":6725,"briefTitle":6726,"status":314,"phases":6727,"primaryCompletion":1288,"completion":4740,"start":5672,"enrollment":4057,"conditions":6728,"interventions":6729},"NCT06080984","The Application of Novel Oncolytic Virus in Late Stage Solid Tumors",[87],[3524],[6718,6730],"Oncolytic Virus YD06-1",{"trials":6732,"activeCount":99},[],{"trials":6734,"activeCount":99},[],{"trials":6736,"activeCount":99},[],{"trials":6738,"activeCount":99},[],{"intervention":6730,"totalTrials":95,"cells":6740},{"EARLY_PHASE1":6741,"PHASE1":6743,"PHASE2":6749,"PHASE3":6751,"PHASE4":6753,"NA":6755},{"trials":6742,"activeCount":99},[],{"trials":6744,"activeCount":99},[6745],{"nctId":6725,"briefTitle":6726,"status":314,"phases":6746,"primaryCompletion":1288,"completion":4740,"start":5672,"enrollment":4057,"conditions":6747,"interventions":6748},[87],[3524],[6718,6730],{"trials":6750,"activeCount":99},[],{"trials":6752,"activeCount":99},[],{"trials":6754,"activeCount":99},[],{"trials":6756,"activeCount":99},[],{"intervention":6758,"totalTrials":1183,"cells":6759},"Propofol",{"EARLY_PHASE1":6760,"PHASE1":6762,"PHASE2":6764,"PHASE3":6766,"PHASE4":6768,"NA":6774},{"trials":6761,"activeCount":99},[],{"trials":6763,"activeCount":99},[],{"trials":6765,"activeCount":99},[],{"trials":6767,"activeCount":99},[],{"trials":6769,"activeCount":99},[6770],{"nctId":5178,"briefTitle":5179,"status":314,"phases":6771,"primaryCompletion":5181,"completion":5182,"start":5183,"enrollment":345,"conditions":6772,"interventions":6773},[90],[5185,5186,4903],[5165,5188,5189,5190,5165],{"trials":6775,"activeCount":99},[6776,6785,6793,6803],{"nctId":6777,"briefTitle":6778,"status":280,"phases":6779,"primaryCompletion":6780,"completion":5601,"start":5301,"enrollment":6781,"conditions":6782,"interventions":6784},"NCT02214368","Noninvasive Ventilation Bundle in Postoperative Respiratory Failure",[91],"2014-10",158,[6783],"Respiratory Insufficiency",[6758],{"nctId":6786,"briefTitle":6787,"status":280,"phases":6788,"primaryCompletion":3608,"completion":3608,"start":1747,"enrollment":6789,"conditions":6790,"interventions":6792},"NCT05773807","Effect of Bispectral Index Monitoring (BIS) on Body Movement of Outpatients Undergoing Gastroscopy",[91],400,[6791],"Gastroscopy",[6758],{"nctId":6794,"briefTitle":6795,"status":280,"phases":6796,"primaryCompletion":6797,"completion":6798,"start":6799,"enrollment":6789,"conditions":6800,"interventions":6802},"NCT05158426","Application of the Propofol Precise Infusion Model",[],"2021-11-15","2021-11-18","2019-11-20",[6801],"Propofol Overdose of Undetermined Intent",[6758],{"nctId":6804,"briefTitle":6805,"status":314,"phases":6806,"primaryCompletion":6807,"completion":6807,"start":6808,"enrollment":204,"conditions":6809,"interventions":6811},"NCT06208956","A Low Dose Dexmedetomidine in Sedation Colonoscopy",[91],"2024-02-29","2024-01-20",[6810],"Colonoscopy",[5190,6758],{"intervention":6813,"totalTrials":1055,"cells":6814},"N-butyl-2-cyanoacrylate",{"EARLY_PHASE1":6815,"PHASE1":6817,"PHASE2":6819,"PHASE3":6821,"PHASE4":6823,"NA":6825},{"trials":6816,"activeCount":99},[],{"trials":6818,"activeCount":99},[],{"trials":6820,"activeCount":99},[],{"trials":6822,"activeCount":99},[],{"trials":6824,"activeCount":99},[],{"trials":6826,"activeCount":99},[6827,6836,6843],{"nctId":6828,"briefTitle":6829,"status":314,"phases":6830,"primaryCompletion":6831,"completion":6831,"start":905,"enrollment":2228,"conditions":6832,"interventions":6834},"NCT02468180","Primary Prophylaxis of Gastric Variceal Bleed",[91],"2022-07",[6833],"Gastric Varices",[6813,6835],"Lauromacrogol",{"nctId":6837,"briefTitle":6838,"status":314,"phases":6839,"primaryCompletion":6840,"completion":6840,"start":905,"enrollment":2228,"conditions":6841,"interventions":6842},"NCT02468167","Acute Gastric Variceal Bleeding: Endoscopic Treatment Versus BRTO",[91],"2020-07",[6833],[6813,6835],{"nctId":6844,"briefTitle":6845,"status":280,"phases":6846,"primaryCompletion":6847,"completion":6848,"start":905,"enrollment":3069,"conditions":6849,"interventions":6850},"NCT02468206","Secondary Prophylaxis of Gastric Variceal Bleed",[91],"2018-02-28","2019-01-07",[6833],[6813,6835],{"intervention":6835,"totalTrials":1055,"cells":6852},{"EARLY_PHASE1":6853,"PHASE1":6855,"PHASE2":6857,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6854,"activeCount":99},[],{"trials":6856,"activeCount":99},[],{"trials":6858,"activeCount":99},[],{"trials":6860,"activeCount":99},[],{"trials":6862,"activeCount":99},[],{"trials":6864,"activeCount":99},[6865,6869,6873],{"nctId":6828,"briefTitle":6829,"status":314,"phases":6866,"primaryCompletion":6831,"completion":6831,"start":905,"enrollment":2228,"conditions":6867,"interventions":6868},[91],[6833],[6813,6835],{"nctId":6837,"briefTitle":6838,"status":314,"phases":6870,"primaryCompletion":6840,"completion":6840,"start":905,"enrollment":2228,"conditions":6871,"interventions":6872},[91],[6833],[6813,6835],{"nctId":6844,"briefTitle":6845,"status":280,"phases":6874,"primaryCompletion":6847,"completion":6848,"start":905,"enrollment":3069,"conditions":6875,"interventions":6876},[91],[6833],[6813,6835],{"intervention":6878,"totalTrials":1055,"cells":6879},"Lidocaine Hydrochloride, Injectable",{"EARLY_PHASE1":6880,"PHASE1":6882,"PHASE2":6884,"PHASE3":6896,"PHASE4":6898,"NA":6900},{"trials":6881,"activeCount":99},[],{"trials":6883,"activeCount":99},[],{"trials":6885,"activeCount":99},[6886],{"nctId":6887,"briefTitle":6888,"status":314,"phases":6889,"primaryCompletion":6890,"completion":6890,"start":6891,"enrollment":6892,"conditions":6893,"interventions":6894},"NCT05492669","Intravenous Lidocaine on Chronic Pain in Patients Undergoing Hepatectomy",[88],"2024-07-27","2020-02-27",260,[4854],[6878,6895],"0.9% normal saline",{"trials":6897,"activeCount":99},[],{"trials":6899,"activeCount":99},[],{"trials":6901,"activeCount":99},[6902,6910],{"nctId":6903,"briefTitle":6904,"status":280,"phases":6905,"primaryCompletion":6906,"completion":6906,"start":6891,"enrollment":6892,"conditions":6907,"interventions":6909},"NCT04295330","Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy",[91],"2022-05-27",[6908],"Primary Liver Cancer",[6878,6895],{"nctId":6911,"briefTitle":6912,"status":314,"phases":6913,"primaryCompletion":6906,"completion":6914,"start":6915,"enrollment":440,"conditions":6916,"interventions":6917},"NCT05369650","To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients",[91],"2022-09-27","2019-07-27",[27],[6878],{"intervention":6919,"totalTrials":259,"cells":6920},"Shenlingcao Oral Liquid",{"EARLY_PHASE1":6921,"PHASE1":6923,"PHASE2":6925,"PHASE3":6927,"PHASE4":6929,"NA":6943},{"trials":6922,"activeCount":99},[],{"trials":6924,"activeCount":99},[],{"trials":6926,"activeCount":99},[],{"trials":6928,"activeCount":99},[],{"trials":6930,"activeCount":99},[6931],{"nctId":6932,"briefTitle":6933,"status":280,"phases":6934,"primaryCompletion":6935,"completion":6936,"start":6937,"enrollment":6938,"conditions":6939,"interventions":6942},"NCT03712969","Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC",[90],"2022-03-14","2023-05-04","2018-11-05",527,[6940,6941],"Carcinoma, Non-Small-Cell Lung","Chemotherapy, Adjuvant",[6919],{"trials":6944,"activeCount":99},[6945],{"nctId":6946,"briefTitle":6947,"status":6948,"phases":6949,"primaryCompletion":6950,"completion":6950,"start":6951,"enrollment":25,"conditions":6952,"interventions":6953},"NCT03479294","Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection","TERMINATED",[],"2018-09-10","2018-03-28",[6940,6941],[6919],{"intervention":5190,"totalTrials":259,"cells":6955},{"EARLY_PHASE1":6956,"PHASE1":6958,"PHASE2":6960,"PHASE3":6962,"PHASE4":6964,"NA":6970},{"trials":6957,"activeCount":99},[],{"trials":6959,"activeCount":99},[],{"trials":6961,"activeCount":99},[],{"trials":6963,"activeCount":99},[],{"trials":6965,"activeCount":99},[6966],{"nctId":5178,"briefTitle":5179,"status":314,"phases":6967,"primaryCompletion":5181,"completion":5182,"start":5183,"enrollment":345,"conditions":6968,"interventions":6969},[90],[5185,5186,4903],[5165,5188,5189,5190,5165],{"trials":6971,"activeCount":99},[6972],{"nctId":6804,"briefTitle":6805,"status":314,"phases":6973,"primaryCompletion":6807,"completion":6807,"start":6808,"enrollment":204,"conditions":6974,"interventions":6975},[91],[6810],[5190,6758],{"intervention":6895,"totalTrials":259,"cells":6977},{"EARLY_PHASE1":6978,"PHASE1":6980,"PHASE2":6982,"PHASE3":6988,"PHASE4":6990,"NA":6992},{"trials":6979,"activeCount":99},[],{"trials":6981,"activeCount":99},[],{"trials":6983,"activeCount":99},[6984],{"nctId":6887,"briefTitle":6888,"status":314,"phases":6985,"primaryCompletion":6890,"completion":6890,"start":6891,"enrollment":6892,"conditions":6986,"interventions":6987},[88],[4854],[6878,6895],{"trials":6989,"activeCount":99},[],{"trials":6991,"activeCount":99},[],{"trials":6993,"activeCount":99},[6994],{"nctId":6903,"briefTitle":6904,"status":280,"phases":6995,"primaryCompletion":6906,"completion":6906,"start":6891,"enrollment":6892,"conditions":6996,"interventions":6997},[91],[6908],[6878,6895],{"intervention":6999,"totalTrials":259,"cells":7000},"Isoniazid",{"EARLY_PHASE1":7001,"PHASE1":7003,"PHASE2":7005,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":7002,"activeCount":99},[],{"trials":7004,"activeCount":99},[],{"trials":7006,"activeCount":99},[],{"trials":7008,"activeCount":99},[],{"trials":7010,"activeCount":99},[],{"trials":7012,"activeCount":99},[7013,7025],{"nctId":7014,"briefTitle":7015,"status":314,"phases":7016,"primaryCompletion":1608,"completion":7017,"start":7018,"enrollment":7019,"conditions":7020,"interventions":7024},"NCT05249699","The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation",[91],"2023-08-01","2022-04-01",303,[7021,7022,7023],"Kidney Transplant Infection","Tuberculosis","Isoniazid Toxicity",[6999],{"nctId":7026,"briefTitle":7027,"status":280,"phases":7028,"primaryCompletion":7029,"completion":5954,"start":7030,"enrollment":7031,"conditions":7032,"interventions":7034},"NCT06512831","Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients",[91],"2024-02-01","2023-06-01",1348,[7033,7022,7023],"Kidney Transplantation",[6999],{"intervention":7036,"totalTrials":95,"cells":7037},"chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs",{"EARLY_PHASE1":7038,"PHASE1":7040,"PHASE2":7042,"PHASE3":7044,"PHASE4":7046,"NA":7048},{"trials":7039,"activeCount":99},[],{"trials":7041,"activeCount":99},[],{"trials":7043,"activeCount":99},[],{"trials":7045,"activeCount":99},[],{"trials":7047,"activeCount":99},[],{"trials":7049,"activeCount":99},[7050],{"nctId":7051,"briefTitle":7052,"status":280,"phases":7053,"primaryCompletion":418,"completion":950,"start":7054,"enrollment":7055,"conditions":7056,"interventions":7060},"NCT05620056","A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)",[],"2013-01-01",564760,[7057,7058,7059],"Pregnancy","Congenital Malformation","Drug Exposure",[7036],{"intervention":7062,"totalTrials":95,"cells":7063},"low molecular weight heparin",{"EARLY_PHASE1":7064,"PHASE1":7066,"PHASE2":7068,"PHASE3":7070,"PHASE4":7072,"NA":7074},{"trials":7065,"activeCount":99},[],{"trials":7067,"activeCount":99},[],{"trials":7069,"activeCount":99},[],{"trials":7071,"activeCount":99},[],{"trials":7073,"activeCount":99},[],{"trials":7075,"activeCount":99},[7076],{"nctId":7077,"briefTitle":7078,"status":314,"phases":7079,"primaryCompletion":7080,"completion":7081,"start":419,"enrollment":7082,"conditions":7083,"interventions":7084},"NCT03171727","Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction",[91],"2019-05-15","2019-12-30",117,[4785,21],[7062],{"intervention":288,"totalTrials":95,"cells":7086},{"EARLY_PHASE1":7087,"PHASE1":7089,"PHASE2":7091,"PHASE3":7093,"PHASE4":7095,"NA":7097},{"trials":7088,"activeCount":99},[],{"trials":7090,"activeCount":99},[],{"trials":7092,"activeCount":99},[],{"trials":7094,"activeCount":99},[],{"trials":7096,"activeCount":99},[],{"trials":7098,"activeCount":99},[7099],{"nctId":278,"briefTitle":279,"status":280,"phases":7100,"primaryCompletion":282,"completion":60,"start":283,"enrollment":284,"conditions":7101,"interventions":7102},[91],[286],[288,255],{"intervention":7104,"totalTrials":95,"cells":7105},"Ferric Derisomaltose",{"EARLY_PHASE1":7106,"PHASE1":7108,"PHASE2":7110,"PHASE3":7112,"PHASE4":7114,"NA":7116},{"trials":7107,"activeCount":99},[],{"trials":7109,"activeCount":99},[],{"trials":7111,"activeCount":99},[],{"trials":7113,"activeCount":99},[],{"trials":7115,"activeCount":99},[],{"trials":7117,"activeCount":99},[7118],{"nctId":7119,"briefTitle":7120,"status":314,"phases":7121,"primaryCompletion":882,"completion":7122,"start":7123,"enrollment":7124,"conditions":7125,"interventions":7127},"NCT05911438","Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia",[91],"2025-06","2023-07",419,[7126],"Total Knee Arthroplasty",[7104],{"intervention":7129,"totalTrials":95,"cells":7130},"Trolamine",{"EARLY_PHASE1":7131,"PHASE1":7133,"PHASE2":7135,"PHASE3":7137,"PHASE4":7139,"NA":7141},{"trials":7132,"activeCount":99},[],{"trials":7134,"activeCount":99},[],{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":99},[],{"trials":7140,"activeCount":99},[],{"trials":7142,"activeCount":99},[7143],{"nctId":7144,"briefTitle":7145,"status":280,"phases":7146,"primaryCompletion":1494,"completion":6013,"start":2519,"enrollment":7147,"conditions":7148,"interventions":7149},"NCT06484166","Efficacy of Fullerene in Preventing Radiation Dermatitis in Patients With Head and Neck Cancer .",[91],132,[4743],[7129],{"intervention":7151,"totalTrials":95,"cells":7152},"Vitamin A",{"EARLY_PHASE1":7153,"PHASE1":7155,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7163},{"trials":7154,"activeCount":99},[],{"trials":7156,"activeCount":99},[],{"trials":7158,"activeCount":99},[],{"trials":7160,"activeCount":99},[],{"trials":7162,"activeCount":99},[],{"trials":7164,"activeCount":99},[7165],{"nctId":7166,"briefTitle":7167,"status":314,"phases":7168,"primaryCompletion":60,"completion":7169,"start":950,"enrollment":7170,"conditions":7171,"interventions":7174},"NCT04127968","Efficacy and Safety of Vitamin A Treatment for Children With Sepsis",[91],"2024-05-31",450,[7172,7173,34],"Vitamin A Deficiency","Pediatric",[7151,7175],"Oil",{"intervention":7175,"totalTrials":95,"cells":7177},{"EARLY_PHASE1":7178,"PHASE1":7180,"PHASE2":7182,"PHASE3":7184,"PHASE4":7186,"NA":7188},{"trials":7179,"activeCount":99},[],{"trials":7181,"activeCount":99},[],{"trials":7183,"activeCount":99},[],{"trials":7185,"activeCount":99},[],{"trials":7187,"activeCount":99},[],{"trials":7189,"activeCount":99},[7190],{"nctId":7166,"briefTitle":7167,"status":314,"phases":7191,"primaryCompletion":60,"completion":7169,"start":950,"enrollment":7170,"conditions":7192,"interventions":7193},[91],[7172,7173,34],[7151,7175],{"intervention":7195,"totalTrials":95,"cells":7196},"Substance use",{"EARLY_PHASE1":7197,"PHASE1":7199,"PHASE2":7201,"PHASE3":7203,"PHASE4":7205,"NA":7207},{"trials":7198,"activeCount":99},[],{"trials":7200,"activeCount":99},[],{"trials":7202,"activeCount":99},[],{"trials":7204,"activeCount":99},[],{"trials":7206,"activeCount":99},[],{"trials":7208,"activeCount":99},[7209],{"nctId":7210,"briefTitle":7211,"status":280,"phases":7212,"primaryCompletion":5181,"completion":7213,"start":7214,"enrollment":7215,"conditions":7216,"interventions":7218},"NCT02621411","Observational Study of Preoperative Screen for Substance Abuse",[],"2017-03","2015-11",1031,[7217],"Preoperative Screen for Substance Abuse in in Patients Undergoing Emergency Operation",[7195],{"intervention":7220,"totalTrials":95,"cells":7221},"Ropivacaine",{"EARLY_PHASE1":7222,"PHASE1":7224,"PHASE2":7226,"PHASE3":7228,"PHASE4":7230,"NA":7232},{"trials":7223,"activeCount":99},[],{"trials":7225,"activeCount":99},[],{"trials":7227,"activeCount":99},[],{"trials":7229,"activeCount":99},[],{"trials":7231,"activeCount":99},[],{"trials":7233,"activeCount":99},[7234],{"nctId":7235,"briefTitle":7236,"status":280,"phases":7237,"primaryCompletion":7238,"completion":7238,"start":905,"enrollment":7239,"conditions":7240,"interventions":7242},"NCT02502487","Dorsal Penile Nerve Block for Rigid Cystoscopy in Men",[91],"2016-03",258,[7241],"Pain",[7220,7243],"Tetracaine",{"intervention":7243,"totalTrials":95,"cells":7245},{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7250,"PHASE3":7252,"PHASE4":7254,"NA":7256},{"trials":7247,"activeCount":99},[],{"trials":7249,"activeCount":99},[],{"trials":7251,"activeCount":99},[],{"trials":7253,"activeCount":99},[],{"trials":7255,"activeCount":99},[],{"trials":7257,"activeCount":99},[7258],{"nctId":7235,"briefTitle":7236,"status":280,"phases":7259,"primaryCompletion":7238,"completion":7238,"start":905,"enrollment":7239,"conditions":7260,"interventions":7261},[91],[7241],[7220,7243],{"intervention":7263,"totalTrials":95,"cells":7264},"Lidocaine Hydrochloride 2% Injection Solution",{"EARLY_PHASE1":7265,"PHASE1":7267,"PHASE2":7269,"PHASE3":7271,"PHASE4":7273,"NA":7275},{"trials":7266,"activeCount":99},[],{"trials":7268,"activeCount":99},[],{"trials":7270,"activeCount":99},[],{"trials":7272,"activeCount":99},[],{"trials":7274,"activeCount":99},[],{"trials":7276,"activeCount":99},[7277],{"nctId":7278,"briefTitle":7279,"status":280,"phases":7280,"primaryCompletion":7281,"completion":7282,"start":1210,"enrollment":7283,"conditions":7284,"interventions":7285},"NCT05412576","a Pilot Study of Lidocaine Infusion for Postoperative Analgesia in Elderly Patients With Colorectal Cancer Surgery",[91],"2022-10-24","2022-12-25",220,[15],[7263,7286],"0.9% NaCl",{"intervention":7286,"totalTrials":95,"cells":7288},{"EARLY_PHASE1":7289,"PHASE1":7291,"PHASE2":7293,"PHASE3":7295,"PHASE4":7297,"NA":7299},{"trials":7290,"activeCount":99},[],{"trials":7292,"activeCount":99},[],{"trials":7294,"activeCount":99},[],{"trials":7296,"activeCount":99},[],{"trials":7298,"activeCount":99},[],{"trials":7300,"activeCount":99},[7301],{"nctId":7278,"briefTitle":7279,"status":280,"phases":7302,"primaryCompletion":7281,"completion":7282,"start":1210,"enrollment":7283,"conditions":7303,"interventions":7304},[91],[15],[7263,7286],{"intervention":7306,"totalTrials":95,"cells":7307},"Herbal medicines",{"EARLY_PHASE1":7308,"PHASE1":7310,"PHASE2":7312,"PHASE3":7314,"PHASE4":7316,"NA":7318},{"trials":7309,"activeCount":99},[],{"trials":7311,"activeCount":99},[],{"trials":7313,"activeCount":99},[],{"trials":7315,"activeCount":99},[],{"trials":7317,"activeCount":99},[],{"trials":7319,"activeCount":99},[7320],{"nctId":7321,"briefTitle":7322,"status":314,"phases":7323,"primaryCompletion":79,"completion":248,"start":7324,"enrollment":7325,"conditions":7326,"interventions":7329},"NCT06048276","Miscarriage Preventing Herbal Medicines and the Risk of Birth Defects: a Population-based Cohort Study",[],"2023-01-01",200000,[7057,7327,7328],"Birth Defects","Drug Exposures",[7306],{"intervention":7331,"totalTrials":95,"cells":7332},"Intravenous tramadol",{"EARLY_PHASE1":7333,"PHASE1":7335,"PHASE2":7337,"PHASE3":7339,"PHASE4":7341,"NA":7343},{"trials":7334,"activeCount":99},[],{"trials":7336,"activeCount":99},[],{"trials":7338,"activeCount":99},[],{"trials":7340,"activeCount":99},[],{"trials":7342,"activeCount":99},[],{"trials":7344,"activeCount":99},[7345],{"nctId":7346,"briefTitle":7347,"status":314,"phases":7348,"primaryCompletion":7349,"completion":7350,"start":7238,"enrollment":7351,"conditions":7352,"interventions":7354},"NCT02683070","Pudendal Nerve Block for Catheter-related Bladder Discomfort Prevention",[91],"2018-02","2018-08",94,[7353],"Catheter Site Discomfort",[7331],{"intervention":889,"totalTrials":95,"cells":7356},{"EARLY_PHASE1":7357,"PHASE1":7359,"PHASE2":7361,"PHASE3":7363,"PHASE4":7365,"NA":7367},{"trials":7358,"activeCount":99},[],{"trials":7360,"activeCount":99},[],{"trials":7362,"activeCount":99},[],{"trials":7364,"activeCount":99},[],{"trials":7366,"activeCount":99},[],{"trials":7368,"activeCount":99},[7369],{"nctId":879,"briefTitle":880,"status":314,"phases":7370,"primaryCompletion":882,"completion":882,"start":883,"enrollment":884,"conditions":7371,"interventions":7372},[91],[21,886,887],[889,831],{"intervention":7374,"totalTrials":95,"cells":7375},"Ropivacaine Hydrochloride 10 MG\u002FML [Naropin]",{"EARLY_PHASE1":7376,"PHASE1":7378,"PHASE2":7380,"PHASE3":7382,"PHASE4":7384,"NA":7386},{"trials":7377,"activeCount":99},[],{"trials":7379,"activeCount":99},[],{"trials":7381,"activeCount":99},[],{"trials":7383,"activeCount":99},[],{"trials":7385,"activeCount":99},[],{"trials":7387,"activeCount":99},[7388],{"nctId":7389,"briefTitle":7390,"status":314,"phases":7391,"primaryCompletion":7392,"completion":7393,"start":7394,"enrollment":25,"conditions":7395,"interventions":7396},"NCT06006026","The Safety of Ropivacaine TAP Block Combined With Intravenous Lidocaine in Patients Undergoing Colorectal Cancer Surgery",[91],"2024-05-10","2024-05-20","2023-08-28",[15],[7374],{"intervention":7398,"totalTrials":95,"cells":7399},"Coronary angiography,Canadian Cardiovascular Society angina pectoris classification for the severity of angina and electronic Von Frey instrument for testing the degree of acupoint sensitization",{"EARLY_PHASE1":7400,"PHASE1":7402,"PHASE2":7404,"PHASE3":7406,"PHASE4":7408,"NA":7410},{"trials":7401,"activeCount":99},[],{"trials":7403,"activeCount":99},[],{"trials":7405,"activeCount":99},[],{"trials":7407,"activeCount":99},[],{"trials":7409,"activeCount":99},[],{"trials":7411,"activeCount":99},[7412],{"nctId":7413,"briefTitle":7414,"status":280,"phases":7415,"primaryCompletion":7416,"completion":7417,"start":7418,"enrollment":7419,"conditions":7420,"interventions":7425},"NCT03341663","The Diagnostic Value of Acupoint Sensitization Based on Stable Angina Pectoris",[],"2018-10-28","2018-11-29","2017-12-06",183,[7421,7422,7423,7424],"Stable Angina Pectoris","Acupoint Sensitization","Correlation Analysis","Diagnostic Value",[7398],{"intervention":7427,"totalTrials":95,"cells":7428},"SGLT2 inhibitor",{"EARLY_PHASE1":7429,"PHASE1":7431,"PHASE2":7433,"PHASE3":7435,"PHASE4":7437,"NA":7439},{"trials":7430,"activeCount":99},[],{"trials":7432,"activeCount":99},[],{"trials":7434,"activeCount":99},[],{"trials":7436,"activeCount":99},[],{"trials":7438,"activeCount":99},[],{"trials":7440,"activeCount":99},[7441],{"nctId":7442,"briefTitle":7443,"status":280,"phases":7444,"primaryCompletion":113,"completion":113,"start":7324,"enrollment":7445,"conditions":7446,"interventions":7450},"NCT05013112","Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)",[91],105,[7033,7447,7448,7449],"Metabolic Disorder","Metformin","Empagliflozin",[7427,7448],{"intervention":7448,"totalTrials":95,"cells":7452},{"EARLY_PHASE1":7453,"PHASE1":7455,"PHASE2":7457,"PHASE3":7459,"PHASE4":7461,"NA":7463},{"trials":7454,"activeCount":99},[],{"trials":7456,"activeCount":99},[],{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[],{"trials":7462,"activeCount":99},[],{"trials":7464,"activeCount":99},[7465],{"nctId":7442,"briefTitle":7443,"status":280,"phases":7466,"primaryCompletion":113,"completion":113,"start":7324,"enrollment":7445,"conditions":7467,"interventions":7468},[91],[7033,7447,7448,7449],[7427,7448],{"intervention":7470,"totalTrials":95,"cells":7471},"RL",{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7476,"PHASE3":7478,"PHASE4":7480,"NA":7482},{"trials":7473,"activeCount":99},[],{"trials":7475,"activeCount":99},[],{"trials":7477,"activeCount":99},[],{"trials":7479,"activeCount":99},[],{"trials":7481,"activeCount":99},[],{"trials":7483,"activeCount":99},[7484],{"nctId":7485,"briefTitle":7486,"status":314,"phases":7487,"primaryCompletion":7488,"completion":7489,"start":7490,"enrollment":7491,"conditions":7492,"interventions":7494},"NCT03813563","Lactated Ringer's and PlasmaLyte in Critically Ill Adults",[],"2018-12-15","2019-02","2018-01-13",12000,[7493],"Critical Illness",[7470,7495],"PLA",{"intervention":7495,"totalTrials":95,"cells":7497},{"EARLY_PHASE1":7498,"PHASE1":7500,"PHASE2":7502,"PHASE3":7504,"PHASE4":7506,"NA":7508},{"trials":7499,"activeCount":99},[],{"trials":7501,"activeCount":99},[],{"trials":7503,"activeCount":99},[],{"trials":7505,"activeCount":99},[],{"trials":7507,"activeCount":99},[],{"trials":7509,"activeCount":99},[7510],{"nctId":7485,"briefTitle":7486,"status":314,"phases":7511,"primaryCompletion":7488,"completion":7489,"start":7490,"enrollment":7491,"conditions":7512,"interventions":7513},[],[7493],[7470,7495],{"intervention":7515,"totalTrials":95,"cells":7516},"Dexmedetomidine group",{"EARLY_PHASE1":7517,"PHASE1":7519,"PHASE2":7521,"PHASE3":7523,"PHASE4":7525,"NA":7527},{"trials":7518,"activeCount":99},[],{"trials":7520,"activeCount":99},[],{"trials":7522,"activeCount":99},[],{"trials":7524,"activeCount":99},[],{"trials":7526,"activeCount":99},[],{"trials":7528,"activeCount":99},[7529],{"nctId":7530,"briefTitle":7531,"status":280,"phases":7532,"primaryCompletion":6337,"completion":6337,"start":7533,"enrollment":204,"conditions":7534,"interventions":7535},"NCT03892928","Safety and Efficacy of Dexmedetomidine in Painless Colonoscopy",[91],"2019-12-01",[6810],[7515],{"intervention":7537,"totalTrials":95,"cells":7538},"concentrated growth factor + bone substitute",{"EARLY_PHASE1":7539,"PHASE1":7541,"PHASE2":7543,"PHASE3":7545,"PHASE4":7547,"NA":7549},{"trials":7540,"activeCount":99},[],{"trials":7542,"activeCount":99},[],{"trials":7544,"activeCount":99},[],{"trials":7546,"activeCount":99},[],{"trials":7548,"activeCount":99},[],{"trials":7550,"activeCount":99},[7551],{"nctId":7552,"briefTitle":7553,"status":314,"phases":7554,"primaryCompletion":882,"completion":882,"start":5789,"enrollment":896,"conditions":7555,"interventions":7558},"NCT05938907","Effect of Concentrated Growth Factors on Healing of Apicomarginal Defects: a Prospective Study",[91],[7556,7557],"Concentrated Growth Factor","Bone Substitute",[7537],{"intervention":7560,"totalTrials":95,"cells":7561},"CO2 portograms guidance",{"EARLY_PHASE1":7562,"PHASE1":7564,"PHASE2":7566,"PHASE3":7568,"PHASE4":7570,"NA":7572},{"trials":7563,"activeCount":99},[],{"trials":7565,"activeCount":99},[],{"trials":7567,"activeCount":99},[],{"trials":7569,"activeCount":99},[],{"trials":7571,"activeCount":99},[],{"trials":7573,"activeCount":99},[7574],{"nctId":7575,"briefTitle":7576,"status":314,"phases":7577,"primaryCompletion":5183,"completion":5183,"start":905,"enrollment":3600,"conditions":7578,"interventions":7579},"NCT02480426","3D CT Guidance for Transjugular Intrahepatic Portosystemic Shunt Creation",[91],[21],[7560]]